<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">49044</article-id><article-id pub-id-type="doi">10.7554/eLife.49044</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>NEIL1 and NEIL2 DNA glycosylases protect neural crest development against mitochondrial oxidative stress</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-155072"><name><surname>Han</surname><given-names>Dandan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0585-2451</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-144803"><name><surname>Schomacher</surname><given-names>Lars</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3841-5258</contrib-id><email>l.schomacher@imb-mainz.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-144804"><name><surname>Schüle</surname><given-names>Katrin M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6642-0030</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" id="author-144805"><name><surname>Mallick</surname><given-names>Medhavi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" id="author-144806"><name><surname>Musheev</surname><given-names>Michael U</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0499-9689</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" id="author-144807"><name><surname>Karaulanov</surname><given-names>Emil</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" id="author-144808"><name><surname>Krebs</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" id="author-144809"><name><surname>von Seggern</surname><given-names>Annika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/><xref ref-type="other" rid="dataset1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-144359"><name><surname>Niehrs</surname><given-names>Christof</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9561-9302</contrib-id><email>C.Niehrs@imb-mainz.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Institute of Molecular Biology (IMB)</institution><addr-line><named-content content-type="city">Mainz</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Division of Molecular Embryology</institution><institution>DKFZ-ZMBH Alliance</institution><addr-line><named-content content-type="city">Heidelberg</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Reviewing Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Senior Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>30</day><month>09</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e49044</elocation-id><history><date date-type="received" iso-8601-date="2019-06-04"><day>04</day><month>06</month><year>2019</year></date><date date-type="accepted" iso-8601-date="2019-09-12"><day>12</day><month>09</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Han et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Han et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-49044-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.49044.001</object-id><p>Base excision repair (BER) functions not only in the maintenance of genomic integrity but also in active DNA demethylation and epigenetic gene regulation. This dual role raises the question if phenotypic abnormalities resulting from deficiency of BER factors are due to DNA damage or impaired DNA demethylation. Here we investigate the bifunctional DNA glycosylases/lyases NEIL1 and NEIL2, which act in repair of oxidative lesions and in epigenetic demethylation. <italic>Neil</italic>-deficiency in <italic>Xenopus</italic> embryos and differentiating mouse embryonic stem cells (mESCs) leads to a surprisingly restricted defect in cranial neural crest cell (cNCC) development. <italic>Neil</italic>-deficiency elicits an oxidative stress-induced TP53-dependent DNA damage response, which impairs early cNCC specification. Epistasis experiments with <italic>Tdg</italic>-deficient mESCs show no involvement of epigenetic DNA demethylation. Instead, <italic>Neil</italic>-deficiency results in oxidative damage specific to mitochondrial DNA, which triggers a TP53-mediated intrinsic apoptosis. Thus, NEIL1 and NEIL2 DNA glycosylases protect mitochondrial DNA against oxidative damage during neural crest differentiation.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.49044.002</object-id><title>eLife digest</title><p>The face of animals with a backbone is formed in great part by a group of cells called cranial neural crest cells. When too few of these cells are made, the skull and the face can become deformed. For example, the jaw- or cheekbones can be underdeveloped or there may be defects in the eyes or ears. These types of abnormalities are among the most common birth defects known in humans.</p><p>NEIL1 and NEIL2 are mouse proteins with two roles. On the one hand, they help protect DNA from damage by acting as so-called ‘base excision repair enzymes’, meaning they remove damaged building blocks of DNA. On the other hand, they help remove a chemical group known as a methyl from DNA building blocks in a process called demethylation, which is involved both in development and disease. Previous research by Schomacher et al. in 2016 showed that, in frogs, the absence of a similar protein called Neil2, leads to deformities of the face and skull.</p><p>Han et al. – who include some of the researchers involved in the 2016 study – have now used frog embryos and mouse embryonic stem cells to examine the role of the NEIL proteins in cranial neural crest cells. Stem cells can become any type of cell in the body, but when NEIL1 and NEIL2 are missing, these cells lose the ability to become cranial neural crest cells.</p><p>To determine whether the effects of removing NEIL1 and NEIL2 were due to their role in DNA damage repair or demethylation, Han et al. removed two proteins, each involved in one of the two processes. Removing APEX1, which is involved in DNA damage repair, had similar effects to the removal of NEIL1 and NEIL2, while removing TDG, which only works in demethylation, did not. This indicates that NEIL1 and NEIL2’s role in DNA damage repair is likely necessary for stem cells to become cranial neural crest cells.</p><p>Although NEIL1 and NEIL2 are part of the DNA repair machinery, Han et al. showed that when stem cells turn into cranial neural crest cells, these proteins are not protecting the cell’s genomic DNA. Instead, they are active in the mitochondria, the compartments of the cell responsible for producing energy, which have their own DNA. Mitochondria use oxygen to produce energy, but by-products of these reactions damage mitochondrial DNA, explaining why mitochondria need NEIL1 and NEIL2. These results suggest that antioxidants, which are molecules that protect the cells from the damaging oxygen derivatives, may help prevent deformities in the face and skull. This theory could be tested using mice that do not produce proteins involved in base excision repair, which could be derived from the cells lacking NEIL1 and NEIL2.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>base excision repair</kwd><kwd>NEIL DNA glycosylases</kwd><kwd>TDG</kwd><kwd>TP53</kwd><kwd>mitochondria</kwd><kwd>neural crest</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd><italic>Xenopus</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>NI286/17-1</award-id><principal-award-recipient><name><surname>Niehrs</surname><given-names>Christof</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>393547839 - SFB 1361, sub-project 03</award-id><principal-award-recipient><name><surname>Niehrs</surname><given-names>Christof</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>NEIL DNA glycosylases are required to counteract oxidative base damages within the mitochondrial genome to safeguard neural crest cell differentiation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>DNA repair is crucial to maintain genomic integrity in the face of exogenous and endogenous challenges. Cells express an arsenal of DNA repair enzymes that maintain genomic integrity, and mouse mutants have revealed a critical role of DNA repair in both organismic ageing and disease (<xref ref-type="bibr" rid="bib50">Jacobs and Schär, 2012</xref>; <xref ref-type="bibr" rid="bib64">Lombard et al., 2005</xref>). In addition, there is now compelling evidence that DNA repair enzymes function not only in lesion control but have been co-opted in epigenetic gene regulation via active DNA demethylation (<xref ref-type="bibr" rid="bib7">Bellacosa and Drohat, 2015</xref>; <xref ref-type="bibr" rid="bib87">Schuermann et al., 2016</xref>; <xref ref-type="bibr" rid="bib113">Wu and Zhang, 2017</xref>). The best understood active demethylation mechanism involves TET dioxygenases, which iteratively oxidize the methyl group at C5 to yield 5-hydroxymethylcytosine (5hmC) (<xref ref-type="bibr" rid="bib56">Kriaucionis and Heintz, 2009</xref>; <xref ref-type="bibr" rid="bib98">Tahiliani et al., 2009</xref>), 5-formylcytosine (5fC) (<xref ref-type="bibr" rid="bib49">Ito et al., 2011</xref>; <xref ref-type="bibr" rid="bib73">Pfaffeneder et al., 2011</xref>), and 5-carboxylcytosine (5caC) (<xref ref-type="bibr" rid="bib38">He et al., 2011</xref>; <xref ref-type="bibr" rid="bib49">Ito et al., 2011</xref>). Thymine DNA glycosylase (TDG) excises 5fC and 5caC and the ensuing abasic site intermediate is processed by BER to restore unmethylated C (<xref ref-type="bibr" rid="bib23">Cortázar et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Cortellino et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">He et al., 2011</xref>; <xref ref-type="bibr" rid="bib67">Maiti and Drohat, 2011</xref>; <xref ref-type="bibr" rid="bib88">Shen et al., 2013</xref>; <xref ref-type="bibr" rid="bib93">Song et al., 2013</xref>). The need for abasic site processing during active DNA demethylation therefore places BER enzymes center stage in epigenetic gene regulation.</p><p>Deficiency of the BER enzymes (e.g. TDG, APEX1, POLB, LIG3, XRCC1) can lead to abnormalities or lethality during embryogenesis (<xref ref-type="bibr" rid="bib23">Cortázar et al., 2011</xref>; <xref ref-type="bibr" rid="bib24">Cortellino et al., 2011</xref>; <xref ref-type="bibr" rid="bib76">Puebla-Osorio et al., 2006</xref>; <xref ref-type="bibr" rid="bib96">Sugo et al., 2000</xref>; <xref ref-type="bibr" rid="bib101">Tebbs et al., 1999</xref>; <xref ref-type="bibr" rid="bib114">Xanthoudakis et al., 1996</xref>), but the etiology of the physiological defects is often poorly understood. Notably, it is unclear if the phenotypic abnormalities are due to accumulating DNA damage or impaired DNA demethylation.</p><p>An example for BER enzymes acting both in lesion control and in epigenetic gene regulation are the endonuclease VIII-like glycosylases 1 and 2 (NEIL1 and NEIL2). These enzymes process oxidative DNA base lesions (<xref ref-type="bibr" rid="bib5">Bandaru et al., 2002</xref>; <xref ref-type="bibr" rid="bib36">Hazra et al., 2002a</xref>; <xref ref-type="bibr" rid="bib37">Hazra et al., 2002b</xref>; <xref ref-type="bibr" rid="bib99">Takao et al., 2002</xref>), but recently they have also been implicated in the machinery that removes 5-methylcytosine (5mC) from DNA during epigenetic DNA demethylation (<xref ref-type="bibr" rid="bib69">Müller et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>; <xref ref-type="bibr" rid="bib91">Slyvka et al., 2017</xref>; <xref ref-type="bibr" rid="bib94">Spruijt et al., 2013</xref>). NEIL1 and NEIL2 are bifunctional enzymes, which not only excise the damaged base but introduce a DNA single strand break via their AP lyase activity (<xref ref-type="bibr" rid="bib36">Hazra et al., 2002a</xref>; <xref ref-type="bibr" rid="bib37">Hazra et al., 2002b</xref>), while NEIL3 is mainly a monofunctional DNA glycosylase (<xref ref-type="bibr" rid="bib57">Krokeide et al., 2013</xref>). NEIL1 is involved in prereplicative repair during S-phase (<xref ref-type="bibr" rid="bib40">Hegde et al., 2013</xref>), and NEIL2 preferentially processes oxidized bases from transcribing genes via transcription-coupled BER (<xref ref-type="bibr" rid="bib6">Banerjee et al., 2011</xref>). During epigenetic DNA demethylation NEIL1 and NEIL2 cooperate with TDG to excise oxidized 5mC intermediates generated by TET enzymes (<xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>; <xref ref-type="bibr" rid="bib91">Slyvka et al., 2017</xref>).</p><p>Mice deficient of NEIL1 are viable but display metabolic syndrome and brain dysfunction (<xref ref-type="bibr" rid="bib14">Canugovi et al., 2012</xref>; <xref ref-type="bibr" rid="bib82">Rolseth et al., 2017</xref>; <xref ref-type="bibr" rid="bib105">Vartanian et al., 2006</xref>). <italic>Neil2</italic> null mice are also viable but are susceptible to inflammation (<xref ref-type="bibr" rid="bib16">Chakraborty et al., 2015</xref>), while Neil2-deficient frog embryos display neural crest defects (<xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>). This raises the question why and how does a defect in NEIL DNA glycosylases lead to these diverse and tissue-specific phenotypes? Both epigenetic regulation and DNA damage can, in principle, impact neural crest development (<xref ref-type="bibr" rid="bib46">Hu et al., 2014</xref>; <xref ref-type="bibr" rid="bib85">Sakai and Trainor, 2016</xref>; <xref ref-type="bibr" rid="bib89">Simões-Costa and Bronner, 2015</xref>), thus what is the relative contribution of oxidative lesion control and epigenetic DNA demethylation to the NEIL phenotypes?</p><p>To address these questions we have investigated Neil-deficient <italic>Xenopus</italic> embryos and created and characterized seven mouse embryonic stem cell (mESC) lines deficient for <italic>Neil1,2,3</italic> (triple and single knockouts), <italic>AP-endonuclease 1</italic> (<italic>Apex1</italic>), <italic>Thymine DNA glycosylase</italic> (<italic>Tdg</italic>) and <italic>Neil1/Tdg</italic>. We describe a mechanism where NEIL-deficiency elicits an oxidative stress-induced, TP53-dependent DNA damage response (DDR), which induces apoptosis and impairs early cNCC specification. We show that <italic>Neil1-</italic> and <italic>Neil2</italic>-deficiency leads to accumulation of oxidative DNA damage in mitochondria. Our work demonstrates how impaired removal of oxidative lesions can lead to a selective lineage defect during embryonic development. Our study contributes to the understanding of aberrant cNCC development, the root cause of congenital craniofacial malformations (<xref ref-type="bibr" rid="bib111">Wilkie and Morriss-Kay, 2001</xref>).</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Neil2-deficiency induces a Tp53 DNA damage response in <italic>Xenopus</italic> embryos</title><p>We showed previously that in <italic>Xenopus</italic> embryos knockdown of Neil2 with an antisense morpholino oligonucleotide (<italic>neil2</italic> MO) induces head and tail abnormalities at tailbud stage, which are caused by impaired cranial neural crest cell (cNCC) specification at neurula stage (<xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>). Of note, MOs are the loss-of-function approach of choice in model systems with large maternal stores of mRNA such as <italic>Xenopus</italic>, which can be targeted by MOs but not by for example TALEN or CRISPR/Cas9 approaches (<xref ref-type="bibr" rid="bib10">Blum et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">El-Brolosy et al., 2019</xref>; <xref ref-type="bibr" rid="bib28">El-Brolosy and Stainier, 2017</xref>; <xref ref-type="bibr" rid="bib83">Rossi et al., 2015</xref>). The specificity of the <italic>neil2</italic> MO had been documented (<xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>) i) by phenocopy with a second non-overlapping morpholino, and ii) by rescue of the head and tail abnormalities with orthologous human <italic>NEIL2</italic> mRNA, which was not targeted by <italic>neil2</italic> MO (<xref ref-type="fig" rid="fig1">Figure 1A</xref>).</p><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.003</object-id><label>Figure 1.</label><caption><title>Neil2 protects against a Tp53 DNA damage response-induced apoptosis in <italic>Xenopus</italic> neuroectoderm.</title><p>(<bold>A</bold>) Phenotypes at stage 32 of <italic>Xenopus leavis</italic> embryos injected at one-cell stage with control- or <italic>neil2</italic> MO (left). Human <italic>NEIL2</italic> or bovine <italic>Preprolactin</italic> (control) mRNA was co-injected for rescue experiments (right). Scale bars, 500 µm. (<bold>B</bold>) Left, representative stainings of cranial cartilage of stage 45 embryos unilaterally injected with control or <italic>neil2</italic> MO, and control or human <italic>NEIL2</italic> mRNA for rescue purpose as indicated. PQ, palatoquadrate cartilage; ME, Meckel’s cartilage; CE, ceratohyal cartilage; BR, branchial cartilage. Arrow indicates cartilage defects in Neil2 morphants. Scale bars, 500 µM. Right, quantification of embryo malformations (n = 15, 21, 20 and 15 embryos per group, from left to right). (<bold>C</bold>) Quantification of differentially expressed genes at stage 23 of <italic>neil2</italic> MO-injected embryos. (<bold>D</bold>) Pathway enrichment analysis of <italic>neil2</italic> MO upregulated genes. Dashed line indicates the significance threshold FDR = 0.05. (<bold>E</bold>) Western blot for total Tp53 and phosphoserine (pS345) Chk1 in dissected stage 14 neural plates of control and <italic>neil2</italic> MO-injected embryos. Alpha (a-) Tubulin served as loading control. Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. Note that <italic>X. laevis</italic> Tp53 migrates at ~43 kDa. (<bold>F</bold>) qPCR expression analysis of <italic>tp53</italic> and Tp53 target genes in control- and <italic>neil2</italic> MO-injected embryos at stage 14. Expression of examined genes was normalized to <italic>h4</italic> and is presented relative to mRNA levels in control MO-injected embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (<bold>G</bold>) Western blot for pS345 Chk1 and NEIL2 in neural plates from control and <italic>neil2</italic> MO-injected stage 14 embryos co-injected with control or human <italic>NEIL2</italic> mRNA. Alpha (a-) Tubulin served as loading control. (<bold>H</bold>) Western blot for phosphoserine (pS10) histone H3 in neural plates from control and <italic>neil2</italic> MO-injected embryos at stage 15. Total histone H3 served as loading control. (<bold>I</bold>) Western blot analysis for Caspase-3 in dissected non-neural tissue and neural plates from control and <italic>neil2</italic> MO-injected stage 14 embryos co-injected with control and human <italic>NEIL2</italic> mRNA. Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows). (<bold>J</bold>) TUNEL (apoptosis) assay of stage 16 embryos injected unilaterally with <italic>neil2</italic> MO and <italic>lacZ</italic> lineage tracer (TUNEL, dark blue speckles; <italic>lacZ</italic>, light blue speckles). Scale bars, 200 µM. Right, quantification of TUNEL signal (n = 7 and 10 embryos per group, from left to right).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig1-v1.tif"/></fig><p>Proper differentiation of cNCCs is crucial for the development of craniofacial cartilage and bone structures (<xref ref-type="bibr" rid="bib85">Sakai and Trainor, 2016</xref>). Indeed, Alcian blue staining of head cartilage in <italic>neil2</italic> MO-injected embryos (single blastomere injection at 2-cell stage) revealed head cartilage, notably branchial cartilage defects at tadpole stage (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), which were rescued by simultaneous injection of human <italic>NEIL2</italic> mRNA (<xref ref-type="fig" rid="fig1">Figure 1B</xref>).</p><p>To gain insight into the underlying mechanism leading to the cNCC phenotype, we microinjected <italic>Xenopus</italic> embryos with <italic>neil2</italic> MO and carried out RNA-seq gene expression profiling at early tailbud stage (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Differential expression analysis yielded a similar number of a few hundred up- and downregulated genes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Interestingly, pathway enrichment analysis revealed significant results only for the upregulated genes with the top hits ‘Tp53 pathway’ and ‘Tp53 pathway feedback loops’ suggestive of a DNA damage response (DDR) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Indeed, protein levels of both Tp53 and its upstream regulator phospho-Chk1 (pChk1) were induced in neural plates of Neil2 morphants, indicative for a DDR (<xref ref-type="fig" rid="fig1">Figure 1E</xref>). RT-qPCR confirmed upregulation of <italic>tp53</italic> and its target genes, including <italic>ccng1</italic>, <italic>eda2r</italic>, <italic>aen</italic>, and <italic>riok3</italic> (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Furthermore, co-injection of human <italic>NEIL2</italic> mRNA rescued induced pChk1 in Neil2 morphants, ruling out an unspecific Tp53-response to MO injection (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Notably, human <italic>NEIL2</italic> mRNA also reduced basal pChk1 levels.</p><p>The DDR in Neil2 morphants induced direct Tp53 targets characteristic for apoptosis (e.g. <italic>eda2r</italic>, <italic>aen</italic>). Apoptosis is linked to cNCC developmental defects since ablation of Tp53 and concomitant block of apoptosis suppress cranial facial abnormalities in <italic>Tcof1</italic> mouse mutants (<xref ref-type="bibr" rid="bib51">Jones et al., 2008</xref>). Indeed, while cell proliferation seemed unaffected in <italic>neil2</italic> MO-injected embryos as judged by phospho-histone H3 levels (<xref ref-type="fig" rid="fig1">Figure 1H</xref>), we observed elevated Caspase-3 cleavage in dissected neural plates but less in non-neural tissue (<xref ref-type="fig" rid="fig1">Figure 1I</xref>), indicative of cNCC-specific apoptosis in Neil2 morphants. Consistently, human <italic>NEIL2</italic> mRNA injection in Neil2 morphants rescued elevated Caspase-3 cleavage to endogenous levels, corroborating the specificity of the <italic>neil2</italic> MO-induced apoptosis in neural plates. Human <italic>NEIL2</italic> mRNA injection also decreased basal levels of cleaved Caspase-3, both in neural plates and non-neural tissue (<xref ref-type="fig" rid="fig1">Figure 1I</xref>), suggesting that elevated <italic>Neil2</italic> expression protects against apoptosis in whole embryos. Whole mount TUNEL assay of unilaterally <italic>neil2</italic> MO-injected embryos confirmed elevated apoptosis by <italic>Neil2</italic>-deficiency in stage 16 embryos (<xref ref-type="fig" rid="fig1">Figure 1J</xref>). We conclude that Neil2 protects against Tp53-mediated cell apoptosis in <italic>Xenopus</italic> embryos, notably in neural plate tissue.</p></sec><sec id="s2-2"><title>Intrinsic apoptosis triggers malformations in Neil2-deficient <italic>Xenopus</italic> embryos</title><p>To test if the phenotypic malformations in Neil2-morphants are related to elevated apoptosis, we blocked the apoptosis pathway by co-injection with <italic>bcl2l1</italic> mRNA. <italic>Bcl2l1</italic> is a <italic>Xenopus</italic> homologue of mammalian BCL2, an anti-apoptotic factor acting downstream of TP53 (<xref ref-type="bibr" rid="bib41">Hemann and Lowe, 2006</xref>; <xref ref-type="bibr" rid="bib103">Tsujimoto, 1998</xref>). Importantly, <italic>bcl2l1</italic> overexpression substantially reduced phenotypic abnormalities of Neil2 morphants (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), and rescued elevated cleaved Caspase-3 levels in a dose-dependent manner (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). As expected, <italic>bcl2l1</italic> expression had no effect on endogenous nor induced Tp53 protein levels (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.004</object-id><label>Figure 2.</label><caption><title>Malformations in Neil2-deficient <italic>Xenopus</italic> embryos are mediated by intrinsic apoptosis.</title><p>(<bold>A</bold>) Top, representative phenotypes at stage 32 of <italic>Xenopus laevis</italic> embryos injected at one-cell stage with control- or <italic>neil2</italic> MO (bottom). <italic>Xenopus bcl2l1</italic> or bovine <italic>Preprolactin</italic> (control) mRNA was co-injected for rescue purpose. Scale bars, 500 µm. Bottom, quantification of embryo malformations (n = 17, 23, 24 and 14 embryos per group, from left to right). (<bold>B</bold>) Western blot for Caspase-3 (top) and Tp53 (bottom) in neural plates from control and <italic>neil2</italic> MO-injected stage 14 embryos co-injected with control or increasing amounts of <italic>bcl2l1</italic> mRNA (0.5, 1 and 2 ng). Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows). Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. (<bold>C</bold>) qPCR expression analysis of mitochondrial (mt) genes in control- and <italic>neil2</italic> MO-injected embryos at stage 14. Expression of mt-genes was normalized to <italic>h4</italic> and is presented relative to mRNA levels in control MO-injected embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig2-v1.tif"/></fig><p>BCL2 regulates the intrinsic apoptosis pathway that is associated with mitochondria and results in mitochondrial dysfunction. Upregulation of mitochondrial (mt) gene expression is a characteristic response to mitochondrial dysfunction (<xref ref-type="bibr" rid="bib39">Heddi et al., 1999</xref>; <xref ref-type="bibr" rid="bib80">Reinecke et al., 2009</xref>). Indeed, we observed increased expression of <italic>mt-Nd1,4</italic> and <italic>5</italic> (<italic>NADH dehydrogenase 1,4</italic> and <italic>5</italic>) and <italic>mt-co3</italic> (<italic>cytochrome c oxidase III</italic>) in Neil2-morphant whole embryos, supporting ongoing intrinsic apoptosis and mitochondrial dysfunction (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p></sec><sec id="s2-3"><title>Oxidative stress causes neural crest defects in Neil2-deficient <italic>Xenopus</italic> embryos</title><p>What leads to the induction of a Tp53 DDR in Neil2 morphants? NEIL2 processes oxidative base lesions induced by reactive oxygen species (ROS), such as 8-oxoguanine (8oxoG), 5-hydroxyuracil (5hU), thymine glycol, and the formamidopyrimidines FapyG and FapyA (<xref ref-type="bibr" rid="bib34">Hailer et al., 2005</xref>; <xref ref-type="bibr" rid="bib50">Jacobs and Schär, 2012</xref>), suggesting that accumulation of ROS DNA damage may account for embryonic abnormalities in Neil2-deficient <italic>Xenopus</italic> embryos. We therefore analyzed if <italic>Xenopus</italic> embryos are competent to mount a DDR following oxidative damage and if a DDR results in developmental abnormalities. Embryo treatment with the ROS producer pyocyanin (<xref ref-type="bibr" rid="bib117">Zhao et al., 2014</xref>) upregulated Tp53 and pChk1 protein (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), induced expression of <italic>tp53</italic> and its target genes (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), and elevated Caspase-3 cleavage (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Moreover, pyocyanin-treated embryos phenocopied Neil2 morphants, displaying similar head and tail abnormalities (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Neurula stage embryos showed cNCC specification defects, where the cNCC markers <italic>sox10</italic>, <italic>twist</italic>, and <italic>snail2</italic> were downregulated, while the markers <italic>sox3</italic> (pan-neural), <italic>en2</italic> (midbrain), and <italic>rx1</italic> (eye) were unaffected (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Elevated ROS levels sensitized Neil2 morphants since pyocyanin treatment of embryos injected with a sub-critical dose of <italic>neil2</italic> MO, which alone did not yield abnormalities, elicited exacerbated abnormalities (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). We conclude that <italic>Neil2</italic>-deficiency and ROS damage induce a Tp53 DDR in <italic>Xenopus</italic> embryos, leading to cNCC defects.</p><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.005</object-id><label>Figure 3.</label><caption><title>Oxidative stress causes neural crest defects in <italic>Neil2</italic>-deficient <italic>Xenopus</italic> embryos.</title><p>(<bold>A</bold>) Western blot analysis for total Tp53 and pS345 Chk1 of stage 14 embryos cultivated in 25 µM pyocyanin or DMSO (solvent). Alpha (a-) Tubulin served as loading control. Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. (<bold>B</bold>) qPCR expression analysis of <italic>tp53</italic> and Tp53 target genes in embryos at stage 14 cultivated in 25 µM pyocyanin or DMSO. Expression of examined genes was normalized to <italic>h4</italic> and is presented relative to mRNA level of DMSO treated embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (<bold>C</bold>) Western blot analysis for Caspase-3 of stage 14 embryos cultivated in 25 µM pyocyanin or DMSO (solvent). Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows). (<bold>D</bold>) Left, representative phenotypes of stage 32 embryos treated with 25 µM pyocyanin or DMSO (solvent). Right, quantification of embryo malformations (n = 25 and 15 embryos per group, from left to right). Scale bars, 500 µM. (<bold>E</bold>) Left, whole mount in situ hybridization of the indicated marker genes in stage 16 <italic>Xenopus</italic> embryos treated with 25 µM pyocyanin or DMSO (solvent). Right, quantification of embryo malformations [n = 10 and 14 embryos per group for <italic>sox10</italic>; 2 × 11 (<italic>twist</italic>); 15 and 7 (<italic>snail2</italic>); 11 and 14 (<italic>sox3</italic>); 2 × 11 (<italic>en2</italic>); 15 and 20 (<italic>rx1</italic>), from left to right]. Scale bars, 200 µM (<bold>F</bold>) Top, phenotypes of stage 39 embryos treated with 10 µM pyocyanin and injected with 15 ng/embryo of control and <italic>neil2</italic> MOs (subthreshold dose). Bottom, quantification of embryo malformations (n = 12, 11, 6 and 8 embryos per group, from left to right). Scale bars, 500 µM. (<bold>G</bold>) Top, phenotypes of stage 37 embryos injected with 40 ng/embryo of control and <italic>neil2</italic> MOs and treated with 100 µM Vitamin C. Bottom, quantification of embryo malformations (n = 16, 22, 33 and 10 embryos per group, from left to right). Scale bars, 500 µM.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig3-v1.tif"/></fig><p>Importantly, treatment of embryos with Vitamin C, a prominent antioxidant (<xref ref-type="bibr" rid="bib3">Arrigoni and De Tullio, 2002</xref>), attenuated the severe malformations of Neil2 morphants (<xref ref-type="fig" rid="fig3">Figure 3G</xref>), supporting ROS as the basis of cNCC defects in the absence of Neil2.</p></sec><sec id="s2-4"><title>A neuroectoderm-restricted Tp53 response triggers neural crest defects in <italic>Xenopus</italic> embryos</title><p>The Tp53 response to DNA damage is a widespread cellular phenomenon (<xref ref-type="bibr" rid="bib21">Ciccia and Elledge, 2010</xref>). Hence, what restricts the DDR mostly to neuroectoderm during <italic>Xenopus</italic> development? Among the most upregulated genes in Neil2 morphants was the direct Tp53 target gene <italic>cyclin-G1</italic> (<italic>ccng1</italic>) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>) (<xref ref-type="bibr" rid="bib72">Okamoto and Beach, 1994</xref>). Ccng1 interacts with Mdm2, another Tp53 target gene, and is involved in a negative feedback loop regulating Tp53 protein levels induced by DNA damage (<xref ref-type="bibr" rid="bib53">Kimura and Nojima, 2002</xref>; <xref ref-type="bibr" rid="bib71">Okamoto et al., 2002</xref>). Unilateral injection of <italic>neil2</italic> MO in <italic>Xenopus</italic> embryos with the lineage tracer β-galactosidase confirmed upregulation of <italic>ccng1</italic> on the injected side (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). <italic>Ccng1</italic> induction was restricted to the neural plate even in embryos where the lineage tracer extended to mesoderm and endoderm (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). To test if the spatial restriction of <italic>ccng1</italic> expression reflects tissue-specificity of the DDR, we provoked a systemic DDR using pyocyanin, which induced strong <italic>ccng1</italic> expression (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). As observed in Neil2 morphants, <italic>ccng1</italic> expression was spatially restricted to the neural plate. Spatial restriction of the DDR may be related to patterned expression of <italic>tp53</italic> itself, as in situ hybridization showed preferential <italic>tp53</italic> expression in the neural plate, notably in the anterior wherefrom cNCCs arise (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). High-level expression of <italic>tp53</italic> in the embryonic CNS is observed in diverse vertebrates, including zebrafish, <italic>Xenopus</italic>, chick, and mouse (<xref ref-type="bibr" rid="bib44">Hoever et al., 1997</xref>; <xref ref-type="bibr" rid="bib60">Lee et al., 2008</xref>; <xref ref-type="bibr" rid="bib81">Rinon et al., 2011</xref>).</p><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.006</object-id><label>Figure 4.</label><caption><title>A neuroectoderm-restricted Tp53 DNA damage response triggers neural crest defects in <italic>Xenopus</italic> embryos.</title><p>(<bold>A–D</bold>) Whole mount in situ hybridization for the indicated marker genes in stage 18 <italic>Xenopus</italic> embryos shown in dorsal view or as indicated. Scale bars, 200 µm. (<bold>A</bold>) Embryos were injected unilaterally with control or <italic>neil2</italic> MO (lineage-traced by co-injected <italic>lacZ</italic> mRNA, light blue speckles). (<bold>B</bold>) Embryos were treated with 25 µM pyocyanin or DMSO (solvent). (<bold>C</bold>) Expression of <italic>tp53</italic> in untreated embryos. (<bold>D</bold>) Left, embryos were unilaterally injected with control or <italic>tp53</italic> mRNA (lineage-traced by co-injected <italic>lacZ</italic> mRNA, light blue speckles). Note reduced <italic>snail2</italic> expression in neural crest cells after <italic>tp53</italic> mRNA injection (red arrow). Right, quantification of reduced <italic>snail2</italic> expression (n = 24 and 20 embryos per group, from left to right). (<bold>E</bold>) Left, phenotype of stage 32 embryos injected with control or <italic>tp53</italic> mRNA. Right, quantification of embryo malformations (n = 23 and 19 embryos per group, from left to right). Scale bars, 500 µm. (<bold>F</bold>) qPCR expression analysis of <italic>ccng1</italic> and <italic>eda2r</italic> in embryos at stage 14 injected with MOs as indicated. Expression of <italic>ccng1</italic> and <italic>eda2r</italic> was normalized to <italic>h4</italic> expression and is presented relative to control MO-injected embryos. (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (<bold>G</bold>) Left, phenotypes of stage 32 embryos injected with the indicated MOs. Scale bars, 500 µm. Right, quantification of embryo malformations (n = 25, 26, 19 and 28 embryos per group, from left to right). (<bold>H</bold>) Model for Neil2 function in <italic>Xenopus</italic> neural crest specification. During neural crest development ROS levels are increased and DNA is oxidatively damaged. Unrepaired DNA damage in the absence of Neil2 induces Tp53-DDR followed by intrinsic apoptosis and malformation of neural crest derivatives in the developing embryo. ROS, reactive oxygen species.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig4-v1.tif"/></fig><p>The results suggest that the cNCC defects in Neil2 morphants reflect a neural plate-restricted Tp53-response to oxidative DNA damage. Consistently, <italic>tp53</italic> mRNA injection downregulated the cNCC marker <italic>snail2</italic> at mid neurula stage (<xref ref-type="fig" rid="fig4">Figure 4D</xref>) and induced head and tail abnormalities (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Importantly, injection of a <italic>tp53</italic> antisense MO (<xref ref-type="bibr" rid="bib100">Takebayashi-Suzuki, 2003</xref>) not only blocked induction of Tp53 target genes in Neil2 morphants but also rescued phenotypic abnormalities substantially (<xref ref-type="fig" rid="fig4">Figure 4F–G</xref>). In sum, we propose that Neil2 protects against an oxidative DNA damage-induced Tp53 response and intrinsic apoptosis in the neural plate, thereby safeguarding cNCC development (<xref ref-type="fig" rid="fig4">Figure 4H</xref>).</p></sec><sec id="s2-5"><title>Apex1-deficiency phenocopies neural crest defects of Neil2 morphant <italic>Xenopus</italic> embryos</title><p>We asked if other BER factors have roles similar to Neil2 in <italic>Xenopus</italic> embryogenesis. APEX1 (Apurinic/Apyrimidinic Endodeoxyribonuclease 1) functions downstream of DNA glycosylases, processing the abasic (apurinic/apyrimidinic (AP)) sites produced during BER (<xref ref-type="bibr" rid="bib1">Abbotts and Madhusudan, 2010</xref>), and <italic>Apex1</italic>-deficiency in mice leads to early embryonic lethality (<xref ref-type="bibr" rid="bib114">Xanthoudakis et al., 1996</xref>). Injection of <italic>apex1</italic> MO at similar dosage as <italic>neil2</italic> MO induced severe abnormalities and early lethality confirming essentiality of Apex1 also for <italic>Xenopus</italic> embryonic development (data not shown). Interestingly, injection of reduced amounts of <italic>apex1</italic> MO phenocopied Neil2 morphants, with embryos displaying microcephaly, and reduced or absent dorsal and tail fins (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Human <italic>APEX1</italic> mRNA partially rescued the phenotype confirming specificity of the <italic>apex1</italic> MO (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). While Tp53 and phospho-Chk1 levels were unaltered (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), Tp53 target genes were induced in Apex1 morphants (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). As in Neil2 morphants, phospho-histone H3 levels were unchanged and Caspase-3 cleavage was induced (<xref ref-type="fig" rid="fig5">Figure 5D–E</xref>). Hence, the BER enzymes Neil2 and Apex1 exhibit similar functions in <italic>Xenopus</italic> neural crest development.</p><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.007</object-id><label>Figure 5.</label><caption><title><italic>Apex1</italic>-deficiency phenocopies neural crest defects of <italic>Neil2</italic>-morphant <italic>Xenopus</italic> embryos.</title><p>(<bold>A</bold>) Left, phenotypes of stage 39 embryos injected with control and <italic>apex1</italic> MO, and control and human <italic>APEX1</italic> mRNA for phenotypic rescue. Scale bars, 500 µm. Right, quantification of embryo malformation in all four injection groups (n = 34, 23, 29 and 34 embryos per group, from left to right). (<bold>B</bold>) Western blot for total Tp53 and phosphoserine (pS345) Chk1 in stage 14 control and <italic>apex1</italic> MO-injected embryos. Alpha (a-) Tubulin served as loading control. Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. (<bold>C</bold>) qPCR expression analysis of Tp53 target genes in control and <italic>apex1</italic> MO-injected embryos at stage 14. Expression of target genes was normalized to <italic>h4</italic> and is presented as relative mRNA level of control MO-injected embryos (mean ±s.d., n = 3 embryo batches consisting of 6 embryos each). (<bold>D</bold>) Western blot for phosphoserine (pS10) histone H3 from control and <italic>apex1</italic> MO-injected stage 14 embryos. Alpha (a-) Tubulin served as loading control. (<bold>E</bold>) Western blot analysis for Caspase-3 in control and <italic>apex1</italic> MO-injected stage 14 embryos. Alpha (a-) Tubulin served as loading control. Uncleaved and cleaved (active) Caspase-3 are indicated (arrows).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig5-v1.tif"/></fig></sec><sec id="s2-6"><title><italic>Neil1,2,3</italic> triple-mutant teratomas display cNCC differentiation defects</title><p>We next investigated if the role of NEIL DNA glycosylases to protect against ROS damage and safeguard neural crest development is conserved in mammals, and used mouse embryonic stem cells (mESCs) as a model system. We generated <italic>Neil1,2,3</italic> triple-knockout (TKO) mESCs by CRISPR/Cas9 genome editing (<xref ref-type="bibr" rid="bib22">Cong et al., 2013</xref>). We included NEIL3 in addition to NEIL1 and NEIL2 to account for any possible functional redundancy among the NEIL family. The biochemical and biological properties of NEIL3, however, are quite distinct from those of NEIL1 and NEIL2 (<xref ref-type="bibr" rid="bib57">Krokeide et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Liu et al., 2013</xref>). We flanked and deleted the coding region of the catalytic domains with two gRNAs for each <italic>Neil</italic> gene (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>), as validated by genotyping PCR (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Gene inactivation was further confirmed by western blot analysis for NEIL1 and RT-qPCR for <italic>Neil2</italic> and <italic>Neil3</italic> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C-D</xref>). Expression of pluripotency markers was unaltered for <italic>Pou5f1</italic> and <italic>Klf4</italic>, whereas <italic>Nanog</italic> expression was slightly reduced in <italic>Neil1,2,3</italic> TKO mESCs compared to control cells that originated from mock transfections lacking specific guide RNAs (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1E</xref>).</p><p>We subjected control and <italic>Neil</italic>-TKO mESCs to teratoma assays (<xref ref-type="bibr" rid="bib79">Ralston and Rossant, 2010</xref>) using three independent clones of each, to average-out clonal variation. When transplanted subcutaneously into immunodeficient mice, teratomas grew from all six mESC lines. Histological analysis of control and <italic>Neil</italic>-TKO teratomas revealed derivatives of ectoderm, endoderm and mesoderm in all samples confirming pluripotency of <italic>Neil</italic>-deficient mESCs (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). However, transcriptome analysis by RNA-seq uncovered thousands of genes differentially expressed between control and <italic>Neil</italic>-TKO teratomas (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Intriguingly, pathway enrichment analysis of &gt;2 fold differentially expressed genes yielded one significant hit for the up- and downregulated genes each, ‘PluriNetWork’ and ‘neural crest differentiation’, respectively (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). The term ‘PluriNetWork’ refers to the genes regulating pluripotency in mouse stem cells (<xref ref-type="bibr" rid="bib92">Som et al., 2010</xref>). We confirmed upregulation of pluripotency markers (<italic>Pou5f1, Nanog and Klf4)</italic>, suggesting incomplete silencing of the pluripotent state in <italic>Neil-</italic>TKO teratomas (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). Downregulated genes included neural crest effectors such as <italic>Pax3</italic> (<xref ref-type="bibr" rid="bib58">LaBonne and Bronner-Fraser, 1998</xref>), <italic>Tfap2b, Phox2b, Dbh, Crabp1, Neurog1</italic> and <italic>Wnt3a</italic>, besides a suite of downregulated <italic>Hox</italic> genes (<italic>Hoxa2, Hoxa3, Hoxa4, Hoxa5, Hoxa9, Hoxb1, Hoxb2, Hoxb3, Hoxb4, Hoxb5, Hoxc4, Hoxc5, Hoxd3</italic>), which are prominently expressed during neural crest/pharyngeal arch patterning, where they control head skeletal development (<xref ref-type="bibr" rid="bib102">Trainor and Krumlauf, 2001</xref>) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In fact, marker gene analysis for endoderm (<italic>Gata6</italic>), mesoderm (<italic>Eomes</italic>), neuroectoderm (<italic>Pax6, Nestin, Sox1 and Pax2</italic>), and neural crest (<italic>Pax3, Hoxa2, Tfap2b and Neurog1)</italic> indicated mild neural and severe neural crest differentiation defects (<xref ref-type="fig" rid="fig6">Figure 6E</xref> and <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>). Moreover, the TP53 target genes <italic>Ccng1, Mdm2, Sesn2</italic> and <italic>Eda2r</italic> were significantly upregulated in <italic>Neil</italic> TKO teratomas (<xref ref-type="fig" rid="fig6">Figure 6F</xref>) indicative of a TP53 DDR. These results indicate that the requirement for NEIL function in cNCC development is evolutionarily conserved between amphibians and mammals.</p><fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.008</object-id><label>Figure 6.</label><caption><title><italic>Neil1,2,3</italic>-deficient mESCs display neural crest cell differentiation defects.</title><p>(<bold>A</bold>) Histological analysis of H and E stained teratomas derived from control and <italic>Neil1,2,3</italic>-deficient mESC lines. Arrows indicate neural tube- (ectoderm), gut epithelium- (endoderm) and cartilage- (mesoderm) related structures within each section. (<bold>B</bold>) Quantification of differentially expressed genes in <italic>Neil1,2,3</italic>-deficient teratomas. (<bold>C</bold>) Pathway enrichment analysis of up- and downregulated genes in <italic>Neil1,2,3</italic>-deficient teratomas. Dashed line indicates the significance threshold FDR = 0.05. (<bold>D</bold>) qPCR expression analysis of pluripotency genes in control and <italic>Neil1,2,3</italic> triple-deficient teratomas. Marker gene expression was normalized to <italic>Tbp</italic> and is presented relative to control teraomas (mean ±s.d., n = 3 biological replicates with each three technical replicates). (<bold>E</bold>) qPCR expression analysis as in (<bold>D</bold>) but of endoderm (<italic>Gata6</italic>), mesoderm (<italic>Eomes</italic>), neuroectoderm (<italic>Pax6</italic>) and neural crest (<italic>Pax3</italic>) marker genes of control and <italic>Neil1,2,3</italic>-deficient teratomas. (<bold>F</bold>) qPCR expression analysis as in (<bold>D</bold>) but of selected TP53 target genes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.009</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Generation and characterization of <italic>Neil</italic>-deficient mESCs.</title><p>(<bold>A</bold>) Scheme of CRISPR/Cas9 targeted <italic>Neil1</italic> exon 2, <italic>Neil2</italic> exon two and <italic>Neil3</italic> exon one deletion mutations. To generate genomic deletions, two guide RNAs (underlined, PAM motif highlighted in red) per gene were designed to flank a 700 bp region harboring the coding sequence for the active site residues in NEIL1 (P2), NEIL2 (P2) and NEIL3 (V2), respectively. Coding region of translational start site including amino acid translation is depicted above the respective gene locus with the active site residue and its coding triplet in bold. Coding sequences are schematically shown by black exons and capitalized letters within the sequences. (<bold>B</bold>) Genotyping PCR of control and <italic>Neil1,2,3</italic> triple-deficient mESC lines. Primers flank a ~ 2 kb region around the coding sequence for the active site residue in each gene. Note the smaller PCR products in <italic>Neil1,2,3</italic> triple-deficient cells indicative of the expected deletions. (<bold>C</bold>) Western blot for NEIL1 in control and <italic>Neil1,2,3</italic> triple-deficient mESC lines. Alpha (a-) TUBULIN served as loading control. Relative molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. The NEIL1-specific band is indicated by an arrow. (<bold>D</bold>) qPCR expression analysis of <italic>Neil2</italic> (left panel) and <italic>Neil3</italic> (right panel) in control and <italic>Neil1,2,3</italic> triple-deficient cell lines. Expression of <italic>Neil2</italic> and <italic>Neil3</italic> was normalized to <italic>Tbp</italic> and is relative to control clone #1. (<bold>E</bold>) qPCR expression analysis of pluripotency genes in control and <italic>Neil1,2,3</italic> triple-deficient mESC lines. Expression of genes was normalized to <italic>Tbp</italic> and is relative to control mESCs (s.d., n = 3 biological replicates with each three technical replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.010</object-id><label>Figure 6—figure supplement 2.</label><caption><title>Extended neural and neural crest marker gene analysis in <italic>Neil</italic> triple-deficient teratomas.</title><p>qPCR expression analysis of marker genes for neuroectoderm (<italic>Nestin, Sox1, Pax2</italic>) and neural crest (<italic>Hoxa2, Tfapb2, Neurog1</italic>) in control and <italic>Neil1,2,3</italic> triple-deficient teratomas. Marker gene expression was normalized to <italic>Tbp</italic> and is presented relative to control teratomas (mean ±s.d., n = 3 biological replicates with each three technical replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig6-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Neural and cNCC differentiation defects are caused by <italic>Neil1</italic>- and <italic>Neil2</italic>-deficiency</title><p>To analyze the individual requirement of NEILs for neural and cNCC specification, we generated single <italic>Neil1, −2, and −3</italic> mutant mESCs (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–D</xref>). <italic>Neil</italic>-mutant mESCs were subjected to in vitro differentiation for eight days in embryoid bodies (EB) in absence or presence of retinoic acid (RA), the latter favoring neural differentiation (<xref ref-type="bibr" rid="bib9">Bibel et al., 2007</xref>). <italic>Neil3</italic> mutants were largely unaffected for all markers tested (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). In contrast, single <italic>Neil1</italic> and <italic>Neil2</italic> mutants showed significant reduction in neural crest marker (<italic>Pax3, Hoxa2, Tfapb2, Neurog1</italic>) and also pan-neuroectodermal marker (<italic>Pax6, Nestin, Sox1, Pax2</italic>) expression, while endoderm- and mesoderm markers were unaffected (<xref ref-type="fig" rid="fig7">Figure 7A</xref> and <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). Importantly, <italic>Pax3</italic> and <italic>Pax6</italic> induction during differentiation was partially restored in <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient cells by stable transfection with catalytically active- but not inactive human NEIL1- and NEIL2<italic>-</italic>encoding constructs (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A</xref>). Note that the degree of rescue was likely limited by the low expression of the transfected NEIL constructs (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3B</xref>). This rescue not only confirms specificity of the <italic>Neil</italic> knockout approach but also demonstrates that the neural and cNCC differentiation defects are not due to mutant mESCs having undergone irreversible changes/DNA damage. Instead, the rescue indicates an acute requirement for NEIL1 and NEIL2 during cNCC differentiation.</p><fig-group><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.011</object-id><label>Figure 7.</label><caption><title><italic>Neil1-</italic> and <italic>Neil2</italic>-deficient mESCs display neural crest cell differentiation defects in vitro.</title><p>(<bold>A</bold>) qPCR expression analysis of pluripotency (<italic>Pou5f1</italic>), endoderm (<italic>Gata6</italic>), mesoderm (<italic>Eomes</italic>), neuroectoderm (<italic>Pax6</italic>) and neural crest (<italic>Pax3</italic>) marker genes of the indicated <italic>Neil</italic>-mutant mESCs. Cells were differentiated into embryoid bodies (EBs) without or with retinoic acid (EBs + RA). Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to control clones in mESC state. (s.d., n = 3 biological replicates). (<bold>B</bold>) Quantification of differentially expressed genes in <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient mESCs, EBs and EBs + RA. (<bold>C</bold>) Overlap of differentially expressed genes from <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient EBs (left panel) and EBs + RA (right panel) (<bold>D</bold>) Pathway enrichment analysis of downregulated genes from <italic>Neil1</italic> (upper) and <italic>Neil2</italic> (lower panel) single-deficient EBs + RA. Dashed lines indicate the significance threshold FDR = 0.05. (<bold>E</bold>) Overlap of downregulated genes from <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient EBs + RA, and downregulated genes from <italic>Neil1,2,3-</italic>deficient teratomas.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.012</object-id><label>Figure 7—figure supplement 1.</label><caption><title>Characterization of <italic>Neil</italic> single-deficient mESCs.</title><p>(<bold>A</bold>) Genotyping PCR of control and <italic>Neil1, Neil2</italic> and <italic>Neil3</italic> single-deficient mESC lines. Primers flank a ~ 2 kb region around the coding sequence for the active site residue in each gene. Note the smaller PCR products in all single-deficient cells indicative of the expected deletions. For construction see scheme of CRISPR/Cas9 targeting in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>. (<bold>B</bold>) Western blot for NEIL1 in control and <italic>Neil1</italic> single-deficient mESC lines. Alpha (a-) TUBULIN served as loading control. Relative molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. The NEIL1-specific band is indicated by an arrow. (<bold>C</bold>) qPCR expression analysis of <italic>Neil2</italic> (left panel) and <italic>Neil3</italic> (right panel) in control and <italic>Neil2</italic> and <italic>Neil3</italic> single-deficient cell lines. Expression of <italic>Neil2</italic> and <italic>Neil3</italic> was normalized to <italic>Tbp</italic> and is relative to control clone #1. (<bold>D</bold>) qPCR expression analysis of pluripotency genes in control and <italic>Neil1,Neil2</italic> and <italic>Neil3</italic> single-deficient mESC lines. Expression of genes was normalized to <italic>Tbp</italic> and is relative to control mESCs (s.d., n = 3 biological replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.013</object-id><label>Figure 7—figure supplement 2.</label><caption><title>Extended neural and neural crest marker gene analysis in <italic>Neil</italic> single-deficient EBs + RA.</title><p>qPCR expression analysis of marker genes for neuroectoderm (<italic>Nestin, Sox1, Pax2</italic>) and neural crest (<italic>Hoxa2, Tfapb2, Neurog1</italic>) in control and <italic>Neil1 and Neil2</italic> single-deficient EBs + RA. Marker gene expression was normalized to <italic>Tbp</italic> and is presented relative to control mESCs (mean ±s.d., n = 3 biological replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig7-figsupp2-v1.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.014</object-id><label>Figure 7—figure supplement 3.</label><caption><title>Knockout specificity of <italic>Neil</italic>-deficient cells.</title><p>(<bold>A</bold>) Right, qPCR expression analysis of pluripotency (<italic>Pou5f1</italic>), endoderm (<italic>Gata6</italic>), mesoderm (<italic>Eomes</italic>), neuroectoderm (<italic>Pax6</italic>) and neural crest (<italic>Pax3</italic>) marker genes in control and <italic>Neil1</italic>-deficient mESCs, EBs and EBs + RA stably transfected with empty vector (control) or human catalytically active and inactive NEIL1 expression constructs, respectively. Left, qPCR expression analysis as on the left but in control and <italic>Neil2</italic>-deficient cells stably transfected with empty vector or human catalytically active and inactive NEIL2 expression constructs, respectively. Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to control mESCs. Fold change of <italic>Pax6</italic> and <italic>Pax3</italic> expression in NEIL-transfected EBs + RA compared to empty vector controls is depicted (s.d., n = 3 biological replicates). (<bold>B</bold>) qPCR expression analysis of murine <italic>Neil1</italic> and human <italic>NEIL1</italic> (top panel) and muirne <italic>Neil2</italic> and human <italic>NEIL2</italic> (bottom panel) in control and <italic>Neil1 or Neil2</italic>-deficient mESCs stably transfected with vector constructs as described in (<bold>A</bold>). Gene expression was normalized to <italic>Tbp</italic> and is relative to <italic>mmNeil1</italic> (top panel) <italic>and mmNeil2</italic> (bottom panel) in control mESCs (s.d., n = 3 biological replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig7-figsupp3-v1.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.015</object-id><label>Figure 7—figure supplement 4.</label><caption><title>Gene misregulation in <italic>Neil</italic>-deficient embryoid bodies.</title><p>(<bold>A</bold>) Pathway enrichment analysis of downregulated genes from <italic>Neil1</italic> (upper) and <italic>Neil2</italic> (lower panel) single-deficient EBs. Dashed lines indicate the significance threshold FDR = 0.05. (<bold>B</bold>) Overlap of downregulated genes from <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient EBs, and downregulated genes from <italic>Neil1,2,3-</italic>deficient teratoma. (<bold>C</bold>) Pathway enrichment analysis of upregulated genes from <italic>Neil1</italic> (upper) and <italic>Neil2</italic> (lower panel) single-deficient EBs + RA. Dashed lines indicate the significance threshold FDR = 0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig7-figsupp4-v1.tif"/></fig></fig-group><p>To corroborate neural and cNCC developmental defects, we carried out RNA-seq analysis of undifferentiated- and embryoid-body differentiated <italic>Neil1</italic> and <italic>Neil2</italic> single-mutant mESCs. While we observed hundreds of differentially expressed (DE) genes in mutant <italic>Neil1</italic> and <italic>Neil2</italic> mESCs (<xref ref-type="fig" rid="fig7">Figure 7B</xref> and <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>–<xref ref-type="supplementary-material" rid="supp4">4</xref>), they did not cluster when subjected to pathway enrichment analysis. Upon differentiation, the number of DE genes increased in <italic>Neil1</italic>- and <italic>Neil2-</italic>deficient cells substantially to several thousand, notably in EBs treated with RA, with up- and downregulated genes equally distributed (<xref ref-type="fig" rid="fig7">Figure 7B</xref> and <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>–<xref ref-type="supplementary-material" rid="supp4">4</xref>). The majority of DE genes overlapped between <italic>Neil1</italic> and <italic>−2</italic> mutant EBs and EBs + RA (<xref ref-type="fig" rid="fig7">Figure 7C</xref>), supporting functional commonality between NEIL1 and NEIL2. Importantly, pathway enrichment analysis of the downregulated genes revealed ‘neural crest differentiation’ as the top hit in both genotypes and in both differentiation regimes (<xref ref-type="fig" rid="fig7">Figure 7D</xref> and <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4A</xref>). Downregulated genes included the neural crest effectors <italic>Pax3, Tfap2b, Phox2b, Crabp1, Neurog1</italic> and a series of <italic>Hox</italic> genes (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>–<xref ref-type="supplementary-material" rid="supp4">4</xref>) similarly as for <italic>Neil</italic>-TKO teratomas. Downregulated genes from <italic>Neil-</italic>TKO teratomas significantly overlapped with downregulated genes from either <italic>Neil1-</italic> or <italic>Neil2</italic>-mutant EBs and EBs + RA (<xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4B</xref> and <xref ref-type="fig" rid="fig7">Figure 7E</xref>). We conclude that in vitro differentiation of <italic>Neil1-</italic> and <italic>Neil2</italic> single-mutant mESCs recapitulates neural and cNCC differentiation defects observed in <italic>Neil</italic>-TKO teratomas. Besides, the upregulated genes of both <italic>Neil1-</italic> and <italic>Neil2-</italic>deficient EBs + RA were significantly enriched for the pathway term ‘TYROBP causal network’ (<xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4C</xref>), associated with late-onset Alzheimer’s disease (<xref ref-type="bibr" rid="bib116">Zhang et al., 2013</xref>).</p></sec><sec id="s2-8"><title><italic>Apex1</italic>-deficiency phenocopies neural and cNCC differentiation defects of <italic>Neil1</italic> and <italic>Neil2</italic> mutants</title><p>We asked if <italic>Apex1</italic>-deficiency in mESC differentiation phenocopies <italic>Neil</italic>-deficiency as observed in <italic>Xenopus</italic> embryos. Hence, we generated and validated an <italic>Apex1</italic> mESC knockout-line (<italic>Apex1</italic> #46, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A–D</xref>) and subjected it to in vitro differentiation. Expression of germ layer marker genes was reduced for all tested tissues in the <italic>Apex1</italic>-mutant line (<xref ref-type="fig" rid="fig8">Figure 8A</xref>), indicating a more severe differentiation defect than in <italic>Neil1</italic> and <italic>Neil2</italic> mutants. Yet, RNA-seq analysis revealed a substantial overlap of commonly deregulated genes between <italic>Neil1</italic>-, <italic>Neil2</italic>- and <italic>Apex1</italic>-deficient EBs treated with RA (<xref ref-type="fig" rid="fig8">Figure 8B–C</xref> and <xref ref-type="supplementary-material" rid="supp5">Supplementary file 5</xref>). Moreover, pathway enrichment analysis of the downregulated genes in <italic>Apex1</italic> EBs + RA once again resulted in ‘neural crest development’ as the top hit (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). Thus, <italic>Apex1</italic>-deficient mESCs substantially phenocopy cNCC differentiation defects of <italic>Neil</italic> mutants similar to <italic>Xenopus</italic> embryos.</p><fig-group><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.016</object-id><label>Figure 8.</label><caption><title><italic>Apex1</italic>-deficiency leads to neural crest cell differentiation defects.</title><p>(<bold>A</bold>) qPCR expression analysis of pluripotency (<italic>Pou5f1</italic>), endoderm (<italic>Gata6</italic>), mesoderm (<italic>Eomes</italic>), neuroectoderm (<italic>Pax6</italic>) and neural crest (<italic>Pax3</italic>) marker genes of control and <italic>Apex1</italic>-deficient mESCs, EBs and EBs + RA. Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to control mESCs (s.d., n = 3 technical replicates). (<bold>B</bold>) Quantification of differentially expressed genes in <italic>Apex1</italic>-deficient mESCs, EBs and EBs + RA. (<bold>C</bold>) Overlap of differentially expressed genes from <italic>Neil1</italic>, <italic>Neil2 and Apex1</italic> single-deficient EBs + RA. (<bold>D</bold>) Pathway enrichment analysis of downregulated genes from <italic>Apex1</italic>-deficient EBs + RA. Dashed line indicates the significance threshold FDR = 0.05.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig8-v1.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.017</object-id><label>Figure 8—figure supplement 1.</label><caption><title>Construction and characterization of <italic>Apex1</italic>-deficient mESCs.</title><p>(<bold>A</bold>) Scheme of CRISPR/Cas9-targeted <italic>Apex1</italic> exon five deletion mutation. To generate a genomic deletion, two guide RNAs (underlined, PAM motif highlighted in red) were designed to flank a 700 bp region harboring the coding sequence for the active site residue in APEX1 (D209). Scheme shows part of exon five coding sequence including amino acid translation above gene locus with the active site residue (D209) and its coding triplet in bold. Coding regions are schematically shown by black exons. (<bold>B</bold>) Genotyping PCR of control and <italic>Apex1</italic>-deficient mESC lines. Primers flank a ~ 2.0 kb region around the coding sequence for the active site residue in APEX1. Note the smaller PCR product in the <italic>Apex1</italic>-deficient line indicative of the expected deletion. (<bold>C</bold>) Western blot for APEX1 in control and <italic>Apex1-</italic>deficient mESC lines. Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. The APEX1-specific band is indicated by an arrow. Alpha (a-) TUBULIN served as loading control. (<bold>D</bold>) qPCR expression analysis of pluripotency genes in control and <italic>Apex1</italic>-deficient mESC lines. Expression of genes was normalized to <italic>Tbp</italic> and is relative to control lines (s.d., n = 3 technical replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig8-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-9"><title>Neural and cNCC differentiation in embryoid bodies is independent of oxidative DNA demethylation</title><p>We tested if active removal of the oxidative demethylation intermediates 5fC and 5caC is required for neural and cNCC differentiation in EBs. To this end, we generated a <italic>Tdg</italic> mESC knockout-line using CRISPR/Cas9 (<italic>Tdg</italic> #25, <xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1A–C</xref>). <italic>Tdg</italic> knockout mice are embryonic lethal and <italic>Tdg</italic>-deficient mESCs fail to undergo terminal neuronal differentiation (<xref ref-type="bibr" rid="bib23">Cortázar et al., 2011</xref>). As expected, <italic>Tdg</italic>-deficient mESCs had 3–4-fold increased genomic 5fC and 5caC levels (<xref ref-type="bibr" rid="bib88">Shen et al., 2013</xref>; <xref ref-type="bibr" rid="bib95">Steinacher et al., 2019</xref>), but they showed no change in pluripotency marker expression (<xref ref-type="fig" rid="fig9s1">Figure 9—figure supplement 1D–E</xref>). Moreover, <italic>Tdg</italic>-deficient cells subjected to EB differentiation induced marker gene expression of all germ layers with no significant difference from control cells (<xref ref-type="fig" rid="fig9">Figure 9A</xref>). We conclude that oxidative <italic>Tdg</italic>-dependent DNA demethylation is not required for early cNCC differentiation in embryoid bodies.</p><fig-group><fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.018</object-id><label>Figure 9.</label><caption><title>Neural differentiation is independent of the role of NEIL DNA glycosylases in oxidative DNA demethylation.</title><p>(<bold>A</bold>) qPCR expression analysis of pluripotency (<italic>Pou5f1</italic>), endoderm (<italic>Gata6</italic>), mesoderm (<italic>Eomes</italic>), neuroectoderm (<italic>Pax6</italic>) and neural crest (<italic>Pax3</italic>) marker genes of control and <italic>Tdg</italic>-deficient mESCs, EBs, and EBs + RA. Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to control mESCs (s.d., n = 3 technical replicates). (<bold>B</bold>) qPCR expression analysis as in (<bold>A</bold>) but of control, <italic>Neil1</italic> and <italic>Tdg</italic> single- and double-deficient mESCs, EBs and EBs + RA. Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to double-control clone in mESC state (s.d., n = 3 technical replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig9-v1.tif"/></fig><fig id="fig9s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.019</object-id><label>Figure 9—figure supplement 1.</label><caption><title>Construction and characterization of <italic>TDG</italic>-deficient mESCs.</title><p>(<bold>A</bold>) Scheme of CRISPR/Cas9-targeted <italic>Tdg</italic> exon four deletion mutation. To generate a genomic deletion, two guide RNAs (underlined, PAM motif highlighted in red) were designed to flank a 700 bp region harboring the coding sequence for the active site residue in TDG (N151). Scheme shows part of exon four coding sequence including amino acid translation above the gene locus with the active site residue (N151) and its coding triplet in bold. (<bold>B</bold>) Genotyping PCR of control and <italic>Tdg</italic>-deficient mESC lines. Primers flank a ~ 2.0 kb region around the coding sequence for the active site residue in TDG. (<bold>C</bold>) Western blot for TDG in control and <italic>Tdg-</italic>deficient mESC lines. Alpha (a-) TUBULIN served as loading control. Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. The TDG-specific band is indicated by an arrow. (<bold>D</bold>) qPCR expression analysis of pluripotency genes in control and <italic>Tdg</italic>-deficient mESC lines. Expression of genes was normalized to <italic>Tbp</italic> and is relative of control lines (s.d., n = 3 technical replicates). (<bold>E</bold>) LC-MS/MS quantification of genomic 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) in control and <italic>Tdg</italic>-deficient mESC lines.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig9-figsupp1-v1.tif"/></fig><fig id="fig9s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.020</object-id><label>Figure 9—figure supplement 2.</label><caption><title>Construction and characterization of <italic>Neil1</italic>/<italic>TDG</italic> double-deficient mESCs.</title><p>(<bold>A</bold>) Genotyping PCR of control, <italic>Neil1</italic> and <italic>Tdg</italic> single- and double-deficient mESC lines as indicated. The asterisk indicates missing <italic>Tdg</italic> locus-specific PCR product in mES clone <italic>Control #4/Tdg #7</italic> probably due to a large deletion around the coding sequence for the active site residue in TDG. (<bold>B</bold>) qPCR expression analysis of <italic>Neil1</italic> in control, <italic>Neil1</italic> and <italic>Tdg</italic> single- and double-deficient mESC lines as indicated. Expression of <italic>Neil1</italic> was normalized to <italic>Tbp</italic> and is relative to clone <italic>Control #4/Control #1</italic> (s.d., n = 3 technical replicates). (<bold>C</bold>) Western blot for TDG in control, <italic>Neil1</italic> and <italic>Tdg</italic> single- and double-deficient mESC lines as indicated. Alpha (a-) TUBULIN served as loading control. Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. The TDG-specific band is indicated by an arrow. (<bold>D</bold>) LC-MS/MS quantification of genomic 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) in control, <italic>Neil1</italic> and <italic>Tdg</italic> single- and double-deficient mESC lines as indicated. (<bold>E</bold>) qPCR expression analysis of pluripotency genes in control, <italic>Neil1</italic> and <italic>Tdg</italic> single- and double-deficient mESC lines as indicated. Expression of genes was normalized to <italic>Tbp</italic> and is relative to clone <italic>Control #4/Control #1</italic> (s.d., n = 3 technical replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig9-figsupp2-v1.tif"/></fig></fig-group><p>NEIL1 and NEIL2 are involved in handover and processing of abasic sites during oxidative DNA demethylation after 5fC/5caC excision by TDG (<xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>). Since abasic sites are genotoxic, <italic>Neil</italic>-deficiency may trigger a DDR because of accumulation of unprocessed TET/TDG-demethylation intermediates. If so, preventing 5fC/5caC excision in the first place should rescue the differentiation defects in <italic>Neil</italic>-deficient cells. To block 5fC/5caC excision, we generated a <italic>Tdg</italic>-knockout mESC line in a <italic>Neil1</italic>-deficient background (<italic>Neil1</italic> #7/<italic>Tdg</italic> #11, <xref ref-type="fig" rid="fig9s2">Figure 9—figure supplement 2A–E</xref>). However, in the <italic>Neil1</italic>/<italic>Tdg</italic> double-knockout line there was no rescue of cNCC differentiation, while the <italic>Tdg</italic>-single mutant line expectedly showed normal neural and cNCC marker gene expression (<xref ref-type="fig" rid="fig9">Figure 9B</xref>). We conclude that the differentiation defects induced by deficiency of <italic>Neils</italic> are independent of a role in oxidative DNA demethylation.</p></sec><sec id="s2-10"><title>Mitochondrial oxidative DNA damage is increased in <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient cells during neural differentiation</title><p>To test if defective neural and cNCC differentiation is related to elevated oxidative DNA damage as in <italic>Xenopus</italic>, we differentiated mESCs in the presence of pyocyanin. Consistently, pyocyanin inhibited neural and cNCC gene expression upon RA-induced EB differentiation, without affecting endoderm or mesoderm differentiation (<xref ref-type="fig" rid="fig10">Figure 10A</xref>). In addition, upon differentiation, TP53 target gene expression significantly increased in presence of pyocyanin compared to mock treatment (<xref ref-type="fig" rid="fig10">Figure 10B</xref>). The results align with the observation that oxidative stress impairs cNCC differentiation (<xref ref-type="bibr" rid="bib19">Chen and Sulik, 1996</xref>; <xref ref-type="bibr" rid="bib85">Sakai and Trainor, 2016</xref>; <xref ref-type="bibr" rid="bib115">Yan et al., 2010</xref>).</p><fig id="fig10" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.021</object-id><label>Figure 10.</label><caption><title>Oxidative stress impairs cNCC differentiation in mESCs.</title><p>(<bold>A</bold>) qPCR expression analysis of pluripotency (<italic>Pou5f1</italic>), endoderm (<italic>Gata6</italic>), mesoderm (<italic>Eomes</italic>), neuroectoderm (<italic>Pax6</italic>) and neural crest (<italic>Pax3</italic>) marker genes of mock and pyocyanin-treated control mESCs, EBs and EBs + RA. Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to mock-treated mESCs (s.d., n = 3 technical replicates). (<bold>B</bold>) qPCR expression analysis as in (<bold>A</bold>) but of selected TP53 target genes of mock (DMSO) and pyocyanin-treated control mESCs, EBs and EBs + RA.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig10-v1.tif"/></fig><p>Hence, the <italic>Xenopus</italic> and mESC data converge on the conclusion that NEIL1 and NEIL2 are required to repair oxidative base lesions during early neural development. Since NEIL1 and NEIL2 localize to- and maintain genomic stability in the nucleus as well as in mitochondria (<xref ref-type="bibr" rid="bib45">Hu et al., 2005</xref>; <xref ref-type="bibr" rid="bib68">Mandal et al., 2012</xref>; <xref ref-type="bibr" rid="bib75">Prakash and Doublié, 2015</xref>; <xref ref-type="bibr" rid="bib105">Vartanian et al., 2006</xref>), this raised the question, in which of these two compartments NEILs may be required during early embryogenesis. To quantify NEIL-processed lesions, we developed a novel protocol. We isolated gDNA and mtDNA (&gt;14 fold enriched for mtDNA, <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1A</xref>), and digested it with <italic>E. coli</italic> EndoIII, a bifunctional DNA glycosylase/AP lyase that excises a similar spectrum of oxidatively damaged DNA bases as NEIL1 and NEIL2 (<xref ref-type="bibr" rid="bib25">Dizdaroglu et al., 2000</xref>). EndoIII base excision at oxidative lesions generates abasic sites (<xref ref-type="bibr" rid="bib35">Hatahet et al., 1994</xref>), which are then quantified by LC-MS/MS mass spectrometry (<xref ref-type="bibr" rid="bib78">Rahimoff et al., 2017</xref>). Since steady state levels of endogenous abasic sites in DNA are more abundant than oxidative base damages (<xref ref-type="bibr" rid="bib97">Swenberg et al., 2011</xref>) we pretreated the DNA with recombinant APEX1 prior to the EndoIII reaction in order to reduce the background from preexisting abasic sites (<xref ref-type="fig" rid="fig11">Figure 11A</xref> and <xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1B</xref>). Quantification of abasic sites on synthetic oligonucleotides mixed with known amounts of AP sites accurately matched the expected result (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1C</xref>), validating the method. We noted, though, that APEX1-treatment did not completely erase abasic sites on oligonucleotides under our reaction conditions. Similarly, EndoIII processed the oxidative damage 5hU on oligonucleotides to abasic sites, but also not completely (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1C</xref>).</p><fig-group><fig id="fig11" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.022</object-id><label>Figure 11.</label><caption><title>Oxidative mtDNA damage and mitochondrial dysfunction in <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient embryoid bodies.</title><p>(<bold>A</bold>) Workflow to quantify oxidative base lesions in DNA. Isolated genomic and mtDNA is consecutively treated with recombinant APEX1 and EndoIII to monitor endogenous EndoIII-processed oxidative base damages by LC-MS/MS. (<bold>B</bold>) LC-MS/MS quantification of base lesions as described in (<bold>A</bold>) using gDNA and mtDNA of control, <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient mESCs, EBs and EBs + RA as indicated (s.d., n = 3 biological replicates). Abasic site levels are presented in percent of total amount of nucleotides (<bold>N</bold>). (<bold>C</bold>) Left, position of the mitochondrial (mt-) genomic fragments tested for DNA damage (1-3) relative to the nucleotide annotation of the mt genome (inner circle numbers in kb). Right, mtDNA damage in mt-fragments 1–3 in <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient mESCs, EBs and EBs + RA, respectively, calculated as lesions over control in 10 kb (s.d., n = 3 biological replicates). Note, a negative value corresponds to less damage in <italic>Neil</italic>-deficient compared to control cells. (<bold>D</bold>) qPCR expression analysis of genes for oxidative phosphorylation (OXPHOS) encoded either on mitochondrial (mt-) or nuclear (n-) DNA in control, <italic>Neil1</italic> and <italic>Neil2</italic> single-mutant mESCs, EBs and EBs + RA. Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to control mESCs (s.d., n = 3 biological replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig11-v1.tif"/></fig><fig id="fig11s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.023</object-id><label>Figure 11—figure supplement 1.</label><caption><title>LC-MS/MS analysis of abasic sites in gDNA and mtDNA of <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient cells.</title><p>(<bold>A</bold>) qPCR analysis following isolation of mtDNA from mESCs, using primers specific for either genomic or mitochondrial DNA sequences. Fold enrichment was calculated by 2<sup>-(ΔΔCp)</sup> and is normalized to the gDNA isolation (s.d., n = 3 technical replicates). (<bold>B</bold>) Workflow to quantify oxidative base lesions in DNA. Isolated genomic and mtDNA is either not-treated or treated with recombinant APEX1 and EndoIII to monitor endogenous abasic sites or EndoIII-processed oxidative base damages, respectively. (<bold>C</bold>) LC-MS/MS quantification of abasic sites in synthetic oligonucleotides treated or not with APEX1 and Endonuclease (Endo) III as indicated (s.d., n = 3 technical replicates).’ Control’ corresponds to an unmodified 40 bp oligo, ‘AP + 5hU’ is a mixture of unmodified 40 bp oligo with 2% of an AP site containing- and 5% of a 5hU-containing 40 bp oligo. The theoretical expected increase of abasic sites in the mock-treated mixture over control is 0.025% of total nucleotides (<bold>N</bold>). The maximum gain of abasic sites by Endo III-treatment of the mixture is 0.063% of total N. Abasic site levels are presented in percent of total N. Note that the unmodified oligo bears a background value of 0.013% abasic site over total N. (<bold>D</bold>) LC-MS/MS-based quantification of abasic sites in gDNA from control mESCs (s.d., n = 3 technical replicates). DNA was mock treated or incubated with APEX1 with or without subsequent Endo III treatment as indicated. Abasic site levels are presented in percent of total N. Gain of abasic sites after EndoIII-treatment of APEX1-pretreated gDNA (=endogenous EndoIII-reactive base damages) is shown. (<bold>E</bold>) LC-MS/MS-based quantification of abasic sites as described in (<bold>B</bold>) without APEX1 and EndoIII-treatment (=endogenous abasic sites) using gDNA and mtDNA of control, <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient mESCs, EBs and EBs + RA as indicated (s.d., n = 3 biological replicates). Abasic site levels are presented in percent of total N.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig11-figsupp1-v1.tif"/></fig></fig-group><p>APEX1-treatment of purified gDNA from mESCs reduced endogenous abasic sites by two-fold, from ~229.000 sites per genome to ~120.000 sites per genome. Subsequent EndoIII incubation led to a statistically significant increase of ~29.000 abasic sites per genome (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1D</xref>). Thus, steady state levels of EndoIII-reactive DNA damage sites were ~8 fold lower than the level of abasic sites, in agreement with previous reports (<xref ref-type="bibr" rid="bib97">Swenberg et al., 2011</xref>). Levels of endogenous abasic sites (without APEX1/EndoIII treatment) were unaffected by <italic>Neil1-</italic> and <italic>Neil2</italic>-deficiency in gDNA and mtDNA, regardless of whether mESCs were differentiated or not (<xref ref-type="fig" rid="fig11s1">Figure 11—figure supplement 1E</xref>). Likewise, there was no significant increase in EndoIII-processed sites in gDNA from <italic>Neil1-</italic> and <italic>Neil2</italic>-knockout cells (<xref ref-type="fig" rid="fig11">Figure 11B</xref>, top). In contrast, in mtDNA from <italic>Neil1-</italic> and <italic>Neil2</italic>-deficient mESCs, EndoIII-created abasic sites were elevated only upon neural differentiation (EB + RA), but not in EBs or undifferentiated mESCs (<xref ref-type="fig" rid="fig11">Figure 11B</xref>, bottom).</p><p>We confirmed elevated mtDNA damage in <italic>Neil1-</italic> and <italic>Neil2</italic>-deficient EBs + RA by an independent method (<xref ref-type="bibr" rid="bib33">Gureev et al., 2017</xref>). Using long-range PCR, levels of DNA damage are monitored based on the fact that DNA lesions inhibit DNA polymerase and slow down accumulation of the PCR product. Therefore, the rate of product amplification is inversely proportional to the number of damaged DNA molecules. Comparing <italic>Neil</italic>-deficient to control cells, this approach revealed increased mtDNA damage in EBs treated with RA, and to lesser extend in EBs without RA (<xref ref-type="fig" rid="fig11">Figure 11C</xref>).</p><p>Moreover, as in <italic>Xenopus</italic> embryos we detected significant upregulation of mitochondrial and nuclear genes encoding components of oxidative phosphorylation as sign of mitochondrial dysfunction in <italic>Neil1</italic>- and <italic>Neil2</italic>-knockout cells, specifically under EB + RA treatment (<xref ref-type="fig" rid="fig11">Figure 11D</xref>) (<xref ref-type="bibr" rid="bib4">Babenko et al., 2018</xref>; <xref ref-type="bibr" rid="bib39">Heddi et al., 1999</xref>; <xref ref-type="bibr" rid="bib80">Reinecke et al., 2009</xref>). Together, the results suggest that NEIL1 and NEIL2 are specifically required for processing of oxidative lesions occurring in mitochondrial DNA during neural differentiation.</p></sec><sec id="s2-11"><title>Mitochondrial TP53 DDR causes neural and cNCC differentiation defects upon <italic>Neil1</italic>- and <italic>Neil2</italic>-deficiency</title><p>We asked if <italic>Neil</italic>-deficiency in mESCs elicits a DNA damage response as in <italic>Xenopus</italic> embryos. Indeed, we found a ~ 40% overlap between the 116 top TP53 target genes (<xref ref-type="bibr" rid="bib29">Fischer, 2017</xref>) and the upregulated genes in <italic>Neil1-</italic> and <italic>Neil2</italic>-mutant EBs + RA (<xref ref-type="fig" rid="fig12">Figure 12A</xref>), but no significant overlap with <italic>Neil1-</italic> and <italic>Neil2</italic>-deficient EBs and mESCs (<xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1A–B</xref>). Furthermore, differentiation of control mESCs in presence of the TP53 stabilizer NSC 146109 (<xref ref-type="bibr" rid="bib8">Berkson et al., 2005</xref>) resulted in specific neural and cNCC differentiation defects, thus mimicking <italic>Neil</italic>-deficiency (<xref ref-type="fig" rid="fig12">Figure 12B</xref>). Moreover, we tested if TP53 inhibition could rescue impaired differentiation of <italic>Neil1-</italic> and <italic>Neil2-</italic>mutant mESCs. We differentiated <italic>Neil1</italic> and <italic>Neil2</italic> single mutant mESCs in the presence of Pifithrin-α, an inhibitor of TP53 (<xref ref-type="bibr" rid="bib55">Komarov et al., 1999</xref>). Strikingly, upon Pifithrin-α treatment the neuronal marker <italic>Pax6</italic> and neural crest marker <italic>Pax3</italic> in <italic>Neil1-</italic> and <italic>Neil2</italic>-mutant EBs + RA regained expression levels of control cells, while endoderm and mesoderm differentiation was marginally inhibited in all tested genotypes (<xref ref-type="fig" rid="fig12">Figure 12C</xref>). In control EBs + RA Pifithrin-α treatment did not affect <italic>Pax6</italic> and <italic>Pax3</italic> expression. We conclude that an upregulated TP53 DDR impairs neural and cNCC differentiation in <italic>Neil1-</italic> and <italic>Neil2</italic>-mutant cells.</p><fig-group><fig id="fig12" position="float"><object-id pub-id-type="doi">10.7554/eLife.49044.024</object-id><label>Figure 12.</label><caption><title><italic>Neil</italic>-deficiency induces a TP53-mediated intrinsic apoptosis in embryoid bodies.</title><p>(<bold>A</bold>) Overlap of upregulated genes from <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient EBs + RA, and 116 direct TP53 target genes (<xref ref-type="bibr" rid="bib29">Fischer, 2017</xref>). (<bold>B</bold>) qPCR expression analysis of the indicated marker genes in mock (DMSO) and NSC 146109- (TP53 stabilizer) treated control mESCs, EBs and EBs + RA. Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to mock-treated mESCs (s.d., n = 3 technical replicates). (<bold>C</bold>) qPCR expression analysis of marker genes as in (<bold>B</bold>) in control, <italic>Neil1</italic> and <italic>Neil2</italic> single-mutant mESCs, EBs and EBs + RA treated with 50 µM Pifithrin-α or mock treated (DMSO). Expression of marker genes was normalized to <italic>Tbp</italic> and is relative to mock-treated control mESCs (s.d., n = 3 biological replicates). (<bold>D</bold>) qPCR expression analysis of <italic>Bcl-2</italic> and <italic>Bak-1</italic> in <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient mESCs, EBs and EBs + RA. Expression of both genes was normalized to <italic>Tbp</italic> and is relative to control mESC clones (s.d., n = 3 biological replicates). (<bold>E</bold>) Model for the role of NEIL1 and NEIL2 in mESC differentiation towards cNCC/neural cells. Neurogenesis is accompanied by a metabolic switch from glycolysis to oxidative phosphorylation, a concomitant increase in mass and number of mitochondria per cell and hence escalated oxidative stress. High ROS levels render neural and neural crest cells particularly vulnerable to oxidative DNA damage and thus dependent on efficient damage repair, including by NEIL1 and NEIL2. Upon NEIL-deficiency, oxidative mtDNA damage induces apoptosis impairing neural and neural crest differentiation. ROS, reactive oxygen species.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig12-v1.tif"/></fig><fig id="fig12s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.025</object-id><label>Figure 12—figure supplement 1.</label><caption><title>TP53 response in <italic>Neil</italic>-deficient cells.</title><p>(<bold>A</bold>) Overlap of upregulated genes from <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient mESCs, and 116 TP53 target genes (<xref ref-type="bibr" rid="bib29">Fischer, 2017</xref>). (<bold>B</bold>) Overlap of upregulated genes from <italic>Neil1</italic> and <italic>Neil2</italic> single-deficient EBs, and 116 TP53 target genes (<xref ref-type="bibr" rid="bib29">Fischer, 2017</xref>). (<bold>C</bold>) qPCR expression analysis of <italic>Bcl2</italic> and <italic>Bak1</italic> in control, <italic>Neil1</italic> and <italic>Neil2</italic> single-mutant mESCs, EBs and EBs + RA treated with 50 µM Pifithrin-α or mock treated (DMSO). Expression of both genes was normalized to <italic>Tbp</italic> and is relative to mock-treated control mESCs (s.d., n = 3 biological replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig12-figsupp1-v1.tif"/></fig><fig id="fig12s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.49044.026</object-id><label>Figure 12—figure supplement 2.</label><caption><title>CASPASE levels and cell cycle profiles of <italic>Neil</italic>-deficient cells.</title><p>(<bold>A</bold>) Western blot analysis for CASPASE-3 in control, <italic>Neil1</italic> and <italic>Neil2</italic>-mutant EBs and EBs + RA. Molecular weight of marker proteins [x10<sup>−3</sup>] is indicated on the left. Uncleaved and cleaved (active) CASPASE-3 are indicated. Alpha (a-) TUBULIN served as loading control. (<bold>B</bold>) Western blot analysis as in (<bold>A</bold>) but for CASPASE-7. (<bold>C</bold>) Cell cycle profiles of control, <italic>Neil1-</italic> and <italic>Neil2</italic>-mutant mESCs, EBs and EBs + RA assessed by flow cytometry analysis (s.d., n = 3 biological replicates).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-49044-fig12-figsupp2-v1.tif"/></fig></fig-group><p>Since we observed mtDNA damage accumulation and mitochondrial dysfunction in <italic>Neil1-</italic> and <italic>Neil2</italic>-deficient cells, we tested specifically for a mitochondrial TP53 DDR (<xref ref-type="bibr" rid="bib106">Vaseva and Moll, 2009</xref>) as in <italic>Xenopus</italic>. Expression of the anti-apoptotic factor <italic>Bcl2</italic> was strongly downregulated in <italic>Neil</italic>-mutant EBs and EBs + RA, while expression of <italic>Bak1</italic>, a pro-apoptotic factor of the <italic>Bcl2</italic> family (<xref ref-type="bibr" rid="bib32">Graupner et al., 2011</xref>; <xref ref-type="bibr" rid="bib103">Tsujimoto, 1998</xref>), was significantly induced in <italic>Neil</italic>-deficient EBs + RA (<xref ref-type="fig" rid="fig12">Figure 12D</xref>), consistent with an intrinsic/mitochondrial TP53 response. Pifithrin-α treatment reversed repression of <italic>Bcl2</italic> and induction of <italic>Bak1</italic> in <italic>Neil</italic>-deficient EBs + RA, confirming a TP53-dependent regulation of both genes (<xref ref-type="fig" rid="fig12s1">Figure 12—figure supplement 1C</xref>).</p><p>The apoptosis effector CASPASE-3 is induced upon- and required for mESC neural differentiation (<xref ref-type="bibr" rid="bib30">Fujita et al., 2008</xref>). Concordantly, levels of CASPASE-3 (cleaved and uncleaved) were systematically decreased in <italic>Neil</italic>-deficient EBs + RA (<xref ref-type="fig" rid="fig12s2">Figure 12—figure supplement 2A</xref>), thus different from Caspase-3-effected apoptosis in <italic>Xenopus</italic> (<xref ref-type="fig" rid="fig1">Figure 1I</xref>). Levels of CASPASE-7, the alternative effector caspase of the intrinsic apoptosis pathway (<xref ref-type="bibr" rid="bib59">Lakhani et al., 2006</xref>), were unchanged (<xref ref-type="fig" rid="fig12s2">Figure 12—figure supplement 2B</xref>).</p><p>Among the upregulated TP53-target genes in <italic>Neil</italic>-deficient EBs + RA were effectors of cell cycle arrest (e.g. <italic>Cdkn1a</italic>). We therefore tested for cell cycle differences in <italic>Neil1-</italic> and <italic>Neil2</italic>-deficient cells by flow cytometry analysis. However, while cell cycle profiles of EBs and EBs + RA were clearly distinguishable from mESCs (more G1-phase and fewer S- and G2/M-phase cells upon mESC differentiation; <xref ref-type="bibr" rid="bib110">White and Dalton, 2005</xref>), there were no significant differences in cell cycle profiles between the control and <italic>Neil1-</italic> or <italic>Neil2</italic>-deficient cells, arguing against a TP53-induced cell cycle arrest (<xref ref-type="fig" rid="fig12s2">Figure 12—figure supplement 2C</xref>). In line, cell cycle effects are also absent after forced TP53 induction in neural crest cells in mice (<xref ref-type="bibr" rid="bib11">Bowen et al., 2019</xref>).</p><p>Collectively, the results support a model in which NEIL1 and NEIL2 function as mitochondrial DNA repair glycosylases to counteract an increased oxidative stress during neurogenesis. Thereby, NEIL1 and NEIL2 protect against a mitochondrial-induced TP53-DDR and an intrinsic apoptosis pathway, and safeguard neural differentiation (<xref ref-type="fig" rid="fig12">Figure 12E</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>One-third of all congenital birth defects are craniofacial malformations that arise by perturbations in cNCC development (<xref ref-type="bibr" rid="bib85">Sakai and Trainor, 2016</xref>). Hence, understanding the environmental and genetic causes leading to perturbations of cNCC development is important for the development of potential therapeutic avenues for their prevention. The main finding of our study is the elucidation of a mechanism whereby disruption of the ubiquitous DNA glycosylases NEIL1 and NEIL2 leads to neural and cNCC differentiation defects during embryonic development. Our study indicates that cNCC defects caused by NEIL1- and NEIL2-deficiency are attributable primarily to their role in protecting against oxidative DNA lesions, in particular of the mitochondrial genome, rather than in promoting epigenetic DNA demethylation. Our study, therefore, links mitochondrial BER to neural cell differentiation.</p><p>The physiological role of NEIL1 and NEIL2 DNA glycosylases has previously been analyzed in mouse mutants. <italic>Neil1</italic> mutants present metabolic syndrome and show impaired brain function and neuronal stress resistance in adults (<xref ref-type="bibr" rid="bib14">Canugovi et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Canugovi et al., 2015</xref>; <xref ref-type="bibr" rid="bib105">Vartanian et al., 2006</xref>). <italic>Neil2</italic>-null mice are susceptible to innate inflammation (<xref ref-type="bibr" rid="bib16">Chakraborty et al., 2015</xref>). These abnormalities were accompanied by BER defects in both types of mutants. <italic>Neil1,2,3</italic> triple-mutant mice were recently reported to be viable, but mice were only analyzed- and reported negative for cancer predisposition (<xref ref-type="bibr" rid="bib82">Rolseth et al., 2017</xref>).</p><p>In contrast, we found that cNCC development showed a surprisingly specific vulnerability towards NEIL-deficiency both in <italic>Xenopus</italic> embryos (Neil2) as well as in differentiating mESCs (NEIL1 and NEIL2). Deficiency of NEIL3, which processes a different spectrum of lesions compared to NEIL1 and NEIL2 and is not found in mitochondria (<xref ref-type="bibr" rid="bib75">Prakash and Doublié, 2015</xref>), had no effect on neural and cNCC development. The cNCC abnormalities in <italic>Xenopus</italic> were mirrored in the transcriptome of differentiating <italic>Neil1-</italic> and <italic>Neil2</italic>-deficient mESCs. In <italic>Xenopus</italic> embryos and mESCs, we elucidated the mechanism as a TP53-mediated DNA damage response, which induced apoptosis in <italic>Xenopus</italic> (Caspase-3-dependent) and mouse EBs (downregulation of <italic>Bcl2</italic> and induction of <italic>Bak1</italic>) without major effects on the cell cycle in both model systems. Moreover, in <italic>Xenopus</italic> and mESCs we found that elevated ROS reduced cNCC specification, supporting a conserved mechanism whereby an oxidative DNA damage response impairs cNCC differentiation.</p><p>Similarly, <italic>Apex1</italic> mutant mESCs and Apex1 <italic>Xenopus</italic> morphants displayed cNCC differentiation defects, although gene misregulation (mESCs) and malformations (<italic>Xenopus</italic>) were more severe than in <italic>Neil</italic>-mutant mESCs and Neil2 morphants, consistent with early embryonic lethality of <italic>Apex1</italic> mutant mice (<xref ref-type="bibr" rid="bib66">Ludwig et al., 1998</xref>; <xref ref-type="bibr" rid="bib114">Xanthoudakis et al., 1996</xref>). In contrast, neither did <italic>Tdg</italic>-deficiency affect cNCC differentiation in mESCs, nor did combined <italic>Tdg/Neil1</italic>-deficiency rescue cNCC differentiation defects, arguing against oxidative DNA demethylation as the primary cause of the differentiation defect.</p><p>The question arises, why are neural and neural crest cells particularly sensitive to oxidative DNA damage? Similarly, why is the systemic oxidative stress response to pyocyanin in <italic>Xenopus</italic> embryos limited to neuroectoderm (<xref ref-type="fig" rid="fig4">Figure 4B</xref>)? Neurogenesis is accompanied by a metabolic switch from glycolysis to oxidative phosphorylation and, hence, escalated oxidative stress (<xref ref-type="bibr" rid="bib52">Khacho and Slack, 2018</xref>). High intrinsic ROS levels may render neural crest cells particularly vulnerable to oxidative DNA damage and thus dependent on efficient damage repair. Consistently, neuroectoderm expresses high levels of DNA repair factors (<xref ref-type="bibr" rid="bib2">Albino et al., 2011</xref>) and of <italic>Tp53</italic> itself (<xref ref-type="bibr" rid="bib20">Cheng et al., 1997</xref>; <xref ref-type="bibr" rid="bib43">Hoever et al., 1994</xref>; <xref ref-type="bibr" rid="bib81">Rinon et al., 2011</xref>); this study), suggesting a specific adaptation to a lesion-prone environment.</p><p>Intriguingly, we identified mitochondrial DNA as the primary target for oxidative DNA damage in the absence of NEIL1 and NEIL2 and specifically upon mESC neural differentiation. This suggests a model whereby NEIL1 and NEIL2 function to repair and protect the mitochondrial genome against oxidative damages that accompany the metabolic switch upon neural differentiation. Thereby, NEIL1 and NEIL2 shelter neural specification from an intrinsic, mitochondrial-induced apoptosis pathway (<xref ref-type="fig" rid="fig12">Figure 12E</xref>). NEIL1 and NEIL2 both localize in mitochondria besides the nucleus (<xref ref-type="bibr" rid="bib45">Hu et al., 2005</xref>; <xref ref-type="bibr" rid="bib68">Mandal et al., 2012</xref>). Moreover, <italic>Neil1</italic>-mutant mice harbor increased mtDNA damage in liver tissue, which might be related to the metabolic syndrome observed in these mice (<xref ref-type="bibr" rid="bib105">Vartanian et al., 2006</xref>). Our study therefore corroborates the physiological relevance of NEIL1 and NEIL2 in mtDNA repair and ties mitochondrial BER to cell differentiation. Similarly, the observed neural and cNCC differentiation defects of <italic>Apex1</italic>-mutant cells (<xref ref-type="fig" rid="fig8">Figure 8</xref>) and <italic>Xenopus</italic> Apex1 morphants (<xref ref-type="fig" rid="fig5">Figure 5</xref>) might partly be due to inefficient abasic site repair of mtDNA, as a truncated APEX1 is present in mitochondria (<xref ref-type="bibr" rid="bib18">Chattopadhyay, 2006</xref>).</p><p>Our findings align with studies, which documented a role of TP53 in vertebrate neural crest formation. In chick embryos, TP53 stabilization decreases cNCC differentiation, while dominant-negative TP53 increases the number of cNCC progenitors (<xref ref-type="bibr" rid="bib81">Rinon et al., 2011</xref>). TP53 activation in mouse embryos specifically causes severe neural crest defects (<xref ref-type="bibr" rid="bib11">Bowen et al., 2019</xref>; <xref ref-type="bibr" rid="bib104">Van Nostrand et al., 2014</xref>). Moreover, Treacher Collins syndrome (TCS), a congenital disorder characterized by severe cNCC and craniofacial anomalies, is caused by impaired ribosomal biogenesis due to deficiency in the Pol I transcription machinery, nucleolar dysfunction and/or rDNA damage, resulting in TP53 activation (<xref ref-type="bibr" rid="bib13">Calo et al., 2018</xref>). Consequently, partial TP53 deficiency or pharmacologic TP53 inhibition ameliorates the craniofacial defects in TCS-mutants (<xref ref-type="bibr" rid="bib51">Jones et al., 2008</xref>; <xref ref-type="bibr" rid="bib84">Sakai et al., 2016</xref>), emphasizing the role of TP53 in cNCC development. Our results support the observation that neural tissue is particularly vulnerable to <italic>Neil1</italic>-deficiency in adults and is linked to neurodegenerative disease (<xref ref-type="bibr" rid="bib14">Canugovi et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Canugovi et al., 2015</xref>; <xref ref-type="bibr" rid="bib105">Vartanian et al., 2006</xref>).</p><p>Why then do <italic>Neil1-</italic> and <italic>Neil2</italic>-mutant mice develop without obvious neural malformations? First, genetic compensation of <italic>Neil</italic>-mutants may occur via <italic>Nthl1</italic>, which has an overlapping substrate spectrum and also localizes both in the nucleus and mitochondria (<xref ref-type="bibr" rid="bib48">Ikeda et al., 2002</xref>; <xref ref-type="bibr" rid="bib50">Jacobs and Schär, 2012</xref>). Single-knockout mice deficient for <italic>Neil1</italic> and <italic>Nthl1</italic> are phenotypically inconspicuous, the combined knockout, however, is highly cancer prone, indicative of mutual compensation of both factors for oxidative DNA damage repair (<xref ref-type="bibr" rid="bib17">Chan et al., 2009</xref>). mESC differentiation in vitro may not reproduce the complexity of in utero development where transcriptomic fine-tuning can buffer genetic ablations in the developing embryo. Second, differentiating mESCs in vitro experience gas phase oxygen partial pressure (pO<sub>2</sub>) of 142 mmHg, whereas embryonic cells in vivo are exposed to pO<sub>2</sub> values of 0–30 mmHg (<xref ref-type="bibr" rid="bib74">Powers et al., 2008</xref>). Similarly, one millimeter-sized <italic>Xenopus</italic> embryos developing close to the air-aquatic interface likely experience pO<sub>2</sub> levels closer to ambient partial pressure. Hence, cNCCs in differentiating mESCs as well as frog embryos have to cope with higher pO<sub>2</sub> and hence ROS levels than is the case for mouse embryos in utero. Increased basal ROS levels might sensitize cultured cells and frog embryos when challenged by <italic>Neil</italic>-deficiency during neural and cNCC differentiation. Third, apparently none of the <italic>Neil</italic>-mutant studies has specifically investigated whether <italic>Neil</italic>-deficient mice exhibit cNCC development-related cranial malformations, which may require special bone- and cartilage staining procedures for detection. Hence, our results call for a (re-)analysis of <italic>Neil</italic>-mutant mice for cranial abnormalities possibly under high fat diet, which favors basal ROS production (<xref ref-type="bibr" rid="bib107">Vial et al., 2011</xref>).</p><p>Our findings also support the proposition that antioxidant supplementation may be beneficial for the prevention of craniofacial defects (<xref ref-type="bibr" rid="bib84">Sakai et al., 2016</xref>), since environmental factors such as alcohol and nicotine promote ROS formation (<xref ref-type="bibr" rid="bib112">Wright et al., 1999</xref>; <xref ref-type="bibr" rid="bib118">Zhao and Reece, 2005</xref>). We also note that <italic>Neil1</italic> is one of 11 genes affected in a chromosomal micro-deletion of a patient presenting craniofacial defects (<xref ref-type="bibr" rid="bib61">Li and Bodamer, 2014</xref>).</p><p>Finally, while our study demonstrates the importance of NEIL1 and NEIL2 to protect cNCCs against oxidative DNA damage, it does not exclude that NEIL1 and NEIL2 play a physiological role in TET/TDG-mediated gene regulation in other embryonic processes or adult tissues. Elucidating such direct gene-regulatory roles may require genome-wide monitoring of 5mC and its oxidation products in <italic>Neil</italic>-mutants. The here-established <italic>Neil</italic>-, <italic>Apex1-</italic> and <italic>Tdg-</italic>mutant mESCs will be useful for this and other investigations into the biology and mechanisms of BER enzymes.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th>Reagent type <break/>(species) or <break/>resource</th><th>Designation</th><th>Source or <break/>reference</th><th>Identifiers</th><th>Additional <break/>information</th></tr></thead><tbody><tr><td>Gene (<italic>Homo sapiens</italic>)</td><td><italic>NEIL1</italic></td><td>ORFeome clone collection</td><td valign="bottom">BC010876.1</td><td/></tr><tr><td>Gene (<italic>Homo sapiens</italic>)</td><td><italic>NEIL2</italic></td><td>ORFeome clone collection</td><td valign="bottom">BC013964.2</td><td/></tr><tr><td>Gene (<italic>Homo sapiens</italic>)</td><td><italic>APEX1</italic></td><td>ORFeome clone collection</td><td valign="bottom">BC008145.1</td><td/></tr><tr><td>Gene (<italic>Xenopus tropicalis</italic>)</td><td><italic>bcl2l1</italic></td><td>Dharmacon</td><td valign="bottom">MXT1765-202788918</td><td/></tr><tr><td>Strain, strain background (<italic>Xenopus laevis</italic>)</td><td valign="bottom"><italic>Xenopus leavis</italic></td><td>Nasco</td><td>not available</td><td valign="bottom"/></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a</td><td>ATCC</td><td valign="bottom">CRL-1821</td><td>murine embryonic stem cells</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Control #1</td><td>this paper</td><td/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Control #4</td><td>this paper</td><td/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Control #7</td><td>this paper</td><td/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1,2,3-/- #23</td><td>this paper</td><td/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1,2,3-/- #85</td><td>this paper</td><td/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1,2,3-/- #93</td><td>this paper</td><td/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #7</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #9</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #11</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil2-/- #1</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil2-/- #11</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil2-/- #14</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil3-/- #3</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil3-/- #23</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil3-/- #28</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Apex1-/- #46</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Tdg-/- #25</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Control #4 + Control #1</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Control #4</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #7 + Control #1</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil1-/- #7</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Control #4 + Tdg-/- #7</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Control #4</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #7 + Tdg-/- #11</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil1-/- #7</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Control #4 + pcDNA3.1_empty</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Control #4</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #7 + pcDNA3.1_empty</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil1-/- #7</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #7 + pcDNA3.1_NEIL1-2xFLAG (active)</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil1-/- #7</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil1-/- #7 + pcDNA3.1_2xFLAG-NEIL1 (inactive)</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil1-/- #7</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil2-/- #11 + pcDNA3.1_empty</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil2-/- #11</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil2-/- #11 + pcDNA3.1_NEIL2-2xFLAG (active)</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil2-/- #11</td></tr><tr><td>Cell line (<italic>Mus musculus</italic>)</td><td valign="bottom">E14TG2a clone Neil2-/- #11 + pcDNA3.1_2xFLAG-NEIL2 (inactive)</td><td>this paper</td><td valign="bottom"/><td valign="bottom">generated from E14TG2a clone Neil2-/- #11</td></tr><tr><td>Antibody</td><td valign="bottom">mouse monoclonal anti-alpha tubulin</td><td>Sigma</td><td valign="bottom">T5168</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td>rabbit polyclonal anti-NEIL1</td><td>Abcam</td><td>ab21337 (discontinued)</td><td>(1: 500)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-NEIL2</td><td valign="bottom">Abcam</td><td valign="bottom">ab124106 (discontinued)</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-APE1</td><td valign="bottom">Abcam</td><td valign="bottom">ab137708</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-phospho-Chk1 (Ser345)</td><td valign="bottom">Cell Signaling</td><td valign="bottom">#2341</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td valign="bottom">mouse monoclonal anti-p53 (X77)</td><td valign="bottom">Thermo Fisher Scientific</td><td valign="bottom">MA1-12549</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-histone H3</td><td valign="bottom">Abcam</td><td valign="bottom">ab1791</td><td valign="bottom">(1: 5000)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-histone H3 (Ser10)</td><td valign="bottom">Sigma</td><td valign="bottom">06–570</td><td valign="bottom">(1: 500)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-TDG</td><td valign="bottom">Active Motif</td><td valign="bottom">61437</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-Caspase-3</td><td valign="bottom">Cell Signaling</td><td valign="bottom">#9662</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td valign="bottom">rabbit polyclonal anti-Caspase-7</td><td valign="bottom">Cell Signaling</td><td valign="bottom">#9492</td><td valign="bottom">(1: 1000)</td></tr><tr><td>Antibody</td><td valign="bottom">HRP-coupled goat polylonal anti rabbit IgG</td><td valign="bottom">Dianova</td><td valign="bottom">111-035-144</td><td valign="bottom">(1: 10000)</td></tr><tr><td>Antibody</td><td valign="bottom">HRP-coupled goat polyclonal anti mouse IgG</td><td valign="bottom">Dianova</td><td valign="bottom">115-035-146</td><td valign="bottom">(1: 10000)</td></tr><tr><td>Recombinant DNA reagent</td><td>pCS2FLAG</td><td valign="bottom">Addgene</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_16331">Addgene_16331</ext-link></td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="bottom">pcDNA3.1(+)</td><td>Invitrogen</td><td valign="bottom">V79020</td><td/></tr><tr><td>Recombinant DNA reagent</td><td valign="bottom">pX330-U6-Chimeric_BB-CBh-hSpCas9</td><td valign="bottom">Addgene</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_42230">Addgene_42230</ext-link></td><td valign="bottom"/></tr><tr><td>Recombinant DNA reagent</td><td valign="bottom">pPGKPuro</td><td valign="bottom">Addgene</td><td valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/Addgene_11349">Addgene_11349</ext-link></td><td valign="bottom"/></tr><tr><td>Recombinant DNA reagent</td><td valign="bottom">pCS105-xp53</td><td>Stefano Piccolo</td><td>NA</td><td valign="bottom"/></tr><tr><td>Peptide, recombinant protein</td><td>APE 1</td><td>NEB</td><td>M0282</td><td valign="bottom"/></tr><tr><td>Peptide, recombinant protein</td><td>Endonuclease III (Nth)</td><td>NEB</td><td>M0268</td><td valign="bottom"/></tr><tr><td>Commercial assay or kit</td><td>RNeasy Mini Kit</td><td>Qiagen</td><td valign="bottom">74104</td><td/></tr><tr><td>Commercial assay or kit</td><td>DNeasy Blood and Tissue Kit</td><td>Qiagen</td><td valign="bottom">69504</td><td valign="bottom"/></tr><tr><td>Commercial assay or kit</td><td valign="bottom">Blood and Cell Culture DNA Midi Kit</td><td>Qiagen</td><td valign="bottom">13343</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="bottom">RNA 6000 Nano kit</td><td>Agilent</td><td>5067–1511</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="bottom">Qubit dsDNA HS Assay Kit</td><td>Invitrogen</td><td valign="bottom">Q32851</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="bottom">TruSeq RNA Sample Preparation v2 Kit</td><td>Illumna</td><td valign="bottom">RS-122–2001/RS-122–2002</td><td/></tr><tr><td>Commercial assay or kit</td><td valign="bottom">MEGAscript SP6 Transcription kit</td><td>Invitrogen</td><td valign="bottom">AM1330</td><td/></tr><tr><td>Chemical compound, drug</td><td>Pyocyanin</td><td>Sigma</td><td valign="bottom">P0046</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="bottom">L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrat</td><td>Sigma</td><td valign="bottom">A8960</td><td valign="bottom"/></tr><tr><td>Chemical compound, drug</td><td>Pifithrin α</td><td>Sigma</td><td valign="bottom">P4359</td><td/></tr><tr><td>Chemical compound, drug</td><td>NSC 146109</td><td valign="bottom">Santa Cruz Biotechnology</td><td valign="bottom">sc-203652</td><td/></tr><tr><td>Chemical compound, drug</td><td valign="bottom">2,6-Di-<italic>tert</italic>-butyl-4-methylphenol (BHT)</td><td>Sigma</td><td valign="bottom">B1378</td><td valign="bottom"/></tr><tr><td>Chemical compound, drug</td><td valign="bottom">deferoxamine mesylate</td><td>Sigma</td><td valign="bottom">D9533</td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">LightCycler 480 software</td><td>Roche</td><td valign="bottom">4994884001</td><td/></tr><tr><td>Software, algorithm</td><td valign="bottom">bcl2fastq Conversion Software v.1.8.4</td><td>Illumina</td><td><ext-link ext-link-type="uri" xlink:href="http://emea.support.illumina.com/downloads/bcl2fastq_conversion_software_184.html">http://emea.support.illumina.com/downloads/bcl2fastq_conversion_software_184.html</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td valign="bottom">FastQC</td><td>Babraham Bioinformatics</td><td><ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link></td><td/></tr><tr><td>Software, algorithm</td><td valign="bottom">STAR v.2.5.4b</td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/23104886">23104886</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td valign="bottom">Subread featureCounts v.1.5.1</td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/24227677">24227677</ext-link></td><td/><td/></tr><tr><td>Software, algorithm</td><td valign="bottom">DESeq2</td><td>PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/25516281">25516281</ext-link></td><td/><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">PANTHER</td><td valign="bottom">The Gene Ontology Resource</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://pantherdb.org">http://pantherdb.org</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">TopHat v. 2.0.9</td><td valign="bottom">Johns Hopkins University</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://ccb.jhu.edu/software/tophat/index.shtml">https://ccb.jhu.edu/software/tophat/index.shtml</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">iGenomes</td><td valign="bottom">Illumina</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://emea.support.illumina.com/sequencing/sequencing_software/igenome.html">http://emea.support.illumina.com/sequencing/sequencing_software/igenome.html</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">BioVenn</td><td valign="bottom">PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/18925949">18925949</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.biovenn.nl/">http://www.biovenn.nl/</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">WebGestalt</td><td valign="bottom">PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/28472511">28472511</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://webgestalt.org/">http://webgestalt.org/</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">HTSeq-count v. 0.5.4</td><td valign="bottom"/><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://htseq.readthedocs.io/en/release_0.11.1/">https://htseq.readthedocs.io/en/release_0.11.1/</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">Xenbase</td><td valign="bottom">PMID: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29059324">29059324</ext-link></td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="ftp://ftp.xenbase.org/pub/Genomics/JGI/Xenla9.2">ftp://ftp.xenbase.org/pub/Genomics/JGI/Xenla9.2</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">MassHunter Quantitative Analysis, v. B.05.02</td><td valign="bottom">Agilent Technologies</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.agilent.com/en/products/software-informatics/masshunter-suite/masshunter/masshunter-software">https://www.agilent.com/en/products/software-informatics/masshunter-suite/masshunter/masshunter-software</ext-link></td><td valign="bottom"/></tr><tr><td>Software, <break/>algorithm</td><td valign="bottom">FACSDiva</td><td valign="bottom">BD</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.bdbiosciences.com/en-us/instruments/research-instruments/research-software/flow-cytometry-acquisition/facsdiva-software">http://www.bdbiosciences.com/en-us/instruments/research-instruments/research-software/flow-cytometry-acquisition/facsdiva-software</ext-link></td><td valign="bottom"/></tr><tr><td>Software, algorithm</td><td valign="bottom">FlowJo software v. 10.5.3</td><td valign="bottom">BD</td><td valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo/downloads/previous-versions">https://www.flowjo.com/solutions/flowjo/downloads/previous-versions</ext-link></td><td valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Expression constructs</title><p>Human <italic>NEIL1</italic>, <italic>NEIL2</italic> and <italic>APEX1</italic> cDNAs (BC010876.1, BC013964.2 and BC008145.1, respectively) were from the ORFeome clone collection. For in vitro transcription <italic>NEIL2</italic> and <italic>APEX1</italic> cDNA was inserted into pCS2FLAG (Addgene plasmid 16331). Additionally, <italic>NEIL1</italic> and <italic>NEIL2</italic> cDNAs were inserted into pcDNA3.1(+) (Invitrogen) as C-terminal (catalytically active) and N-terminal (catalytically inactive) 2xFLAG-tag expression constructs. pCMV-Sport6-xt.bcl2l1 encoding wild type <italic>Xenopus bcl2l1</italic> was purchased from Dharmacon (MXT1765-202788918). pCS105-xp53 encoding wildtype <italic>Xenopus tp53</italic> was a kind gift from S. Piccolo (University of Padua, Italy).</p></sec><sec id="s4-2"><title>Immunoblotting</title><p>Western blot analysis of <italic>X. laevis</italic> samples was essentially as described (<xref ref-type="bibr" rid="bib54">Kirsch et al., 2017</xref>). Mouse embryoid bodies were incubated in lysate buffer (20 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 2% NP-40 and Complete Mini Protease Inhibitor Cocktail (Roche)). Lysates were cleared by centrifugation and protein concentrations were estimated by bicinchoninic acid (BCA) assay using BSA as standard followed by SDS-PAGE and western blotting. Antibodies are depicted in key resources table.</p></sec><sec id="s4-3"><title>Reverse-transcriptase coupled quantitative real time PCR (RT-qPCR)</title><p>Total RNA was prepared by RNeasy Mini Kit (Qiagen) including an on-column DNase digestion according to the manufacturer’s instructions. Complementary DNA (cDNA) was synthesized using SuperScript II reverse transcriptase (Life Technologies). Quantitative real time PCR was performed on a LightCycler 480 (Roche) in technical duplicates using the Universal ProbeLibrary technology (Roche) including the supplier’s LightCycler 480 Probes Master. Quantitative analysis was performed with LightCycler 480 software (Roche). Primer sequences and hydrolysis probe numbers are listed in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></sec><sec id="s4-4"><title><italic>X. laevis</italic> embryo manipulation and staining</title><p>Animal experiments with <italic>X. laevis</italic> were approved by state authorities (Landesuntersuchungsamt Rheinland-Pfalz, reference number 23177–07/A12-5-001). No blinding or randomization was performed. Embryos were obtained by in vitro fertilization as described (<xref ref-type="bibr" rid="bib31">Gawantka et al., 1995</xref>) and cultivated in 0.1x Barth’s solution (<xref ref-type="bibr" rid="bib108">Wang et al., 2010</xref>). Human and <italic>Xenopus</italic> expression constructs as depicted above were used as templates to generate mRNAs with the MEGAscript SP6 Transcription Kit (Invitrogen) according to the manufacturer’s instructions. Morpholino antisense oligonucleotides (MOs, see <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>) were designed to block translation of the respective gene. MOs and mRNAs were injected two times into animal blastomeres at one-cell stage with a total volume of 10 nl per embryo. For overexpression, each embryo was injected with: human <italic>NEIL2</italic> mRNA, 2 ng; <italic>Xenopus tp53</italic> mRNA, 200 pg; <italic>Xenopus bcl2l1</italic> mRNA, 2 ng. Total amounts of single MOs injected per embryo were as follows: <italic>neil2</italic> MO, 40 ng and <italic>tp53</italic> MO, 20 ng. For double MO injections, each embryo was injected with a mixture of 40 ng <italic>neil2</italic> MO and 20 ng <italic>p53</italic> MO. For cartilage staining, one blastomere of two-cell stage embryos was injected with 5 nl (total volume) of <italic>neil2</italic> MO (7.5 ng) and human <italic>NEIL2</italic> mRNA (375 pg). Control mRNA used for injections was <italic>preprolactin</italic>. For ROS induction embryos were grown in 0.1x Barth’s solution supplemented with pyocyanin (Sigma, P0046; final concentration 10–25 µM). For Vitamin C treatment embryos were grown in 0.1x Barth’s solution supplemented with 100 µM L-Ascorbic acid 2-phosphate (Sigma, A8960). Embryos were fixed at the indicated developmental stage in freshly prepared MEMFA (100 mM MOPS pH 7.4, 2 mM EGTA, 1 mM MgSO<sub>4</sub>, 4% formaldehyde) for 1 hr at RT. After fixation, embryos were washed twice in 100% ethanol at RT for 5 min and stored in 100% ethanol at −20°C. Whole mount in situ hybridization was performed as described (<xref ref-type="bibr" rid="bib12">Bradley et al., 1996</xref>). In situ hybridization probes were generated from cDNAs for <italic>X. laevis</italic> neuronal marker genes, <italic>ccng</italic> and <italic>tp53</italic> using the Dig RNA labeling Kit (Roche). For lineage tracing, <italic>lacZ</italic> mRNA was co-injected (250 pg/blastomere) and β-gal staining was performed as described (<xref ref-type="bibr" rid="bib90">Sive et al., 2000</xref>) using X-gal as substrate. Neural plates were dissected at stage 14 with Dumont No. five forceps. Cartilage staining was performed as described (<xref ref-type="bibr" rid="bib70">Nie and Bronner, 2015</xref>). TUNEL assays were carried out as previously described (<xref ref-type="bibr" rid="bib42">Hensey and Gautier, 1998</xref>). Images were taken on a Zeiss SteREO Discovery.V20 microscope.</p></sec><sec id="s4-5"><title>Cell culture</title><p>Mouse E14TG2a embryonic stem cells (mESCs) were obtained from ATCC, number CRL-1821. Identity has been authenticated by ATCC. E14TG2a were initially tested Mycoplasma-positive, decontaminated using MycoZap Elimination Reagent (Lonza) and subsequently used for the study. E14TG2a cells were cultured on plates coated with 0.1% Gelatin (Millipore) in DMEM supplemented with 15% PANSera ES FBS (PAN Biotech), 2 mM L-Glutamine, 100 µM non-essential amino acids (NEAA, Gibco), 1 mM sodium pyruvate (Gibco), 100 µM 2-mercaptoethanol (Sigma), 1000 U/ml Leukemia inhibitory factor (LIF, Millipore), 100 U/ml PEN-STREP at 37°C in 5% CO<sub>2</sub> and 20% O<sub>2</sub>.</p></sec><sec id="s4-6"><title>CRISPR/Cas9-mediated gene deletions</title><p>To generate mESCs deficient for <italic>Neil1,2,3, Neil1, Neil2, Neil3, Apex1, Tdg</italic>, and <italic>Neil1/Tdg,</italic> 1 × 10<sup>6</sup> mESCs were seeded and transfected the next day with either empty or gRNA encoding pX330-U6-Chimeric_BB-CBh-hSpCas9 (Addgene #42230) mixed with the selection plasmid pPGKPuro (Addgene #11349) using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instruction. Cells were selected with 2 µg/ml puromycin for 6 days, colonies picked, passaged and subjected to genotyping PCR using primers flanking the anticipated deletion region (see <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>). Positive clones were expanded for further analyses.</p></sec><sec id="s4-7"><title>Embryoid body (EB) differentiation</title><p>3.5 × 10<sup>6</sup> mESCs were plated on non-adherent 10 cm bacterial dishes (Greiner) in 15 ml CA medium (<xref ref-type="bibr" rid="bib9">Bibel et al., 2007</xref>). CA medium was changed every second day. For retinoic acid induced neural EB differentiation, CA medium was supplemented with all-<italic>trans</italic>-Retinoic acid (R2625, Sigma; final concentration 5 µM) at days 4 and 6 of differentiation. EBs were harvested after 8 days of differentiation. For EB differentiation in presence of ROS inducer pyocyanin (Sigma, P0046; final concentration 2 µM), TP53 stabilizer NSC 146109 (Santa Cruz Biotechnology, sc-203652; final concentration 40 nM) and TP53 inhibitor Pifithrin-α (Sigma, P4359; final concentration 50 µM) drug treatment of cells was started 24 hr prior to plating mESCs on non-adherent dishes and was continued throughout differentiation.</p><p>Stable transfection mESCs were transfected with empty vector or human <italic>NEIL1</italic> and <italic>NEIL2</italic> expressing pcDNA3.1 constructs (see ‘Expression constructs’) using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instructions. Following selection for 6 days with 500 µg/ml G-418 (Gibco) single colonies were picked, expanded in selection medium and analyzed by RT qPCR for expression of the transgene.</p></sec><sec id="s4-8"><title>Teratoma assay</title><p>Transplantation of mESCs into immunodeficient (NSG) mice, animal husbandry and tumor preparation was performed by EPO Berlin GmbH. Resulting tumors were split and either shock frozen, or formalin fixed, paraffin embedded, sectioned and stained with hematoxylin and eosin for histological analysis. Tumors from each three independent control and <italic>Neil1,2,3</italic><sup>−/−</sup> mESC lines were grown in technical triplicates.</p></sec><sec id="s4-9"><title>RNA sequencing</title><sec id="s4-9-1"><title>Frog embryos</title><p>Control MO and <italic>neil2</italic> MO-injected <italic>Xenopus laevis</italic> embryos in triplicates (n ≥ 5 per batch of embryo) at stage 23 were lysed with 700 μl Qiazol reagent and homogenized by pipetting. After 5 min incubation at room temperature, 200 μl chloroform was added and samples were shaken vigorously. RNA was isolated subsequently using a Qiagen RNeasy Mini Kit according to the manufacturer’s instructions. RNA integrity was validated using an RNA 6000 Nano kit on an Agilent 2100 Bioanalyzer. NGS library preparation was performed using Illumina's TruSeq RNA Sample Preparation v2 Kit followed the standard protocol. Libraries were prepared with a starting amount of 1 μg, amplified in 12 PCR cycles, profiled in a DNA 1000 chip on an Agilent 2100 Bioanalyzer and quantified using the Qubit dsDNA HS Assay Kit in a Qubit 2.0 Fluorometer (Life Technologies). All six libraries were pooled in equimolar ratio and sequenced on HiSeq 2000 in single read mode for 50 cycles plus additional eight cycles for the index read. Sample demultiplexing and FastQ file generation was performed using Illumina's bcl2fastq Conversion Software v.1.8.4. The raw sequence reads were quality assessed using FastQC (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) and aligned to the <italic>Xenopus laevis</italic> v.9.2 genome assembly with JGI gene annotation from Xenbase (<ext-link ext-link-type="uri" xlink:href="ftp://ftp.xenbase.org/pub/Genomics/JGI/Xenla9.2">ftp://ftp.xenbase.org/pub/Genomics/JGI/Xenla9.2</ext-link>) using STAR v.2.5.4b (<xref ref-type="bibr" rid="bib26">Dobin et al., 2013</xref>) with option ‘--outFilterMismatchNmax 2’. The mapped reads were summarised on the gene level using Subread featureCounts v.1.5.1 (<xref ref-type="bibr" rid="bib62">Liao et al., 2014</xref>) with default parameters. Differential gene expression analysis was performed with the Bioconductor package DESeq2 v.1.18.1 (<xref ref-type="bibr" rid="bib65">Love et al., 2014</xref>) following the recommended analysis workflow with independent gene filtering. Differentially expressed genes were identified using a statistical cutoff of 10% false discovery rate (FDR) and an effect size filter ‘log2 fold change (FC)’ above 0.5. Differentially expressed up- and downregulated genes at log2FC &gt;1 were subjected to pathway enrichment analysis with PANTHER (<ext-link ext-link-type="uri" xlink:href="http://pantherdb.org">http://pantherdb.org</ext-link>) using the <italic>Xenopus laevis</italic> gene symbols without L/S alloallele suffixes, background list of all DESeq2-tested genes, human pathway annotation and the default enrichment cutoff of 5% FDR.</p></sec><sec id="s4-9-2"><title>Mouse cells</title><p>Snap frozen teratomas derived from each three control and <italic>Neil1,2,3</italic><sup>−/−</sup> mESC lines in triplicates were homogenized with an Ultra-TURRAX disperser (IKA) in presence of 2 ml TRIzol reagent (Invitrogen) using ~200 mg tissue per tumor. After clearance of supernatant by centrifugation for 5 min at 12.000 x g at 4°C, 0.4 ml of chloroform was added and the solution centrifuged for 15 min at 12.000 x g at 4°C. RNA from the aqueous phase was precipitated with 1 ml isopropanol, washed with 75% ethanol, air dried and resuspended in RNase-free water. Contaminating DNA was digested with DNase I followed by an RNA cleanup (RNeasy kit, Qiagen) according to manufacturer’s instructions. Total RNA from control, <italic>Neil1</italic><sup>−/−</sup>, <italic>Neil2</italic><sup>−/−</sup> mESCs, EBs and EBs+RA in biological triplicates and <italic>Apex1</italic><sup>−/−</sup> mESCs, EBs and EBs + RA in technical duplicates was isolated using the Qiagen RNeasy Mini Kit according to the manufacturer’s instructions, including on-column DNase I digest.</p><p>RNA was quantified with a Thermo NanoDrop and quality tested on Agilent 2100 Bioanalyzer. Only samples with RIN values &gt; 9 were used for RNA-seq. NGS libraries were prepared from total RNA using the TruSeq RNA Sample Prep Kit v2 (Illumina) according to the manufacturer’s recommendations and amplified in 12 PCR cycles. Libraries were profiled in a High Sensitivity DNA chip on a 2100 Bioanalyzer and quantified using the Qubit dsDNA HS Assay Kit, in a Qubit 2.0 Fluorometer (Life Technologies). The NGS libraries were sequenced on a HiSeq 2000 Illumina sequencer, for 51 cycles plus seven cycles for the index read. Raw reads were quality assessed using FastQC (<ext-link ext-link-type="uri" xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/">https://www.bioinformatics.babraham.ac.uk/projects/</ext-link> fastqc/) and mapped to the mouse genome assembly NCBIM37/mm9 using TopHat v. 2.0.9 (<ext-link ext-link-type="uri" xlink:href="https://ccb.jhu.edu/software/tophat">https://ccb.jhu.edu/software/tophat</ext-link>) and a GTF gene annotation file from Illumina iGenomes. HTSeq-count v. 0.5.4 (<ext-link ext-link-type="uri" xlink:href="https://htseq.readthedocs.io/en/release_0.11.1/">https://htseq.readthedocs.io/en/release_0.11.1/</ext-link>) was used for summarizing the mapped reads on genes. The Bioconductor package DESeq2 (<ext-link ext-link-type="uri" xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link>) was used to identify genes with significant differential expression in <italic>Neil1,2,3</italic><sup>−/−</sup> teratomas, and <italic>Neil1</italic>, <italic>Neil2</italic> and <italic>Apex1</italic> single-knockout samples compared to the control samples with a statistical cutoff of 10% false discovery rate (FDR) and an effect size filter log2FC &gt; 0.5. Overlap of differentially expressed genes was created with BioVenn (<xref ref-type="bibr" rid="bib47">Hulsen et al., 2008</xref>). Pathway enrichment analysis was performed with WebGestalt (<xref ref-type="bibr" rid="bib109">Wang et al., 2017</xref>) using ‘Wikipathway’ as functional database with the default 5% FDR enrichment cutoff, differentially expressed up- and downregulated genes at log2FC &gt; 1 and background list of all DESeq2-tested genes.</p><p>The RNA-seq datasets have been deposited in the NCBI GEO database under accession number GSE130082.</p></sec></sec><sec id="s4-10"><title>Preparation of genomic, mitochondrial and synthetic DNA for LC-MS/MS analysis</title><p>Genomic DNA for analysis of 5mC, 5hmC, 5fC and 5caC was prepared using the DNeasy Kit (Qiagen) according to manufacturer’s instructions.</p><p>Genomic DNA for abasic site analysis was prepared with the Qiagen Blood and Cell Culture DNA Midi Kit essentially as described (<xref ref-type="bibr" rid="bib78">Rahimoff et al., 2017</xref>) but using buffers G2, QC, QF supplemented with each 400 µM of the antioxidants 2,6-Di-<italic>tert</italic>-butyl-4-methylphenol (BHT, Sigma B1378) and deferoxamine mesylate (DFOM, Sigma D9533). DNA was stored at −20°C in H<sub>2</sub>O supplemented with 40 µM BHT and DFOM.</p><p>Preparation of mtDNA was performed using the QIAprep Spin Miniprep Kit (Qiagen) following manufacturer’s instructions. Buffers P1, P2, N3, PB and PE were supplemented with 400 µM BHT and DFOM. DNA was eluted with H<sub>2</sub>O containing 40 µM BHT and DFOM. Quantitative real time PCR as described above was used to calculate the enrichment of mtDNA over gDNA by the ΔΔCp method (<xref ref-type="bibr" rid="bib77">Quispe-Tintaya et al., 2013</xref>). PCR mixture contained 1 ng of DNA and gDNA- and mtDNA-specific primers (mmActB and mmCytB, see <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref> for sequences).</p><p>Endogenous abasic sites on genomic and mtDNA (3 µg each) were processed by incubation with 20 units APE 1 (NEB, M0282) in a 50 µl reaction volume for 2 hr at 37°C. After phenol/chloroform extraction, DNA was further incubated with 20 units Endonuclease III (Nth, NEB, M0268) in a 50 µl reaction volume for 2 hr at 37°C, phenol/chloroform extracted, ethanol precipitated and resuspended in H<sub>2</sub>O supplemented with 40 µM BHT and DFOM.</p><p>Synthetic oligonucleotides were resuspended in H<sub>2</sub>O supplemented with 40 µM BHT and DFOM. The unmodified (40mer) and 5hU-containing oligo (40mer_5hU) were hybridized in 1x SSC (150 mM NaCl, 15 mM trisodium citrate, pH 7.0) to the complementary strand (40mer_complementary) in a 1:1 molar ratio. For abasic site production 500 pmoles of the single-stranded uracil-containing oligo (40mer_U) were incubated with 25 units UDG (NEB, M0280) in a 50 µl reaction volume for 30 min at 37°C. After phenol/chloroform extraction and ethanol precipitation the abasic site oligo was hybridized to the complementary strand as described above. APE 1- and Endonuclease III-treatment was performed as depicted above with 3 µg of double-stranded oligonucleotides. DNA was purified by phenol/chloroform, ethanol precipitated and resuspended in H<sub>2</sub>O supplemented with 40 µM BHT and DFOM for abasic site derivatization as outlined below. Oligonucleotide sequences are listed in <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></sec><sec id="s4-11"><title>Quantitative mass spectrometry (LC-MS/MS)</title><p>Quantification of 5mC and oxidative derivatives was carried out as described before (<xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>).</p><p>Quantification of abasic sites by LC-MS/MS was performed according to the published protocol (<xref ref-type="bibr" rid="bib78">Rahimoff et al., 2017</xref>) with specific changes: Derivatization was performed with 1–2 µg of DNA and 30 nmoles of reagent 1a for 60 min at 37°C. After an additional incubation with 30 nmoles of reagent 1a for 60 min at 37°C reaction was stopped, the DNA ethanol precipitated, dissolved in 15 µl H<sub>2</sub>O and digested as described (<xref ref-type="bibr" rid="bib86">Schomacher et al., 2016</xref>). After digest, DNA was mixed with an equal volume of isotopic standards, and 5 μL were injected for LC-MS/MS analysis. The chromatographic separation was performed on a ZORBAX SB-C18 column (Agilent, 5 μm, 2.1 ×50 mm). Elution was performed with 5 mM Ammonium acetate pH 6.9 and Acetonitrile (ACN), the flow rates were 0.4 ml/min for 0–7 min, 0.5 ml/min for 7–9 min and 0.4 ml/min for 9–10 min at 30°C with the following gradient: 0–2 min, 0% ACN; 2–5 min, 0–5% ACN; 5–9 min, 5–50% ACN; 9–10 min, 0% ACN. Transitions corresponding to dG, 9a_1, 10a_1 and their respective isotopic standards <sup>15</sup>N<sub>5</sub>-dG, 9b_1, 10b_1 were monitored (for compounds 9a_1, 9_b1, 10_a1, 10_b1 see <xref ref-type="bibr" rid="bib78">Rahimoff et al., 2017</xref>). The source‐dependent parameters were as follow: gas temperature 110°C, gas flow 19 l/min (N<sub>2</sub>), Nebulizer 25 psi, sheath gas heater 375°C, sheath gas flow 11 l/min (N<sub>2</sub>), capillary voltage 2000 V (positive mode), nozzle voltage 0 V, fragmentor voltage 300 V. Compound dependent parameters were as previously described (<xref ref-type="bibr" rid="bib78">Rahimoff et al., 2017</xref>) except that MS1 resolution for dG and <sup>15</sup>N<sub>5</sub>-dG were enhanced and MS2 was unit. For the rest of ions all MS1 and MS2 resolution were set to unit. Abasic sites were initially quantified over total dG and subsequently calculated over total N using a GC content of 42% of the mouse genome.</p></sec><sec id="s4-12"><title>Detection of mtDNA damage by quantitative PCR</title><p>Preparation of mtDNA was performed as described above. Quantitative PCR was essentially as described (<xref ref-type="bibr" rid="bib33">Gureev et al., 2017</xref>) using 500 pg of mtDNA on a LightCycler 480 (Roche) in technical duplicates. Short fragments were amplified each with 20 s, long fragments with 2 min elongation steps in 35 cycles. SYBR Green was from Sigma (S9430). Calculation of lesions per 10 kb was as described (<xref ref-type="bibr" rid="bib33">Gureev et al., 2017</xref>). For primer sequences and amplicon lengths see <xref ref-type="supplementary-material" rid="supp6">Supplementary file 6</xref>.</p></sec><sec id="s4-13"><title>Flow cytometry analysis</title><p>Cells were detached using 0.25% trypsin and washed with PBS containing 1% ESC grade FBS. Cells were fixed by adding dropwise ice-cold ethanol and subsequent incubation at −20°C for 30 min or storage at this point. For propidium iodide staining, cells were washed twice with PBS containing 0.1% ESC grade FBS and 100 µg/ml RNAse A (Qiagen). Cells were then resuspended in PBS containing 50 µg/ml propidium iodide (Sigma) according to the cell number and incubated at room temperature for 10 min in the dark. Stained cells were then analysed by the BD LSRFortessaSORP flow cytometry system using FACSDiva software. Data analysis was performed with FlowJo software v. 10.5.3 (BD).</p></sec><sec id="s4-14"><title>Statistical analysis</title><p>Data presented are displayed as arithmetic mean, error bars represent standard deviations (s.d.) of the indicated replicates. Statistical significance as shown in bar diagrams was determined by two-tailed unpaired Student’s t-test. Significance of overlapping groups of genes presented in Venn Diagrams was calculated by hypergeometric distribution (<ext-link ext-link-type="uri" xlink:href="http://nemates.org/MA/progs/overlap_stats.html">http://nemates.org/MA/progs/overlap_stats.html</ext-link>) using a total number of 17 000 expressed genes per calculation. In triple overlaps significance was calculated on the basis of commonly deregulated genes in <italic>Neil1</italic> and <italic>Neil2</italic>-deficient cells. Significances are displayed as *p&lt;0.05, **p&lt;0.01, ***p&lt;0.005. NS, not significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We are grateful for technical support by the IMB Core Facilities Genomics, Bioinformatics, Microscopy and Flow Cytometry. We thank T Dehn (IMB) for animal care taking, R Rahimoff, E Korytiakova and T Carell (LMU Munich) for LC-MS/MS reagents, and S Piccolo (University of Padua) for reagents. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) – project numbers NI286/17-1 and SFB 1361–03.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Validation, Investigation, Visualization, Methodology, Writing—original draft, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation, Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Supervision, Funding acquisition, Writing—original draft, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Animal experimentation: Animal experiments with <italic>X. laevis</italic> were approved by state authorities (Landesuntersuchungsamt Rheinland-Pfalz, reference number 23177-07/A12-5-001).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="supp1"><object-id pub-id-type="doi">10.7554/eLife.49044.027</object-id><label>Supplementary file 1.</label><caption><title>Differentially expressed genes in <italic>Neil2</italic> MO vs. control MO stage 23 <italic>Xenopus laevis</italic> embryos.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49044-supp1-v1.xlsx"/></supplementary-material><supplementary-material id="supp2"><object-id pub-id-type="doi">10.7554/eLife.49044.028</object-id><label>Supplementary file 2.</label><caption><title>Differentially expressed genes in <italic>Neil1,2,3</italic>-triple knockout compared to control teratomas.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49044-supp2-v1.xlsx"/></supplementary-material><supplementary-material id="supp3"><object-id pub-id-type="doi">10.7554/eLife.49044.029</object-id><label>Supplementary file 3.</label><caption><title>Differentially expressed genes in <italic>Neil1</italic>-knockout compared to control mESCs, EBs and EBs + RA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49044-supp3-v1.xlsx"/></supplementary-material><supplementary-material id="supp4"><object-id pub-id-type="doi">10.7554/eLife.49044.030</object-id><label>Supplementary file 4.</label><caption><title>Differentially expressed genes in <italic>Neil2</italic>-knockout compared to control mESCs, EBs and EBs + RA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49044-supp4-v1.xlsx"/></supplementary-material><supplementary-material id="supp5"><object-id pub-id-type="doi">10.7554/eLife.49044.031</object-id><label>Supplementary file 5.</label><caption><title>Differentially expressed genes in <italic>Apex1</italic>-knockout compared to control mESCs, EBs and EBs + RA.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-49044-supp5-v1.xlsx"/></supplementary-material><supplementary-material id="supp6"><object-id pub-id-type="doi">10.7554/eLife.49044.032</object-id><label>Supplementary file 6.</label><caption><title>Oligonucleotides used in this study.</title></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-49044-supp6-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.49044.033</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-49044-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>The RNA-seq datasets have been deposited in the NCBI GEO database under accession number GSE130082.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Dandan</surname><given-names>Han</given-names></name><name><surname>Lars</surname><given-names>Schomacher</given-names></name><name><surname>Katrin</surname><given-names>M. Schüle</given-names></name><name><surname>Medhavi</surname><given-names>Mallick</given-names></name><name><surname>Michael</surname><given-names>U. Musheev</given-names></name><name><surname>Emil</surname><given-names>Karaulanov</given-names></name><name><surname>Laura</surname><given-names>Krebs</given-names></name><name><surname>Annika</surname><given-names>von Seggern</given-names></name><name><surname>and</surname><given-names>Christof Niehrs</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>NEIL1 and NEIL2 DNA glycosylases protect against oxidative stress-induced inhibition of neural crest development</data-title><source>NCBI Gene Expression Omnibus</source><pub-id assigning-authority="NCBI" pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE130082">GSE130082</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abbotts</surname> <given-names>R</given-names></name><name><surname>Madhusudan</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in Cancer</article-title><source>Cancer Treatment Reviews</source><volume>36</volume><fpage>425</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2009.12.006</pub-id><pub-id pub-id-type="pmid">20056333</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albino</surname> <given-names>D</given-names></name><name><surname>Brizzolara</surname> <given-names>A</given-names></name><name><surname>Moretti</surname> <given-names>S</given-names></name><name><surname>Falugi</surname> <given-names>C</given-names></name><name><surname>Mirisola</surname> <given-names>V</given-names></name><name><surname>Scaruffi</surname> <given-names>P</given-names></name><name><surname>Di Candia</surname> <given-names>M</given-names></name><name><surname>Truini</surname> <given-names>M</given-names></name><name><surname>Coco</surname> <given-names>S</given-names></name><name><surname>Bonassi</surname> <given-names>S</given-names></name><name><surname>Tonini</surname> <given-names>GP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Gene expression profiling identifies eleven DNA repair genes down-regulated during mouse neural crest cell migration</article-title><source>The International Journal of Developmental Biology</source><volume>55</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1387/ijdb.092970da</pub-id><pub-id pub-id-type="pmid">21425081</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arrigoni</surname> <given-names>O</given-names></name><name><surname>De Tullio</surname> <given-names>MC</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Ascorbic acid: much more than just an antioxidant</article-title><source>Biochimica Et Biophysica Acta (BBA) - General Subjects</source><volume>1569</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0304-4165(01)00235-5</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babenko</surname> <given-names>VN</given-names></name><name><surname>Smagin</surname> <given-names>DA</given-names></name><name><surname>Galyamina</surname> <given-names>AG</given-names></name><name><surname>Kovalenko</surname> <given-names>IL</given-names></name><name><surname>Kudryavtseva</surname> <given-names>NN</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Altered Slc25 family gene expression as markers of mitochondrial dysfunction in brain regions under experimental mixed anxiety/depression-like disorder</article-title><source>BMC Neuroscience</source><volume>19</volume><fpage>79</fpage><pub-id pub-id-type="doi">10.1186/s12868-018-0480-6</pub-id><pub-id pub-id-type="pmid">30537945</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandaru</surname> <given-names>V</given-names></name><name><surname>Sunkara</surname> <given-names>S</given-names></name><name><surname>Wallace</surname> <given-names>SS</given-names></name><name><surname>Bond</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A novel human DNA glycosylase that removes oxidative DNA damage and is homologous to Escherichia coli endonuclease VIII</article-title><source>DNA Repair</source><volume>1</volume><fpage>517</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1016/S1568-7864(02)00036-8</pub-id><pub-id pub-id-type="pmid">12509226</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname> <given-names>D</given-names></name><name><surname>Mandal</surname> <given-names>SM</given-names></name><name><surname>Das</surname> <given-names>A</given-names></name><name><surname>Hegde</surname> <given-names>ML</given-names></name><name><surname>Das</surname> <given-names>S</given-names></name><name><surname>Bhakat</surname> <given-names>KK</given-names></name><name><surname>Boldogh</surname> <given-names>I</given-names></name><name><surname>Sarkar</surname> <given-names>PS</given-names></name><name><surname>Mitra</surname> <given-names>S</given-names></name><name><surname>Hazra</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Preferential repair of oxidized base damage in the transcribed genes of mammalian cells</article-title><source>Journal of Biological Chemistry</source><volume>286</volume><fpage>6006</fpage><lpage>6016</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.198796</pub-id><pub-id pub-id-type="pmid">21169365</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellacosa</surname> <given-names>A</given-names></name><name><surname>Drohat</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Role of base excision repair in maintaining the genetic and epigenetic integrity of CpG sites</article-title><source>DNA Repair</source><volume>32</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2015.04.011</pub-id><pub-id pub-id-type="pmid">26021671</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berkson</surname> <given-names>RG</given-names></name><name><surname>Hollick</surname> <given-names>JJ</given-names></name><name><surname>Westwood</surname> <given-names>NJ</given-names></name><name><surname>Woods</surname> <given-names>JA</given-names></name><name><surname>Lane</surname> <given-names>DP</given-names></name><name><surname>Lain</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Pilot screening programme for small molecule activators of p53</article-title><source>International Journal of Cancer</source><volume>115</volume><fpage>701</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1002/ijc.20968</pub-id><pub-id pub-id-type="pmid">15729694</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bibel</surname> <given-names>M</given-names></name><name><surname>Richter</surname> <given-names>J</given-names></name><name><surname>Lacroix</surname> <given-names>E</given-names></name><name><surname>Barde</surname> <given-names>YA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Generation of a defined and uniform population of CNS progenitors and neurons from mouse embryonic stem cells</article-title><source>Nature Protocols</source><volume>2</volume><fpage>1034</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1038/nprot.2007.147</pub-id><pub-id pub-id-type="pmid">17546008</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blum</surname> <given-names>M</given-names></name><name><surname>De Robertis</surname> <given-names>EM</given-names></name><name><surname>Wallingford</surname> <given-names>JB</given-names></name><name><surname>Niehrs</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Morpholinos: antisense and sensibility</article-title><source>Developmental Cell</source><volume>35</volume><fpage>145</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2015.09.017</pub-id><pub-id pub-id-type="pmid">26506304</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname> <given-names>ME</given-names></name><name><surname>McClendon</surname> <given-names>J</given-names></name><name><surname>Long</surname> <given-names>HK</given-names></name><name><surname>Sorayya</surname> <given-names>A</given-names></name><name><surname>Van Nostrand</surname> <given-names>JL</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name><name><surname>Attardi</surname> <given-names>LD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The spatiotemporal pattern and intensity of p53 activation dictates phenotypic diversity in p53-Driven developmental syndromes</article-title><source>Developmental Cell</source><volume>50</volume><fpage>212</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.05.015</pub-id><pub-id pub-id-type="pmid">31178404</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradley</surname> <given-names>L</given-names></name><name><surname>Wainstock</surname> <given-names>D</given-names></name><name><surname>Sive</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Positive and negative signals modulate formation of the xenopus cement gland</article-title><source>Development</source><volume>122</volume><fpage>2739</fpage><lpage>2750</lpage><pub-id pub-id-type="pmid">8787748</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calo</surname> <given-names>E</given-names></name><name><surname>Gu</surname> <given-names>B</given-names></name><name><surname>Bowen</surname> <given-names>ME</given-names></name><name><surname>Aryan</surname> <given-names>F</given-names></name><name><surname>Zalc</surname> <given-names>A</given-names></name><name><surname>Liang</surname> <given-names>J</given-names></name><name><surname>Flynn</surname> <given-names>RA</given-names></name><name><surname>Swigut</surname> <given-names>T</given-names></name><name><surname>Chang</surname> <given-names>HY</given-names></name><name><surname>Attardi</surname> <given-names>LD</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tissue-selective effects of nucleolar stress and rDNA damage in developmental disorders</article-title><source>Nature</source><volume>554</volume><fpage>112</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nature25449</pub-id><pub-id pub-id-type="pmid">29364875</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canugovi</surname> <given-names>C</given-names></name><name><surname>Yoon</surname> <given-names>JS</given-names></name><name><surname>Feldman</surname> <given-names>NH</given-names></name><name><surname>Croteau</surname> <given-names>DL</given-names></name><name><surname>Mattson</surname> <given-names>MP</given-names></name><name><surname>Bohr</surname> <given-names>VA</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endonuclease VIII-like 1 (NEIL1) promotes short-term spatial memory retention and protects from ischemic stroke-induced brain dysfunction and death in mice</article-title><source>PNAS</source><volume>109</volume><fpage>14948</fpage><lpage>14953</lpage><pub-id pub-id-type="doi">10.1073/pnas.1204156109</pub-id><pub-id pub-id-type="pmid">22927410</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canugovi</surname> <given-names>C</given-names></name><name><surname>Misiak</surname> <given-names>M</given-names></name><name><surname>Scheibye-Knudsen</surname> <given-names>M</given-names></name><name><surname>Croteau</surname> <given-names>DL</given-names></name><name><surname>Mattson</surname> <given-names>MP</given-names></name><name><surname>Bohr</surname> <given-names>VA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Loss of NEIL1 causes defects in olfactory function in mice</article-title><source>Neurobiology of Aging</source><volume>36</volume><fpage>1007</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.09.026</pub-id><pub-id pub-id-type="pmid">25448603</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chakraborty</surname> <given-names>A</given-names></name><name><surname>Wakamiya</surname> <given-names>M</given-names></name><name><surname>Venkova-Canova</surname> <given-names>T</given-names></name><name><surname>Pandita</surname> <given-names>RK</given-names></name><name><surname>Aguilera-Aguirre</surname> <given-names>L</given-names></name><name><surname>Sarker</surname> <given-names>AH</given-names></name><name><surname>Singh</surname> <given-names>DK</given-names></name><name><surname>Hosoki</surname> <given-names>K</given-names></name><name><surname>Wood</surname> <given-names>TG</given-names></name><name><surname>Sharma</surname> <given-names>G</given-names></name><name><surname>Cardenas</surname> <given-names>V</given-names></name><name><surname>Sarkar</surname> <given-names>PS</given-names></name><name><surname>Sur</surname> <given-names>S</given-names></name><name><surname>Pandita</surname> <given-names>TK</given-names></name><name><surname>Boldogh</surname> <given-names>I</given-names></name><name><surname>Hazra</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title><italic>Neil2</italic>-null mice accumulate oxidized DNA bases in the transcriptionally active sequences of the genome and are susceptible to innate inflammation</article-title><source>Journal of Biological Chemistry</source><volume>290</volume><fpage>24636</fpage><lpage>24648</lpage><pub-id pub-id-type="doi">10.1074/jbc.M115.658146</pub-id><pub-id pub-id-type="pmid">26245904</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>MK</given-names></name><name><surname>Ocampo-Hafalla</surname> <given-names>MT</given-names></name><name><surname>Vartanian</surname> <given-names>V</given-names></name><name><surname>Jaruga</surname> <given-names>P</given-names></name><name><surname>Kirkali</surname> <given-names>G</given-names></name><name><surname>Koenig</surname> <given-names>KL</given-names></name><name><surname>Brown</surname> <given-names>S</given-names></name><name><surname>Lloyd</surname> <given-names>RS</given-names></name><name><surname>Dizdaroglu</surname> <given-names>M</given-names></name><name><surname>Teebor</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Targeted deletion of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence of novel carcinogenic oxidative damage to DNA</article-title><source>DNA Repair</source><volume>8</volume><fpage>786</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2009.03.001</pub-id><pub-id pub-id-type="pmid">19346169</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chattopadhyay</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Identification and characterization of mitochondrial abasic (AP)-endonuclease in mammalian cells</article-title><source>Nucleic Acids Research</source><volume>34</volume><fpage>2067</fpage><lpage>2076</lpage><pub-id pub-id-type="doi">10.1093/nar/gkl177</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>S-yu</given-names></name><name><surname>Sulik</surname> <given-names>KK</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Free radicals and ethanol-induced cytotoxicity in neural crest cells</article-title><source>Alcoholism: Clinical and Experimental Research</source><volume>20</volume><fpage>1071</fpage><lpage>1076</lpage><pub-id pub-id-type="doi">10.1111/j.1530-0277.1996.tb01948.x</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname> <given-names>R</given-names></name><name><surname>Ford</surname> <given-names>BL</given-names></name><name><surname>O'Neal</surname> <given-names>PE</given-names></name><name><surname>Mathews</surname> <given-names>CZ</given-names></name><name><surname>Bradford</surname> <given-names>CS</given-names></name><name><surname>Thongtan</surname> <given-names>T</given-names></name><name><surname>Barnes</surname> <given-names>DW</given-names></name><name><surname>Hendricks</surname> <given-names>JD</given-names></name><name><surname>Bailey</surname> <given-names>GS</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Zebrafish (Danio rerio) p53 tumor suppressor gene: cdna sequence and expression during embryogenesis</article-title><source>Molecular Marine Biology and Biotechnology</source><volume>6</volume><fpage>88</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">9200835</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciccia</surname> <given-names>A</given-names></name><name><surname>Elledge</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The DNA damage response: making it safe to play with knives</article-title><source>Molecular Cell</source><volume>40</volume><fpage>179</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.09.019</pub-id><pub-id pub-id-type="pmid">20965415</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname> <given-names>L</given-names></name><name><surname>Ran</surname> <given-names>FA</given-names></name><name><surname>Cox</surname> <given-names>D</given-names></name><name><surname>Lin</surname> <given-names>S</given-names></name><name><surname>Barretto</surname> <given-names>R</given-names></name><name><surname>Habib</surname> <given-names>N</given-names></name><name><surname>Hsu</surname> <given-names>PD</given-names></name><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Jiang</surname> <given-names>W</given-names></name><name><surname>Marraffini</surname> <given-names>LA</given-names></name><name><surname>Zhang</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id><pub-id pub-id-type="pmid">23287718</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortázar</surname> <given-names>D</given-names></name><name><surname>Kunz</surname> <given-names>C</given-names></name><name><surname>Selfridge</surname> <given-names>J</given-names></name><name><surname>Lettieri</surname> <given-names>T</given-names></name><name><surname>Saito</surname> <given-names>Y</given-names></name><name><surname>MacDougall</surname> <given-names>E</given-names></name><name><surname>Wirz</surname> <given-names>A</given-names></name><name><surname>Schuermann</surname> <given-names>D</given-names></name><name><surname>Jacobs</surname> <given-names>AL</given-names></name><name><surname>Siegrist</surname> <given-names>F</given-names></name><name><surname>Steinacher</surname> <given-names>R</given-names></name><name><surname>Jiricny</surname> <given-names>J</given-names></name><name><surname>Bird</surname> <given-names>A</given-names></name><name><surname>Schär</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Embryonic lethal phenotype reveals a function of TDG in maintaining epigenetic stability</article-title><source>Nature</source><volume>470</volume><fpage>419</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/nature09672</pub-id><pub-id pub-id-type="pmid">21278727</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortellino</surname> <given-names>S</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Sannai</surname> <given-names>M</given-names></name><name><surname>Moore</surname> <given-names>R</given-names></name><name><surname>Caretti</surname> <given-names>E</given-names></name><name><surname>Cigliano</surname> <given-names>A</given-names></name><name><surname>Le Coz</surname> <given-names>M</given-names></name><name><surname>Devarajan</surname> <given-names>K</given-names></name><name><surname>Wessels</surname> <given-names>A</given-names></name><name><surname>Soprano</surname> <given-names>D</given-names></name><name><surname>Abramowitz</surname> <given-names>LK</given-names></name><name><surname>Bartolomei</surname> <given-names>MS</given-names></name><name><surname>Rambow</surname> <given-names>F</given-names></name><name><surname>Bassi</surname> <given-names>MR</given-names></name><name><surname>Bruno</surname> <given-names>T</given-names></name><name><surname>Fanciulli</surname> <given-names>M</given-names></name><name><surname>Renner</surname> <given-names>C</given-names></name><name><surname>Klein-Szanto</surname> <given-names>AJ</given-names></name><name><surname>Matsumoto</surname> <given-names>Y</given-names></name><name><surname>Kobi</surname> <given-names>D</given-names></name><name><surname>Davidson</surname> <given-names>I</given-names></name><name><surname>Alberti</surname> <given-names>C</given-names></name><name><surname>Larue</surname> <given-names>L</given-names></name><name><surname>Bellacosa</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair</article-title><source>Cell</source><volume>146</volume><fpage>67</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.06.020</pub-id><pub-id pub-id-type="pmid">21722948</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dizdaroglu</surname> <given-names>M</given-names></name><name><surname>Bauche</surname> <given-names>C</given-names></name><name><surname>Rodriguez</surname> <given-names>H</given-names></name><name><surname>Laval</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Novel substrates of <italic>Escherichia coli</italic> nth protein and its kinetics for excision of modified bases from DNA damaged by free radicals</article-title><source>Biochemistry</source><volume>39</volume><fpage>5586</fpage><lpage>5592</lpage><pub-id pub-id-type="doi">10.1021/bi9927787</pub-id><pub-id pub-id-type="pmid">10820032</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname> <given-names>A</given-names></name><name><surname>Davis</surname> <given-names>CA</given-names></name><name><surname>Schlesinger</surname> <given-names>F</given-names></name><name><surname>Drenkow</surname> <given-names>J</given-names></name><name><surname>Zaleski</surname> <given-names>C</given-names></name><name><surname>Jha</surname> <given-names>S</given-names></name><name><surname>Batut</surname> <given-names>P</given-names></name><name><surname>Chaisson</surname> <given-names>M</given-names></name><name><surname>Gingeras</surname> <given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Brolosy</surname> <given-names>MA</given-names></name><name><surname>Kontarakis</surname> <given-names>Z</given-names></name><name><surname>Rossi</surname> <given-names>A</given-names></name><name><surname>Kuenne</surname> <given-names>C</given-names></name><name><surname>Günther</surname> <given-names>S</given-names></name><name><surname>Fukuda</surname> <given-names>N</given-names></name><name><surname>Kikhi</surname> <given-names>K</given-names></name><name><surname>Boezio</surname> <given-names>GLM</given-names></name><name><surname>Takacs</surname> <given-names>CM</given-names></name><name><surname>Lai</surname> <given-names>SL</given-names></name><name><surname>Fukuda</surname> <given-names>R</given-names></name><name><surname>Gerri</surname> <given-names>C</given-names></name><name><surname>Giraldez</surname> <given-names>AJ</given-names></name><name><surname>Stainier</surname> <given-names>DYR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Genetic compensation triggered by mutant mRNA degradation</article-title><source>Nature</source><volume>568</volume><fpage>193</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1064-z</pub-id><pub-id pub-id-type="pmid">30944477</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Brolosy</surname> <given-names>MA</given-names></name><name><surname>Stainier</surname> <given-names>DYR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetic compensation: a phenomenon in search of mechanisms</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006780</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006780</pub-id><pub-id pub-id-type="pmid">28704371</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Census and evaluation of p53 target genes</article-title><source>Oncogene</source><volume>36</volume><fpage>3943</fpage><lpage>3956</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.502</pub-id><pub-id pub-id-type="pmid">28288132</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname> <given-names>J</given-names></name><name><surname>Crane</surname> <given-names>AM</given-names></name><name><surname>Souza</surname> <given-names>MK</given-names></name><name><surname>Dejosez</surname> <given-names>M</given-names></name><name><surname>Kyba</surname> <given-names>M</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name><name><surname>Thomson</surname> <given-names>JA</given-names></name><name><surname>Zwaka</surname> <given-names>TP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Caspase activity mediates the differentiation of embryonic stem cells</article-title><source>Cell Stem Cell</source><volume>2</volume><fpage>595</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2008.04.001</pub-id><pub-id pub-id-type="pmid">18522852</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gawantka</surname> <given-names>V</given-names></name><name><surname>Delius</surname> <given-names>H</given-names></name><name><surname>Hirschfeld</surname> <given-names>K</given-names></name><name><surname>Blumenstock</surname> <given-names>C</given-names></name><name><surname>Niehrs</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Antagonizing the Spemann organizer: role of the homeobox gene Xvent-1</article-title><source>The EMBO Journal</source><volume>14</volume><fpage>6268</fpage><lpage>6279</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1995.tb00317.x</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graupner</surname> <given-names>V</given-names></name><name><surname>Alexander</surname> <given-names>E</given-names></name><name><surname>Overkamp</surname> <given-names>T</given-names></name><name><surname>Rothfuss</surname> <given-names>O</given-names></name><name><surname>De Laurenzi</surname> <given-names>V</given-names></name><name><surname>Gillissen</surname> <given-names>BF</given-names></name><name><surname>Daniel</surname> <given-names>PT</given-names></name><name><surname>Schulze-Osthoff</surname> <given-names>K</given-names></name><name><surname>Essmann</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Differential regulation of the proapoptotic multidomain protein bak by p53 and p73 at the promoter level</article-title><source>Cell Death &amp; Differentiation</source><volume>18</volume><fpage>1130</fpage><lpage>1139</lpage><pub-id pub-id-type="doi">10.1038/cdd.2010.179</pub-id><pub-id pub-id-type="pmid">21233848</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gureev</surname> <given-names>AP</given-names></name><name><surname>Shaforostova</surname> <given-names>EA</given-names></name><name><surname>Starkov</surname> <given-names>AA</given-names></name><name><surname>Popov</surname> <given-names>VN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Simplified qPCR method for detecting excessive mtDNA damage induced by exogenous factors</article-title><source>Toxicology</source><volume>382</volume><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.tox.2017.03.010</pub-id><pub-id pub-id-type="pmid">28286206</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hailer</surname> <given-names>MK</given-names></name><name><surname>Slade</surname> <given-names>PG</given-names></name><name><surname>Martin</surname> <given-names>BD</given-names></name><name><surname>Rosenquist</surname> <given-names>TA</given-names></name><name><surname>Sugden</surname> <given-names>KD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Recognition of the oxidized lesions spiroiminodihydantoin and guanidinohydantoin in DNA by the mammalian base excision repair glycosylases NEIL1 and NEIL2</article-title><source>DNA Repair</source><volume>4</volume><fpage>41</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2004.07.006</pub-id><pub-id pub-id-type="pmid">15533836</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatahet</surname> <given-names>Z</given-names></name><name><surname>Kow</surname> <given-names>YW</given-names></name><name><surname>Purmal</surname> <given-names>AA</given-names></name><name><surname>Cunningham</surname> <given-names>RP</given-names></name><name><surname>Wallace</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>New substrates for old enzymes. 5-Hydroxy-2'-deoxycytidine and 5-hydroxy-2'-deoxyuridine are substrates for Escherichia coli endonuclease III and formamidopyrimidine DNA N-glycosylase, while 5-hydroxy-2'-deoxyuridine is a substrate for uracil DNA N-glycosylase</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>18814</fpage><lpage>18820</lpage><pub-id pub-id-type="pmid">8034633</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazra</surname> <given-names>TK</given-names></name><name><surname>Izumi</surname> <given-names>T</given-names></name><name><surname>Boldogh</surname> <given-names>I</given-names></name><name><surname>Imhoff</surname> <given-names>B</given-names></name><name><surname>Kow</surname> <given-names>YW</given-names></name><name><surname>Jaruga</surname> <given-names>P</given-names></name><name><surname>Dizdaroglu</surname> <given-names>M</given-names></name><name><surname>Mitra</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2002">2002a</year><article-title>Identification and characterization of a human DNA glycosylase for repair of modified bases in oxidatively damaged DNA</article-title><source>PNAS</source><volume>99</volume><fpage>3523</fpage><lpage>3528</lpage><pub-id pub-id-type="doi">10.1073/pnas.062053799</pub-id><pub-id pub-id-type="pmid">11904416</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazra</surname> <given-names>TK</given-names></name><name><surname>Kow</surname> <given-names>YW</given-names></name><name><surname>Hatahet</surname> <given-names>Z</given-names></name><name><surname>Imhoff</surname> <given-names>B</given-names></name><name><surname>Boldogh</surname> <given-names>I</given-names></name><name><surname>Mokkapati</surname> <given-names>SK</given-names></name><name><surname>Mitra</surname> <given-names>S</given-names></name><name><surname>Izumi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002b</year><article-title>Identification and characterization of a novel human DNA glycosylase for repair of cytosine-derived lesions</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>30417</fpage><lpage>30420</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200355200</pub-id><pub-id pub-id-type="pmid">12097317</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname> <given-names>YF</given-names></name><name><surname>Li</surname> <given-names>BZ</given-names></name><name><surname>Li</surname> <given-names>Z</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Tang</surname> <given-names>Q</given-names></name><name><surname>Ding</surname> <given-names>J</given-names></name><name><surname>Jia</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>Z</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Sun</surname> <given-names>Y</given-names></name><name><surname>Li</surname> <given-names>X</given-names></name><name><surname>Dai</surname> <given-names>Q</given-names></name><name><surname>Song</surname> <given-names>CX</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Xu</surname> <given-names>GL</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tet-Mediated formation of 5-Carboxylcytosine and its excision by TDG in mammalian DNA</article-title><source>Science</source><volume>333</volume><fpage>1303</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1126/science.1210944</pub-id><pub-id pub-id-type="pmid">21817016</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heddi</surname> <given-names>A</given-names></name><name><surname>Stepien</surname> <given-names>G</given-names></name><name><surname>Benke</surname> <given-names>PJ</given-names></name><name><surname>Wallace</surname> <given-names>DC</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Coordinate induction of energy gene expression in tissues of mitochondrial disease patients</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>22968</fpage><lpage>22976</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.33.22968</pub-id><pub-id pub-id-type="pmid">10438462</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegde</surname> <given-names>ML</given-names></name><name><surname>Hegde</surname> <given-names>PM</given-names></name><name><surname>Bellot</surname> <given-names>LJ</given-names></name><name><surname>Mandal</surname> <given-names>SM</given-names></name><name><surname>Hazra</surname> <given-names>TK</given-names></name><name><surname>Li</surname> <given-names>GM</given-names></name><name><surname>Boldogh</surname> <given-names>I</given-names></name><name><surname>Tomkinson</surname> <given-names>AE</given-names></name><name><surname>Mitra</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Prereplicative repair of oxidized bases in the human genome is mediated by NEIL1 DNA glycosylase together with replication proteins</article-title><source>PNAS</source><volume>110</volume><fpage>E3090</fpage><lpage>E3099</lpage><pub-id pub-id-type="doi">10.1073/pnas.1304231110</pub-id><pub-id pub-id-type="pmid">23898192</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hemann</surname> <given-names>MT</given-names></name><name><surname>Lowe</surname> <given-names>SW</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The p53-Bcl-2 connection</article-title><source>Cell Death &amp; Differentiation</source><volume>13</volume><fpage>1256</fpage><lpage>1259</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401962</pub-id><pub-id pub-id-type="pmid">16710363</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hensey</surname> <given-names>C</given-names></name><name><surname>Gautier</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Programmed cell death during xenopus development: a spatio-temporal analysis</article-title><source>Developmental Biology</source><volume>203</volume><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1006/dbio.1998.9028</pub-id><pub-id pub-id-type="pmid">9806771</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoever</surname> <given-names>M</given-names></name><name><surname>Clement</surname> <given-names>JH</given-names></name><name><surname>Wedlich</surname> <given-names>D</given-names></name><name><surname>Montenarh</surname> <given-names>M</given-names></name><name><surname>Knöchel</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Overexpression of wild-type p53 interferes with normal development in xenopus laevis embryos</article-title><source>Oncogene</source><volume>9</volume><fpage>109</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">8302570</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoever</surname> <given-names>M</given-names></name><name><surname>Herrmann</surname> <given-names>C</given-names></name><name><surname>Montenarh</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Biochemical properties of xenopus laevis p53</article-title><source>International Journal of Oncology</source><volume>10</volume><fpage>195</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.3892/ijo.10.1.195</pub-id><pub-id pub-id-type="pmid">21533364</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>de Souza-Pinto</surname> <given-names>NC</given-names></name><name><surname>Haraguchi</surname> <given-names>K</given-names></name><name><surname>Hogue</surname> <given-names>BA</given-names></name><name><surname>Jaruga</surname> <given-names>P</given-names></name><name><surname>Greenberg</surname> <given-names>MM</given-names></name><name><surname>Dizdaroglu</surname> <given-names>M</given-names></name><name><surname>Bohr</surname> <given-names>VA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Repair of formamidopyrimidines in DNA involves different glycosylases: role of the OGG1, NTH1, and NEIL1 enzymes</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>40544</fpage><lpage>40551</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508772200</pub-id><pub-id pub-id-type="pmid">16221681</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname> <given-names>N</given-names></name><name><surname>Strobl-Mazzulla</surname> <given-names>PH</given-names></name><name><surname>Bronner</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Epigenetic regulation in neural crest development</article-title><source>Developmental Biology</source><volume>396</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2014.09.034</pub-id><pub-id pub-id-type="pmid">25446277</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hulsen</surname> <given-names>T</given-names></name><name><surname>de Vlieg</surname> <given-names>J</given-names></name><name><surname>Alkema</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>BioVenn - a web application for the comparison and visualization of biological lists using area-proportional venn diagrams</article-title><source>BMC Genomics</source><volume>9</volume><elocation-id>488</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2164-9-488</pub-id><pub-id pub-id-type="pmid">18925949</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname> <given-names>S</given-names></name><name><surname>Kohmoto</surname> <given-names>T</given-names></name><name><surname>Tabata</surname> <given-names>R</given-names></name><name><surname>Seki</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Differential intracellular localization of the human and mouse endonuclease III homologs and analysis of the sorting signals</article-title><source>DNA Repair</source><volume>1</volume><fpage>847</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1016/S1568-7864(02)00145-3</pub-id><pub-id pub-id-type="pmid">12531031</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname> <given-names>S</given-names></name><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Dai</surname> <given-names>Q</given-names></name><name><surname>Wu</surname> <given-names>SC</given-names></name><name><surname>Collins</surname> <given-names>LB</given-names></name><name><surname>Swenberg</surname> <given-names>JA</given-names></name><name><surname>He</surname> <given-names>C</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine</article-title><source>Science</source><volume>333</volume><fpage>1300</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1126/science.1210597</pub-id><pub-id pub-id-type="pmid">21778364</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname> <given-names>AL</given-names></name><name><surname>Schär</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>DNA glycosylases: in DNA repair and beyond</article-title><source>Chromosoma</source><volume>121</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1007/s00412-011-0347-4</pub-id><pub-id pub-id-type="pmid">22048164</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>NC</given-names></name><name><surname>Lynn</surname> <given-names>ML</given-names></name><name><surname>Gaudenz</surname> <given-names>K</given-names></name><name><surname>Sakai</surname> <given-names>D</given-names></name><name><surname>Aoto</surname> <given-names>K</given-names></name><name><surname>Rey</surname> <given-names>JP</given-names></name><name><surname>Glynn</surname> <given-names>EF</given-names></name><name><surname>Ellington</surname> <given-names>L</given-names></name><name><surname>Du</surname> <given-names>C</given-names></name><name><surname>Dixon</surname> <given-names>J</given-names></name><name><surname>Dixon</surname> <given-names>MJ</given-names></name><name><surname>Trainor</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Prevention of the neurocristopathy treacher collins syndrome through inhibition of p53 function</article-title><source>Nature Medicine</source><volume>14</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1038/nm1725</pub-id><pub-id pub-id-type="pmid">18246078</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khacho</surname> <given-names>M</given-names></name><name><surname>Slack</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial dynamics in the regulation of neurogenesis: from development to the adult brain</article-title><source>Developmental Dynamics</source><volume>247</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/dvdy.24538</pub-id><pub-id pub-id-type="pmid">28643345</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kimura</surname> <given-names>SH</given-names></name><name><surname>Nojima</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein</article-title><source>Genes to Cells</source><volume>7</volume><fpage>869</fpage><lpage>880</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2443.2002.00564.x</pub-id><pub-id pub-id-type="pmid">12167164</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirsch</surname> <given-names>N</given-names></name><name><surname>Chang</surname> <given-names>LS</given-names></name><name><surname>Koch</surname> <given-names>S</given-names></name><name><surname>Glinka</surname> <given-names>A</given-names></name><name><surname>Dolde</surname> <given-names>C</given-names></name><name><surname>Colozza</surname> <given-names>G</given-names></name><name><surname>Benitez</surname> <given-names>MDJ</given-names></name><name><surname>De Robertis</surname> <given-names>EM</given-names></name><name><surname>Niehrs</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Angiopoietin-like 4 is a wnt signaling antagonist that promotes LRP6 turnover</article-title><source>Developmental Cell</source><volume>43</volume><fpage>71</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.09.011</pub-id><pub-id pub-id-type="pmid">29017031</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komarov</surname> <given-names>PG</given-names></name><name><surname>Komarova</surname> <given-names>EA</given-names></name><name><surname>Kondratov</surname> <given-names>RV</given-names></name><name><surname>Christov-Tselkov</surname> <given-names>K</given-names></name><name><surname>Coon</surname> <given-names>JS</given-names></name><name><surname>Chernov</surname> <given-names>MV</given-names></name><name><surname>Gudkov</surname> <given-names>AV</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>A chemical inhibitor of p53 that protects mice from the side effects of Cancer therapy</article-title><source>Science</source><volume>285</volume><fpage>1733</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1126/science.285.5434.1733</pub-id><pub-id pub-id-type="pmid">10481009</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kriaucionis</surname> <given-names>S</given-names></name><name><surname>Heintz</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The nuclear DNA base 5-hydroxymethylcytosine is present in purkinje neurons and the brain</article-title><source>Science</source><volume>324</volume><fpage>929</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1126/science.1169786</pub-id><pub-id pub-id-type="pmid">19372393</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krokeide</surname> <given-names>SZ</given-names></name><name><surname>Laerdahl</surname> <given-names>JK</given-names></name><name><surname>Salah</surname> <given-names>M</given-names></name><name><surname>Luna</surname> <given-names>L</given-names></name><name><surname>Cederkvist</surname> <given-names>FH</given-names></name><name><surname>Fleming</surname> <given-names>AM</given-names></name><name><surname>Burrows</surname> <given-names>CJ</given-names></name><name><surname>Dalhus</surname> <given-names>B</given-names></name><name><surname>Bjørås</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Human NEIL3 is mainly a monofunctional DNA glycosylase removing spiroimindiohydantoin and guanidinohydantoin</article-title><source>DNA Repair</source><volume>12</volume><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2013.04.026</pub-id><pub-id pub-id-type="pmid">23755964</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LaBonne</surname> <given-names>C</given-names></name><name><surname>Bronner-Fraser</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Neural crest induction in xenopus: evidence for a two-signal model</article-title><source>Development</source><volume>125</volume><fpage>2403</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">9609823</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakhani</surname> <given-names>SA</given-names></name><name><surname>Masud</surname> <given-names>A</given-names></name><name><surname>Kuida</surname> <given-names>K</given-names></name><name><surname>Porter</surname> <given-names>GA</given-names></name><name><surname>Booth</surname> <given-names>CJ</given-names></name><name><surname>Mehal</surname> <given-names>WZ</given-names></name><name><surname>Inayat</surname> <given-names>I</given-names></name><name><surname>Flavell</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Caspases 3 and 7: key mediators of mitochondrial events of apoptosis</article-title><source>Science</source><volume>311</volume><fpage>847</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1126/science.1115035</pub-id><pub-id pub-id-type="pmid">16469926</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname> <given-names>KC</given-names></name><name><surname>Goh</surname> <given-names>WL</given-names></name><name><surname>Xu</surname> <given-names>M</given-names></name><name><surname>Kua</surname> <given-names>N</given-names></name><name><surname>Lunny</surname> <given-names>D</given-names></name><name><surname>Wong</surname> <given-names>JS</given-names></name><name><surname>Coomber</surname> <given-names>D</given-names></name><name><surname>Vojtesek</surname> <given-names>B</given-names></name><name><surname>Lane</surname> <given-names>EB</given-names></name><name><surname>Lane</surname> <given-names>DP</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Detection of the p53 response in zebrafish embryos using new monoclonal antibodies</article-title><source>Oncogene</source><volume>27</volume><fpage>629</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210695</pub-id><pub-id pub-id-type="pmid">17684488</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>D</given-names></name><name><surname>Bodamer</surname> <given-names>OA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A 420 kb deletion within the minimum critical region of the 15q24 microdeletion syndrome in a female infant</article-title><source>North American Journal of Medicine and Science</source><volume>7</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.7156/najms.2014.0704171</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname> <given-names>Y</given-names></name><name><surname>Smyth</surname> <given-names>GK</given-names></name><name><surname>Shi</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>featureCounts: an efficient general purpose program for assigning sequence reads to genomic features</article-title><source>Bioinformatics</source><volume>30</volume><fpage>923</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt656</pub-id><pub-id pub-id-type="pmid">24227677</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>M</given-names></name><name><surname>Doublié</surname> <given-names>S</given-names></name><name><surname>Wallace</surname> <given-names>SS</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Neil3, the final frontier for the DNA glycosylases that recognize oxidative damage</article-title><source>Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis</source><volume>743-744</volume><fpage>4</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2012.12.003</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lombard</surname> <given-names>DB</given-names></name><name><surname>Chua</surname> <given-names>KF</given-names></name><name><surname>Mostoslavsky</surname> <given-names>R</given-names></name><name><surname>Franco</surname> <given-names>S</given-names></name><name><surname>Gostissa</surname> <given-names>M</given-names></name><name><surname>Alt</surname> <given-names>FW</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>DNA repair, genome stability, and aging</article-title><source>Cell</source><volume>120</volume><fpage>497</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.01.028</pub-id><pub-id pub-id-type="pmid">15734682</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname> <given-names>MI</given-names></name><name><surname>Huber</surname> <given-names>W</given-names></name><name><surname>Anders</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname> <given-names>DL</given-names></name><name><surname>MacInnes</surname> <given-names>MA</given-names></name><name><surname>Takiguchi</surname> <given-names>Y</given-names></name><name><surname>Purtymun</surname> <given-names>PE</given-names></name><name><surname>Henrie</surname> <given-names>M</given-names></name><name><surname>Flannery</surname> <given-names>M</given-names></name><name><surname>Meneses</surname> <given-names>J</given-names></name><name><surname>Pedersen</surname> <given-names>RA</given-names></name><name><surname>Chen</surname> <given-names>DJ</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A murine AP-endonuclease gene-targeted deficiency with post-implantation embryonic progression and ionizing radiation sensitivity</article-title><source>Mutation Research/DNA Repair</source><volume>409</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0921-8777(98)00039-1</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiti</surname> <given-names>A</given-names></name><name><surname>Drohat</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>35334</fpage><lpage>35338</lpage><pub-id pub-id-type="doi">10.1074/jbc.C111.284620</pub-id><pub-id pub-id-type="pmid">21862836</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandal</surname> <given-names>SM</given-names></name><name><surname>Hegde</surname> <given-names>ML</given-names></name><name><surname>Chatterjee</surname> <given-names>A</given-names></name><name><surname>Hegde</surname> <given-names>PM</given-names></name><name><surname>Szczesny</surname> <given-names>B</given-names></name><name><surname>Banerjee</surname> <given-names>D</given-names></name><name><surname>Boldogh</surname> <given-names>I</given-names></name><name><surname>Gao</surname> <given-names>R</given-names></name><name><surname>Falkenberg</surname> <given-names>M</given-names></name><name><surname>Gustafsson</surname> <given-names>CM</given-names></name><name><surname>Sarkar</surname> <given-names>PS</given-names></name><name><surname>Hazra</surname> <given-names>TK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Role of human DNA glycosylase Nei-like 2 (NEIL2) and single strand break repair protein polynucleotide kinase 3'-phosphatase in maintenance of mitochondrial genome</article-title><source>Journal of Biological Chemistry</source><volume>287</volume><fpage>2819</fpage><lpage>2829</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.272179</pub-id><pub-id pub-id-type="pmid">22130663</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname> <given-names>U</given-names></name><name><surname>Bauer</surname> <given-names>C</given-names></name><name><surname>Siegl</surname> <given-names>M</given-names></name><name><surname>Rottach</surname> <given-names>A</given-names></name><name><surname>Leonhardt</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>TET-mediated oxidation of methylcytosine causes TDG or NEIL glycosylase dependent gene reactivation</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>8592</fpage><lpage>8604</lpage><pub-id pub-id-type="doi">10.1093/nar/gku552</pub-id><pub-id pub-id-type="pmid">24948610</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname> <given-names>S</given-names></name><name><surname>Bronner</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dual developmental role of transcriptional regulator Ets1 in xenopus cardiac neural crest vs. heart mesoderm</article-title><source>Cardiovascular Research</source><volume>106</volume><fpage>67</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvv043</pub-id><pub-id pub-id-type="pmid">25691536</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname> <given-names>K</given-names></name><name><surname>Li</surname> <given-names>H</given-names></name><name><surname>Jensen</surname> <given-names>MR</given-names></name><name><surname>Zhang</surname> <given-names>T</given-names></name><name><surname>Taya</surname> <given-names>Y</given-names></name><name><surname>Thorgeirsson</surname> <given-names>SS</given-names></name><name><surname>Prives</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cyclin G recruits PP2A to dephosphorylate Mdm2</article-title><source>Molecular Cell</source><volume>9</volume><fpage>761</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(02)00504-X</pub-id><pub-id pub-id-type="pmid">11983168</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okamoto</surname> <given-names>K</given-names></name><name><surname>Beach</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Cyclin G is a transcriptional target of the p53 tumor suppressor protein</article-title><source>The EMBO Journal</source><volume>13</volume><fpage>4816</fpage><lpage>4822</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1994.tb06807.x</pub-id><pub-id pub-id-type="pmid">7957050</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaffeneder</surname> <given-names>T</given-names></name><name><surname>Hackner</surname> <given-names>B</given-names></name><name><surname>Truss</surname> <given-names>M</given-names></name><name><surname>Münzel</surname> <given-names>M</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name><name><surname>Deiml</surname> <given-names>CA</given-names></name><name><surname>Hagemeier</surname> <given-names>C</given-names></name><name><surname>Carell</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The discovery of 5-formylcytosine in embryonic stem cell DNA</article-title><source>Angewandte Chemie International Edition</source><volume>50</volume><fpage>7008</fpage><lpage>7012</lpage><pub-id pub-id-type="doi">10.1002/anie.201103899</pub-id><pub-id pub-id-type="pmid">21721093</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname> <given-names>DE</given-names></name><name><surname>Millman</surname> <given-names>JR</given-names></name><name><surname>Huang</surname> <given-names>RB</given-names></name><name><surname>Colton</surname> <given-names>CK</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Effects of oxygen on mouse embryonic stem cell growth, phenotype retention, and cellular energetics</article-title><source>Biotechnology and Bioengineering</source><volume>101</volume><fpage>241</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1002/bit.21986</pub-id><pub-id pub-id-type="pmid">18727033</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prakash</surname> <given-names>A</given-names></name><name><surname>Doublié</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Base excision repair in the mitochondria</article-title><source>Journal of Cellular Biochemistry</source><volume>116</volume><fpage>1490</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1002/jcb.25103</pub-id><pub-id pub-id-type="pmid">25754732</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Puebla-Osorio</surname> <given-names>N</given-names></name><name><surname>Lacey</surname> <given-names>DB</given-names></name><name><surname>Alt</surname> <given-names>FW</given-names></name><name><surname>Zhu</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Early embryonic lethality due to targeted inactivation of DNA ligase III</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>3935</fpage><lpage>3941</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.10.3935-3941.2006</pub-id><pub-id pub-id-type="pmid">16648486</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quispe-Tintaya</surname> <given-names>W</given-names></name><name><surname>White</surname> <given-names>RR</given-names></name><name><surname>Popov</surname> <given-names>VN</given-names></name><name><surname>Vijg</surname> <given-names>J</given-names></name><name><surname>Maslov</surname> <given-names>AY</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fast mitochondrial DNA isolation from mammalian cells for next-generation sequencing</article-title><source>BioTechniques</source><volume>55</volume><fpage>133</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.2144/000114077</pub-id><pub-id pub-id-type="pmid">24003945</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahimoff</surname> <given-names>R</given-names></name><name><surname>Kosmatchev</surname> <given-names>O</given-names></name><name><surname>Kirchner</surname> <given-names>A</given-names></name><name><surname>Pfaffeneder</surname> <given-names>T</given-names></name><name><surname>Spada</surname> <given-names>F</given-names></name><name><surname>Brantl</surname> <given-names>V</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name><name><surname>Carell</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>5-Formyl- and 5-Carboxydeoxycytidines do not cause accumulation of harmful repair intermediates in stem cells</article-title><source>Journal of the American Chemical Society</source><volume>139</volume><fpage>10359</fpage><lpage>10364</lpage><pub-id pub-id-type="doi">10.1021/jacs.7b04131</pub-id><pub-id pub-id-type="pmid">28715893</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralston</surname> <given-names>A</given-names></name><name><surname>Rossant</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The genetics of induced pluripotency</article-title><source>Reproduction</source><volume>139</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1530/REP-09-0024</pub-id><pub-id pub-id-type="pmid">19605512</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reinecke</surname> <given-names>F</given-names></name><name><surname>Smeitink</surname> <given-names>JAM</given-names></name><name><surname>van der Westhuizen</surname> <given-names>FH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>OXPHOS gene expression and control in mitochondrial disorders</article-title><source>Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease</source><volume>1792</volume><fpage>1113</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1016/j.bbadis.2009.04.003</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinon</surname> <given-names>A</given-names></name><name><surname>Molchadsky</surname> <given-names>A</given-names></name><name><surname>Nathan</surname> <given-names>E</given-names></name><name><surname>Yovel</surname> <given-names>G</given-names></name><name><surname>Rotter</surname> <given-names>V</given-names></name><name><surname>Sarig</surname> <given-names>R</given-names></name><name><surname>Tzahor</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes</article-title><source>Development</source><volume>138</volume><fpage>1827</fpage><lpage>1838</lpage><pub-id pub-id-type="doi">10.1242/dev.053645</pub-id><pub-id pub-id-type="pmid">21447558</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rolseth</surname> <given-names>V</given-names></name><name><surname>Luna</surname> <given-names>L</given-names></name><name><surname>Olsen</surname> <given-names>AK</given-names></name><name><surname>Suganthan</surname> <given-names>R</given-names></name><name><surname>Scheffler</surname> <given-names>K</given-names></name><name><surname>Neurauter</surname> <given-names>CG</given-names></name><name><surname>Esbensen</surname> <given-names>Y</given-names></name><name><surname>Kuśnierczyk</surname> <given-names>A</given-names></name><name><surname>Hildrestrand</surname> <given-names>GA</given-names></name><name><surname>Graupner</surname> <given-names>A</given-names></name><name><surname>Andersen</surname> <given-names>JM</given-names></name><name><surname>Slupphaug</surname> <given-names>G</given-names></name><name><surname>Klungland</surname> <given-names>A</given-names></name><name><surname>Nilsen</surname> <given-names>H</given-names></name><name><surname>Bjørås</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>No Cancer predisposition or increased spontaneous mutation frequencies in NEIL DNA glycosylases-deficient mice</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>4384</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-04472-4</pub-id><pub-id pub-id-type="pmid">28663564</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname> <given-names>A</given-names></name><name><surname>Kontarakis</surname> <given-names>Z</given-names></name><name><surname>Gerri</surname> <given-names>C</given-names></name><name><surname>Nolte</surname> <given-names>H</given-names></name><name><surname>Hölper</surname> <given-names>S</given-names></name><name><surname>Krüger</surname> <given-names>M</given-names></name><name><surname>Stainier</surname> <given-names>DY</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic compensation induced by deleterious mutations but not gene knockdowns</article-title><source>Nature</source><volume>524</volume><fpage>230</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1038/nature14580</pub-id><pub-id pub-id-type="pmid">26168398</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname> <given-names>D</given-names></name><name><surname>Dixon</surname> <given-names>J</given-names></name><name><surname>Achilleos</surname> <given-names>A</given-names></name><name><surname>Dixon</surname> <given-names>M</given-names></name><name><surname>Trainor</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Prevention of Treacher collins syndrome craniofacial anomalies in mouse models via maternal antioxidant supplementation</article-title><source>Nature Communications</source><volume>7</volume><elocation-id>10328</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms10328</pub-id><pub-id pub-id-type="pmid">26792133</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname> <given-names>D</given-names></name><name><surname>Trainor</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Face off against ROS: tcof1/Treacle safeguards neuroepithelial cells and progenitor neural crest cells from oxidative stress during craniofacial development</article-title><source>Development, Growth &amp; Differentiation</source><volume>58</volume><fpage>577</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1111/dgd.12305</pub-id><pub-id pub-id-type="pmid">27481486</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schomacher</surname> <given-names>L</given-names></name><name><surname>Han</surname> <given-names>D</given-names></name><name><surname>Musheev</surname> <given-names>MU</given-names></name><name><surname>Arab</surname> <given-names>K</given-names></name><name><surname>Kienhöfer</surname> <given-names>S</given-names></name><name><surname>von Seggern</surname> <given-names>A</given-names></name><name><surname>Niehrs</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Neil DNA glycosylases promote substrate turnover by tdg during DNA demethylation</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>23</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3151</pub-id><pub-id pub-id-type="pmid">26751644</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schuermann</surname> <given-names>D</given-names></name><name><surname>Weber</surname> <given-names>AR</given-names></name><name><surname>Schär</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Active DNA demethylation by DNA repair: facts and uncertainties</article-title><source>DNA Repair</source><volume>44</volume><fpage>92</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2016.05.013</pub-id><pub-id pub-id-type="pmid">27247237</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname> <given-names>L</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Diep</surname> <given-names>D</given-names></name><name><surname>Yamaguchi</surname> <given-names>S</given-names></name><name><surname>D'Alessio</surname> <given-names>AC</given-names></name><name><surname>Fung</surname> <given-names>HL</given-names></name><name><surname>Zhang</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics</article-title><source>Cell</source><volume>153</volume><fpage>692</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.002</pub-id><pub-id pub-id-type="pmid">23602152</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simões-Costa</surname> <given-names>M</given-names></name><name><surname>Bronner</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Establishing neural crest identity: a gene regulatory recipe</article-title><source>Development</source><volume>142</volume><fpage>242</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1242/dev.105445</pub-id><pub-id pub-id-type="pmid">25564621</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Sive</surname> <given-names>HL</given-names></name><name><surname>Grainiger</surname> <given-names>RM</given-names></name><name><surname>Harland</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2000">2000</year><source>Early Development of Xenopus Laevis: A Laboratory Manual</source><publisher-loc>New York</publisher-loc><publisher-name>Cold Spring Harbor Laboratory Press</publisher-name></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slyvka</surname> <given-names>A</given-names></name><name><surname>Mierzejewska</surname> <given-names>K</given-names></name><name><surname>Bochtler</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Nei-like 1 (NEIL1) excises 5-carboxylcytosine directly and stimulates TDG-mediated 5-formyl and 5-carboxylcytosine excision</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>9001</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-07458-4</pub-id><pub-id pub-id-type="pmid">28827588</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Som</surname> <given-names>A</given-names></name><name><surname>Harder</surname> <given-names>C</given-names></name><name><surname>Greber</surname> <given-names>B</given-names></name><name><surname>Siatkowski</surname> <given-names>M</given-names></name><name><surname>Paudel</surname> <given-names>Y</given-names></name><name><surname>Warsow</surname> <given-names>G</given-names></name><name><surname>Cap</surname> <given-names>C</given-names></name><name><surname>Schöler</surname> <given-names>H</given-names></name><name><surname>Fuellen</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The PluriNetWork: an electronic representation of the network underlying pluripotency in mouse, and its applications</article-title><source>PLOS ONE</source><volume>5</volume><elocation-id>e15165</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0015165</pub-id><pub-id pub-id-type="pmid">21179244</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname> <given-names>CX</given-names></name><name><surname>Szulwach</surname> <given-names>KE</given-names></name><name><surname>Dai</surname> <given-names>Q</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Mao</surname> <given-names>SQ</given-names></name><name><surname>Lin</surname> <given-names>L</given-names></name><name><surname>Street</surname> <given-names>C</given-names></name><name><surname>Li</surname> <given-names>Y</given-names></name><name><surname>Poidevin</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Gao</surname> <given-names>J</given-names></name><name><surname>Liu</surname> <given-names>P</given-names></name><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Xu</surname> <given-names>GL</given-names></name><name><surname>Jin</surname> <given-names>P</given-names></name><name><surname>He</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming</article-title><source>Cell</source><volume>153</volume><fpage>678</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.04.001</pub-id><pub-id pub-id-type="pmid">23602153</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spruijt</surname> <given-names>CG</given-names></name><name><surname>Gnerlich</surname> <given-names>F</given-names></name><name><surname>Smits</surname> <given-names>AH</given-names></name><name><surname>Pfaffeneder</surname> <given-names>T</given-names></name><name><surname>Jansen</surname> <given-names>PW</given-names></name><name><surname>Bauer</surname> <given-names>C</given-names></name><name><surname>Münzel</surname> <given-names>M</given-names></name><name><surname>Wagner</surname> <given-names>M</given-names></name><name><surname>Müller</surname> <given-names>M</given-names></name><name><surname>Khan</surname> <given-names>F</given-names></name><name><surname>Eberl</surname> <given-names>HC</given-names></name><name><surname>Mensinga</surname> <given-names>A</given-names></name><name><surname>Brinkman</surname> <given-names>AB</given-names></name><name><surname>Lephikov</surname> <given-names>K</given-names></name><name><surname>Müller</surname> <given-names>U</given-names></name><name><surname>Walter</surname> <given-names>J</given-names></name><name><surname>Boelens</surname> <given-names>R</given-names></name><name><surname>van Ingen</surname> <given-names>H</given-names></name><name><surname>Leonhardt</surname> <given-names>H</given-names></name><name><surname>Carell</surname> <given-names>T</given-names></name><name><surname>Vermeulen</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives</article-title><source>Cell</source><volume>152</volume><fpage>1146</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.02.004</pub-id><pub-id pub-id-type="pmid">23434322</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinacher</surname> <given-names>R</given-names></name><name><surname>Barekati</surname> <given-names>Z</given-names></name><name><surname>Botev</surname> <given-names>P</given-names></name><name><surname>Kuśnierczyk</surname> <given-names>A</given-names></name><name><surname>Slupphaug</surname> <given-names>G</given-names></name><name><surname>Schär</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>SUMOylation coordinates BERosome assembly in active DNA demethylation during cell differentiation</article-title><source>The EMBO Journal</source><volume>38</volume><elocation-id>e99242</elocation-id><pub-id pub-id-type="doi">10.15252/embj.201899242</pub-id><pub-id pub-id-type="pmid">30523148</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugo</surname> <given-names>N</given-names></name><name><surname>Aratani</surname> <given-names>Y</given-names></name><name><surname>Nagashima</surname> <given-names>Y</given-names></name><name><surname>Kubota</surname> <given-names>Y</given-names></name><name><surname>Koyama</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Neonatal lethality with abnormal neurogenesis in mice deficient in DNA polymerase beta</article-title><source>The EMBO Journal</source><volume>19</volume><fpage>1397</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1093/emboj/19.6.1397</pub-id><pub-id pub-id-type="pmid">10716939</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swenberg</surname> <given-names>JA</given-names></name><name><surname>Lu</surname> <given-names>K</given-names></name><name><surname>Moeller</surname> <given-names>BC</given-names></name><name><surname>Gao</surname> <given-names>L</given-names></name><name><surname>Upton</surname> <given-names>PB</given-names></name><name><surname>Nakamura</surname> <given-names>J</given-names></name><name><surname>Starr</surname> <given-names>TB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Endogenous versus exogenous DNA adducts: their role in carcinogenesis, epidemiology, and risk assessment</article-title><source>Toxicological Sciences</source><volume>120 Suppl 1</volume><fpage>S130</fpage><lpage>S145</lpage><pub-id pub-id-type="doi">10.1093/toxsci/kfq371</pub-id><pub-id pub-id-type="pmid">21163908</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tahiliani</surname> <given-names>M</given-names></name><name><surname>Koh</surname> <given-names>KP</given-names></name><name><surname>Shen</surname> <given-names>Y</given-names></name><name><surname>Pastor</surname> <given-names>WA</given-names></name><name><surname>Bandukwala</surname> <given-names>H</given-names></name><name><surname>Brudno</surname> <given-names>Y</given-names></name><name><surname>Agarwal</surname> <given-names>S</given-names></name><name><surname>Iyer</surname> <given-names>LM</given-names></name><name><surname>Liu</surname> <given-names>DR</given-names></name><name><surname>Aravind</surname> <given-names>L</given-names></name><name><surname>Rao</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1</article-title><source>Science</source><volume>324</volume><fpage>930</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1126/science.1170116</pub-id><pub-id pub-id-type="pmid">19372391</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takao</surname> <given-names>M</given-names></name><name><surname>Kanno</surname> <given-names>S</given-names></name><name><surname>Kobayashi</surname> <given-names>K</given-names></name><name><surname>Zhang</surname> <given-names>QM</given-names></name><name><surname>Yonei</surname> <given-names>S</given-names></name><name><surname>van der Horst</surname> <given-names>GT</given-names></name><name><surname>Yasui</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A back-up glycosylase in <italic>Nth1</italic> knock-out mice is a functional nei (endonuclease VIII) homologue</article-title><source>Journal of Biological Chemistry</source><volume>277</volume><fpage>42205</fpage><lpage>42213</lpage><pub-id pub-id-type="doi">10.1074/jbc.M206884200</pub-id><pub-id pub-id-type="pmid">12200441</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takebayashi-Suzuki</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Interplay between the tumor suppressor p53 and TGF signaling shapes embryonic body axes in Xenopus</article-title><source>Development</source><volume>130</volume><fpage>3929</fpage><lpage>3939</lpage><pub-id pub-id-type="doi">10.1242/dev.00615</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tebbs</surname> <given-names>RS</given-names></name><name><surname>Flannery</surname> <given-names>ML</given-names></name><name><surname>Meneses</surname> <given-names>JJ</given-names></name><name><surname>Hartmann</surname> <given-names>A</given-names></name><name><surname>Tucker</surname> <given-names>JD</given-names></name><name><surname>Thompson</surname> <given-names>LH</given-names></name><name><surname>Cleaver</surname> <given-names>JE</given-names></name><name><surname>Pedersen</surname> <given-names>RA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Requirement for the Xrcc1 DNA base excision repair gene during early mouse development</article-title><source>Developmental Biology</source><volume>208</volume><fpage>513</fpage><lpage>529</lpage><pub-id pub-id-type="doi">10.1006/dbio.1999.9232</pub-id><pub-id pub-id-type="pmid">10191063</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trainor</surname> <given-names>PA</given-names></name><name><surname>Krumlauf</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Hox genes, neural crest cells and branchial arch patterning</article-title><source>Current Opinion in Cell Biology</source><volume>13</volume><fpage>698</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/S0955-0674(00)00273-8</pub-id><pub-id pub-id-type="pmid">11698185</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujimoto</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria?</article-title><source>Genes to Cells</source><volume>3</volume><fpage>697</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2443.1998.00223.x</pub-id><pub-id pub-id-type="pmid">9990505</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Nostrand</surname> <given-names>JL</given-names></name><name><surname>Brady</surname> <given-names>CA</given-names></name><name><surname>Jung</surname> <given-names>H</given-names></name><name><surname>Fuentes</surname> <given-names>DR</given-names></name><name><surname>Kozak</surname> <given-names>MM</given-names></name><name><surname>Johnson</surname> <given-names>TM</given-names></name><name><surname>Lin</surname> <given-names>CY</given-names></name><name><surname>Lin</surname> <given-names>CJ</given-names></name><name><surname>Swiderski</surname> <given-names>DL</given-names></name><name><surname>Vogel</surname> <given-names>H</given-names></name><name><surname>Bernstein</surname> <given-names>JA</given-names></name><name><surname>Attié-Bitach</surname> <given-names>T</given-names></name><name><surname>Chang</surname> <given-names>CP</given-names></name><name><surname>Wysocka</surname> <given-names>J</given-names></name><name><surname>Martin</surname> <given-names>DM</given-names></name><name><surname>Attardi</surname> <given-names>LD</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inappropriate p53 activation during development induces features of CHARGE syndrome</article-title><source>Nature</source><volume>514</volume><fpage>228</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1038/nature13585</pub-id><pub-id pub-id-type="pmid">25119037</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vartanian</surname> <given-names>V</given-names></name><name><surname>Lowell</surname> <given-names>B</given-names></name><name><surname>Minko</surname> <given-names>IG</given-names></name><name><surname>Wood</surname> <given-names>TG</given-names></name><name><surname>Ceci</surname> <given-names>JD</given-names></name><name><surname>George</surname> <given-names>S</given-names></name><name><surname>Ballinger</surname> <given-names>SW</given-names></name><name><surname>Corless</surname> <given-names>CL</given-names></name><name><surname>McCullough</surname> <given-names>AK</given-names></name><name><surname>Lloyd</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The metabolic syndrome resulting from a knockout of the NEIL1 DNA glycosylase</article-title><source>PNAS</source><volume>103</volume><fpage>1864</fpage><lpage>1869</lpage><pub-id pub-id-type="doi">10.1073/pnas.0507444103</pub-id><pub-id pub-id-type="pmid">16446448</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaseva</surname> <given-names>AV</given-names></name><name><surname>Moll</surname> <given-names>UM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The mitochondrial p53 pathway</article-title><source>Biochimica Et Biophysica Acta (BBA) - Bioenergetics</source><volume>1787</volume><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2008.10.005</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vial</surname> <given-names>G</given-names></name><name><surname>Dubouchaud</surname> <given-names>H</given-names></name><name><surname>Couturier</surname> <given-names>K</given-names></name><name><surname>Cottet-Rousselle</surname> <given-names>C</given-names></name><name><surname>Taleux</surname> <given-names>N</given-names></name><name><surname>Athias</surname> <given-names>A</given-names></name><name><surname>Galinier</surname> <given-names>A</given-names></name><name><surname>Casteilla</surname> <given-names>L</given-names></name><name><surname>Leverve</surname> <given-names>XM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Effects of a high-fat diet on energy metabolism and ROS production in rat liver</article-title><source>Journal of Hepatology</source><volume>54</volume><fpage>348</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.06.044</pub-id><pub-id pub-id-type="pmid">21109325</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Fu</surname> <given-names>Y</given-names></name><name><surname>Gao</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>G</given-names></name><name><surname>Liang</surname> <given-names>J</given-names></name><name><surname>Gao</surname> <given-names>C</given-names></name><name><surname>Huang</surname> <given-names>B</given-names></name><name><surname>Fenger</surname> <given-names>U</given-names></name><name><surname>Niehrs</surname> <given-names>C</given-names></name><name><surname>Chen</surname> <given-names>YG</given-names></name><name><surname>Wu</surname> <given-names>W</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Xenopus skip modulates wnt/beta-catenin signaling and functions in neural crest induction</article-title><source>Journal of Biological Chemistry</source><volume>285</volume><fpage>10890</fpage><lpage>10901</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.058347</pub-id><pub-id pub-id-type="pmid">20103590</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>J</given-names></name><name><surname>Vasaikar</surname> <given-names>S</given-names></name><name><surname>Shi</surname> <given-names>Z</given-names></name><name><surname>Greer</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>W130</fpage><lpage>W137</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx356</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname> <given-names>J</given-names></name><name><surname>Dalton</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Cell cycle control of embryonic stem cells</article-title><source>Stem Cell Reviews</source><volume>1</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1385/SCR:1:2:131</pub-id><pub-id pub-id-type="pmid">17142847</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname> <given-names>AOM</given-names></name><name><surname>Morriss-Kay</surname> <given-names>GM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Genetics of craniofacial development and malformation</article-title><source>Nature Reviews Genetics</source><volume>2</volume><fpage>458</fpage><lpage>468</lpage><pub-id pub-id-type="doi">10.1038/35076601</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname> <given-names>RM</given-names></name><name><surname>McManaman</surname> <given-names>JL</given-names></name><name><surname>Repine</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Alcohol-induced breast Cancer: a proposed mechanism</article-title><source>Free Radical Biology and Medicine</source><volume>26</volume><fpage>348</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/S0891-5849(98)00204-4</pub-id><pub-id pub-id-type="pmid">9895226</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>TET-mediated active DNA demethylation: mechanism, function and beyond</article-title><source>Nature Reviews Genetics</source><volume>18</volume><fpage>517</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1038/nrg.2017.33</pub-id><pub-id pub-id-type="pmid">28555658</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xanthoudakis</surname> <given-names>S</given-names></name><name><surname>Smeyne</surname> <given-names>RJ</given-names></name><name><surname>Wallace</surname> <given-names>JD</given-names></name><name><surname>Curran</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice</article-title><source>PNAS</source><volume>93</volume><fpage>8919</fpage><lpage>8923</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.17.8919</pub-id><pub-id pub-id-type="pmid">8799128</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>D</given-names></name><name><surname>Dong</surname> <given-names>J</given-names></name><name><surname>Sulik</surname> <given-names>KK</given-names></name><name><surname>Chen</surname> <given-names>SY</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Induction of the Nrf2-driven antioxidant response by tert-butylhydroquinone prevents ethanol-induced apoptosis in cranial neural crest cells</article-title><source>Biochemical Pharmacology</source><volume>80</volume><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2010.03.004</pub-id><pub-id pub-id-type="pmid">20223225</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>B</given-names></name><name><surname>Gaiteri</surname> <given-names>C</given-names></name><name><surname>Bodea</surname> <given-names>LG</given-names></name><name><surname>Wang</surname> <given-names>Z</given-names></name><name><surname>McElwee</surname> <given-names>J</given-names></name><name><surname>Podtelezhnikov</surname> <given-names>AA</given-names></name><name><surname>Zhang</surname> <given-names>C</given-names></name><name><surname>Xie</surname> <given-names>T</given-names></name><name><surname>Tran</surname> <given-names>L</given-names></name><name><surname>Dobrin</surname> <given-names>R</given-names></name><name><surname>Fluder</surname> <given-names>E</given-names></name><name><surname>Clurman</surname> <given-names>B</given-names></name><name><surname>Melquist</surname> <given-names>S</given-names></name><name><surname>Narayanan</surname> <given-names>M</given-names></name><name><surname>Suver</surname> <given-names>C</given-names></name><name><surname>Shah</surname> <given-names>H</given-names></name><name><surname>Mahajan</surname> <given-names>M</given-names></name><name><surname>Gillis</surname> <given-names>T</given-names></name><name><surname>Mysore</surname> <given-names>J</given-names></name><name><surname>MacDonald</surname> <given-names>ME</given-names></name><name><surname>Lamb</surname> <given-names>JR</given-names></name><name><surname>Bennett</surname> <given-names>DA</given-names></name><name><surname>Molony</surname> <given-names>C</given-names></name><name><surname>Stone</surname> <given-names>DJ</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Myers</surname> <given-names>AJ</given-names></name><name><surname>Schadt</surname> <given-names>EE</given-names></name><name><surname>Neumann</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>J</given-names></name><name><surname>Emilsson</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrated systems approach identifies genetic nodes and networks in late-onset alzheimer's disease</article-title><source>Cell</source><volume>153</volume><fpage>707</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.03.030</pub-id><pub-id pub-id-type="pmid">23622250</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>J</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Alfred</surname> <given-names>AT</given-names></name><name><surname>Wei</surname> <given-names>P</given-names></name><name><surname>Yang</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Anticancer effects of pyocyanin on HepG2 human hepatoma cells</article-title><source>Letters in Applied Microbiology</source><volume>58</volume><fpage>541</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1111/lam.12224</pub-id><pub-id pub-id-type="pmid">24461061</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname> <given-names>Z</given-names></name><name><surname>Reece</surname> <given-names>EA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Nicotine-induced embryonic malformations mediated by apoptosis from increasing intracellular calcium and oxidative stress</article-title><source>Birth Defects Research Part B: Developmental and Reproductive Toxicology</source><volume>74</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="doi">10.1002/bdrb.20052</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.49044.037</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Bronner</surname><given-names>Marianne E</given-names></name><role>Reviewing Editor</role><aff><institution>California Institute of Technology</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Calo</surname><given-names>Eliezer</given-names> </name><role>Reviewer</role><aff><institution/></aff></contrib><contrib contrib-type="reviewer"><name><surname>Tissir</surname><given-names>Fadel</given-names> </name><role>Reviewer</role><aff><institution>Universite' Catholique de Louvain</institution><country>Belgium</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;NEIL1 and NEIL2 DNA glycosylases protect neural crest development against mitochondrial oxidative stress&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Marianne Bronner as the Senior and Reviewing Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Eliezer Calo (Reviewer #1); Fadel Tissir (Reviewer #2).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In this manuscript, Han et al. investigate the role of NEIL family bifunctional DNA glycosylases/lyases in <italic>Xenopus</italic> embryos and differentiating mouse embryonic stem cells (mESCs). They find that in <italic>Xenopus</italic> embryos Neil2 deficiency leads to defects in cranial neural crest cell development and link this to an oxidative stress-induced TP53-dependent mitochondrial DNA damage response that leads to apoptosis. They then use mESCs to confirm similar findings in mammalian cells. They suggest a model whereby NEIL1/NEIL2 function to repair and protect the mitochondrial genome against oxidative damages that accompany the metabolic switch upon neural differentiation. The manuscript presents an interesting connection between mitochondria oxidative stress and neural crest differentiation defects. As presented however, the study needs to be strengthened.</p><p>Essential revisions:</p><p>1) The authors must drop the claim that there is an effect on neural differentiation in <italic>Xenopus</italic> or do the work needed to validate this claim. e.g. look at multiple markers at both neural plate stages and later tailbud stages at neural differentiation markers.</p><p>2) The authors must use multiple markers in mESCs to validate effects on neural crest and neural differentiation.</p><p>3) The authors should examine <italic>tp53</italic> expression in NEIL2 morphants and pyocyanin treated embryos and for pyocyanin treated embryos drug treatment should be done more proximal to the time of neural crest/neural plate formation.</p><p>4) More rigorous validation of the CRISPR-Cas9 mutations is needed.</p><p>5) The authors need to provide additional evidence demonstrating that the oxidative stress response directly causes the phenotype and originates in the mitochondria. To me this is the most novel aspect of the work.</p><p>The full reviews are attached to provide further details, which we advise you to address if possible.</p><p><italic>Reviewer #1:</italic></p><p>This is an intriguing study that reveals how DNA glycosylases, particularly Neil1 and Neil2, protect neural crest cells from oxidative damage to mitochondrial DNA. The most novel aspect of this work is the connection between mitochondria oxidative stress and neural crest differentiation defects. As presented however, the work lacks mechanism and need to be strengthened before this manuscript is accepted for publication. Below I propose some experiments to strengthen the conclusions of the manuscript.</p><p>1) The authors developed a method to detect abasic sites generated by oxidative stress. While useful and informative, there's no validation of this method. How do we know that this method works as intended?</p><p>2) The authors should use an alternative experimental approach to confirm that the oxidative stress response is restricted to the mitochondrial genome.</p><p>3) If oxidative stress in the mitochondria is the major cause of the craniofacial phenotype, then mitochondrial disfunction should be evident in the Neil1/2 mutant background upon neuroectoderm induction. Experimental evidence for this is lacking.</p><p>4) Most of the mechanistic data derived from the interpretation of gene expression analyses. I found these data supportive, but unconvincing. There is a wealth of commercially available antibodies/reagents to study intrinsic apoptosis. The authors should leverage these reagents to solidify their conclusions.</p><p>Lastly, many statements throughout the paper are not accurate and therefore misleading to the reader. Also, the authors are very selective of the literature they chose to reference.</p><p><italic>Reviewer #2:</italic></p><p>In this manuscript, Dandan Han, Christof Niehrs and colleagues describe a mechanism whereby glucosylases NEIL1 and NEIL2 protect cranial neural crest cells (cNCC) against oxidative DNA (particularly mitochondrial DNA) damage. They used a used a series of morpholino-mediated downregulations in <italic>Xenopus</italic>, and Crispr/Cas9 knockouts in the mouse embryonic stem cells and convincingly show that the disruption of NEIL glucosylases (mainly 1 and 2) induces a Tp53 DNA damage response and results in differentiation defects of cNCC. The amount of data is impressive and the quality is very high.</p><p>I have only one major point that needs to be addressed experimentally and few other points that should be clarified in the text.</p><p>The validation of the mESCs Ko is incomplete/insufficient. Western blots for many targeted proteins (Neil2 and 3). The off-target effect inherent to CRISPR/Cas9 is a real issue both in the literature and in this study as well (see for instance Figure 6—figure supplement 1B that shows that 2 distinct deletions occur in a small region (+ 1kb) amplified by PCR in the triple Ko – Introduction). Whole genome sequencing is the only reliable way to rule out the possibility of off target mutations. At least uncropped gel images for all the KO cells have to be shown.</p><p><italic>Reviewer #3:</italic></p><p>In this manuscript Han et al. investigate the role of NEIL family bifunctional DNA glycosylases/lyases in <italic>Xenopus</italic> embryos and differentiating mouse embryonic stem cells (mESCs). They find that in <italic>Xenopus</italic> embryos Neil2 deficiency leads to defects in cranial neural crest cell development and link this to an oxidative stress-induced TP53-dependent mitochondrial DNA damage response that leads to apoptosis. They then use mESCs to confirm similar findings in mammalian cells. They suggest a model whereby NEIL1/NEIL2 function to repair and protect the mitochondrial genome against oxidative damages that accompany the metabolic switch upon neural differentiation. The work in this manuscript is, for the most part, well executed and the findings are potentially of broad interest. A problem that persists throughout the work, however, is the conflating of cranial neural crest formation/development with neural differentiation, which is confusing and detracts from the impact of the work. This is particularly odd given that they one late phenotype that the authors examine is craniofacial cartilage, which is clearly not an example of neural differentiation.</p><p>From the <italic>Xenopus</italic> work it appears that the main finding is that NEIL2 morphants and pyocyanin treated embryos show a loss of neural crest markers at neurula stages and that this ultimately results in a loss of neural crest derivatives as evidenced by the cartilage phenotype. The authors link this to an increase in tp53, and show that tp53 over-expression also leads to a decrease in neural crest markers. Oddly, the authors conclude from this that &quot;the cNCC defects in Neil2 morphants reflect a &quot;neural-restricted Tp53-response to oxidative DNA damage&quot;. However they look at Sox3 expression in the neural plate and it is relatively normal. If the authors wish to extend their conclusions to neural rather than neural crest development then they need to look at a broader range of neural markers, including at later stages. In the absence of this, they can really only make conclusions about neural crest cells.</p><p>The experiments with pyocyanin are problematic as the treatment appears to have been from early cleavage stages so any effects on neural crest could be very indirect – what happens if you treat later, for example at gastrulation?</p><p>In Figure 1H the authors preclude an effect on proliferation using a western blot for p-H3 but one would not likely detect local effects by this assay – they should do whole mount staining</p><p>Tunnel staining in Figure 1J shows increased apoptosis in both neural and non-neural cells but the authors state that cell death is in neural cells.</p><p>It is interesting that p53 expression is elevated at the neural folds relative to other tissues. One might think that would render these cells more rather than less protected against oxidative stress than their neighbors. The authors should comment on this. Also what happens to p53 expression in Neil2 morphants or after pyocyanin treatment?</p><p>The authors see a decrease in Slug expression after tp53 injection, but not loss of the lineage tracer β-galactosidase, so the cells are presumably still there. This call into question whether the decrease observed is really cell death dependent. They should block apoptosis with Bcl2 and determine if expression is rescued. Also given the authors continued focus on neural differentiation, does p53 injection alter sox3 expression or other neural markers such as neural tubulin?</p><p>In the second half of the paper focusing on mESCs the authors interpret their findings as requirement for NEIL function in cNCC development is evolutionarily conserved between amphibians and mammals. However they draw this conclusion without convincing data for neural phenotypes in <italic>Xenopus</italic> and using only one marker each for neural and neural crest (Pax6/Pax3). Multiple markers for each cell type should be examined.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.49044.038</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The authors must drop the claim that there is an effect on neural differentiation in Xenopus or do the work needed to validate this claim. e.g. look at multiple markers at both neural plate stages and later tailbud stages at neural differentiation markers.</p></disp-quote><p>We agree and we now emphasize that the phenotype of Neil2-morphant <italic>Xenopus</italic> is specific to cNCC- but not to neural differentiation.</p><disp-quote content-type="editor-comment"><p>2) The authors must use multiple markers in mESCs to validate effects on neural crest and neural differentiation.</p></disp-quote><p>We have now added three additional markers for neural crest (<italic>Hoxa2, Tfapb2, Neurog1</italic>) and neural (<italic>Nestin, Sox1, Pax2</italic>) differentiation supporting our conclusion about cNCC and neural differentiation defects in <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient mESCs. The results are presented in Figure 6—figure supplement 2 and Figure 7—figure supplement 2.</p><disp-quote content-type="editor-comment"><p>3) The authors should examine tp53 expression in NEIL2 morphants and pyocyanin treated embryos.</p></disp-quote><p>We now performed <italic>tp53</italic> expression analysis in stage 14 Neil2 morphants and pyocyanin-treated embryos. Tp53 expression is significantly elevated in both cases albeit less strong when compared to Tp53 target genes (Figure 1F and 3B).</p><disp-quote content-type="editor-comment"><p>And for pyocyanin treated embryos drug treatment should be done more proximal to the time of neural crest/neural plate formation.</p></disp-quote><p>We treated embryos with pyocyanin from stage 8.5 and 10 onwards and with different doses (25 and 80 µM) but could not detect a Tp53 DDR at stage 14/15 nor any strong phenotype at stage 32 (data not shown) with the exception of high dose pyocyanin from stage 8.5 onwards. The time may be too short for sufficient oxidative DNA damage accumulation and full Tp53 cascade induction. In addition, we showed that <italic>neil2</italic> expression is temporally restricted in <italic>Xenopus</italic> embryos until stage 10 (PMID: 26751644) indicative of a critical requirement for Neil2 in lesion repair in early stages prior to neural crest development. Hence, we conclude that to mimic Neil2-deficiency, Pyocyanin treatment needs to start from early stages onwards.</p><disp-quote content-type="editor-comment"><p>4) More rigorous validation of the CRISPR-Cas9 mutations is needed.</p></disp-quote><p>1) We previously validated the knockouts in all generated cell lines by several means:</p><p>i) Genotyping PCR on gDNA with primers spanning the anticipated deletion region as presented in Figure 6—figure supplement 1, Figure 7—figure supplement 1, Figure 8—figure supplement 1, Figure 9—figure supplement 1 and Figure 9—figure supplement 2 (now also shown as uncropped agarose gels).</p><p>ii) Western blot analysis for endogenous proteins if antibodies were available and working (NEIL1 in Figure 6—figure supplement 1 and Figure 7—figure supplement 1, APEX1 in Figure 8—figure supplement 1, and TDG in Figure 9—figure supplement 1 and Figure 9—figure supplement 2).</p><p>iii) RT-qPCR for expression analysis of the targeted exons (Neil2 and Neil3, Figure 6—figure supplement 1, Figure 7—figure supplement 3). Together, these analyses unambiguously confirmed the anticipated knockouts in the respective lines.</p><p>2) We now analyzed with CRISPOR (PMID: 27380939) off-target probability and potential off-target regions of the 6 gRNAs used to generate the <italic>Neil1, Neil2</italic> and <italic>Apex1</italic> knockout lines. These are the cell lines that showed neural and cNCC differentiation defects and were subjected to RNAseq analysis as undifferentiated mESCs. All 6 gRNAs were scored &gt;75 in the CFD specificity score (scale from 0 – 100, the higher the specificity score, the lower the probability for off-targets in the genome). In addition, we found among the potential off-target regions 25 genes with exonic matches for the two <italic>Neil1</italic> gRNAs, 14 for <italic>Neil2</italic> and 12 for <italic>Apex1</italic> all of which had between 3-4 base mismatches. Frameshift mutations are frequently accompanied by RNA level deregulation due to non-sense mediated decay or compensatory upregulation, respectively. However, only 4 of the 51 total candidates showed slight (log2FC &lt;1.0) RNA deregulation in the respective knockout lines compared to control mESCs (data not shown).</p><p>3) Most importantly, stable expression of <italic>NEIL1</italic> and <italic>NEIL2</italic> in the respective <italic>Neil1</italic> and <italic>Neil2</italic> knockout lines rescued the neural and neural crest differentiation defects (Figure 7—figure supplement 3) showing the specificity of the knockout approach.</p><disp-quote content-type="editor-comment"><p>5) The authors need to provide additional evidence demonstrating that the oxidative stress response directly causes the phenotype and originates in the mitochondria. To me this is the most novel aspect of the work.</p></disp-quote><p>1) We now performed L-ascorbic acid (Vitamin C) antioxidant treatment of <italic>neil2</italic> MO-injected <italic>Xenopus</italic> embryos. Vitamin C partially rescued the severe phenotype induced by Neil2-deficiency supporting the link between the neural crest phenotype and oxidative stress (Figure 3G).</p><p>2) We now confirmed elevated mtDNA damage in <italic>Neil1</italic> and <italic>Neil2</italic>-deficient EBs + RA (Figure 11C) by a mass spectrometry-independent approach based on quantitative PCR for damage detection (PMID: 28286206). In this long-range PCR, levels of DNA damage are monitored based on the fact that DNA lesions inhibit DNA polymerase and slow down accumulation of the PCR product. Therefore, the rate of product amplification is inversely proportional to the number of damaged DNA molecules. The results shows damage accumulation notably under RA-induced neural differentiation but not in undifferentiated mESCs, corroborating our conclusions.</p><p>3) Mutations on mtDNA and subsequent mitochondrial dysfunction result in compensatory upregulation of mitochondrial OXPHOS genes (PMID: 10438462, 19389473). Hence, we monitored the expression of a number of mitochondrial OXPHOS genes in both model systems, <italic>Xenopus</italic> and mESCs, and found a systematic upregulation of these genes in Neil2-deficient <italic>Xenopus</italic> embryos as well as <italic>Neil1-</italic> and <italic>Neil2</italic>-deficient mESCs during neural differentiation (Figure 2C and 11D). The result supports the notion that the stress response leads to mitochondrial dysfunction following mtDNA damage.</p><p>4) We have validated the mass spectrometry-based quantification of abasic sites (PMID: 28715893) and oxidative base damages using synthetic oligonucleotides with defined amounts of lesions. The result confirms the approach to function as intended (presented in Figure 11—figure supplement 1C). Hence, the quantification of base damages on cellular DNA (Figure 11B) is reliable.</p><disp-quote content-type="editor-comment"><p>The full reviews are attached to provide further details, which we advise you to address if possible.</p><p>Reviewer #1:</p><p>[…] 1) The authors developed a method to detect abasic sites generated by oxidative stress. While useful and informative, there's no validation of this method. How do we know that this method work as intended?</p></disp-quote><p>We have validated the mass spectrometry-based quantification of abasic sites (PMID: 28715893) and oxidative base damages using synthetic oligonucleotides with defined amounts of lesions. The result confirms the approach to function as intended (presented in Figure 11—figure supplement 1C). Hence, the quantification of base damages on cellular DNA (Figure 11B) is reliable.</p><disp-quote content-type="editor-comment"><p>2) The authors should use an alternative experimental approach to confirm that the oxidative stress response is restricted to the mitochondrial genome.</p></disp-quote><p>We added further evidence for elevated mtDNA damage in <italic>Neil1</italic> and <italic>Neil2</italic>-deficient EBs + RA (Figure 11C) by a mass spectrometry-independent approach based on quantitative PCR for damage detection (PMID: 28286206). In this long-range PCR, levels of DNA damage are monitored based on the fact that DNA lesions inhibit DNA polymerase and slow down accumulation of the PCR product. Therefore, the rate of product amplification is inversely proportional to the number of damaged DNA molecules. The results shows damage accumulation notably under RA-induced neural differentiation but not in undifferentiated mESCs, corroborating our conclusions.</p><disp-quote content-type="editor-comment"><p>3) If oxidative stress in the mitochondria is the major cause of the craniofacial phenotype, then mitochondrial disfunction should be evident in the Neil1/2 mutant background upon neuroectoderm induction. Experimental evidence for this is lacking.</p></disp-quote><p>We now show elevated mt gene expression indicative of mitochondrial dysfunction in both model systems, <italic>Xenopus</italic> and mESCs (Figure 2C and 11D).</p><disp-quote content-type="editor-comment"><p>4) Most of the mechanistic data derived from the interpretation of gene expression analyses. I found these data supportive, but unconvincing. There is a wealth of commercially available antibodies/reagents to study intrinsic apoptosis. The authors should leverage these reagents to solidify their conclusions.</p><p>We did utilize a variety of antibodies (targeting Caspase-3, Caspase-7, Caspase-9, AIF, Cytochrome C) to confirm an intrinsic apoptosis pathway in EB + RA differentiated cells. However, by Western blot we could not detect substantial activation or translocation of these apoptotic factors in <italic>Neil</italic>-knockout- as compared to control clones (Figure 12—figure supplement 2B). This could be due to insufficient sensitivity in a whole-population analysis with a fraction of cells being affected. Instead, we detected and confirmed a requirement for Caspase-3 (cleaved and uncleaved) during neuronal differentiation (Figure 12 —figure supplement 2A) indicative of a systemic regulation of apoptotic factors. Moreover, TP53 target gene activation in EB + RA cells was moderate (&lt; 2-fold) though significant as assessed by RT-qPCR analysis (Figure 12D and Figure 12—figure supplement 1C). Importantly, we now show a rescue of the Neil2 MO-induced phenotype by <italic>bcl2l1</italic> overexpression in <italic>Xenopus</italic> embryos confirming ongoing intrinsic apoptosis by <italic>Neil2</italic>-deficiency (Figure 2A-B).</p><p>Lastly, many statements throughout the paper are not accurate and therefore misleading to the reader. Also, the authors are very selective of the literature they chose to reference.</p></disp-quote><p>We apologize for the missing accuracy and tried our best to improve the manuscript text and references, see below.</p><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>[…] I have only one major point that needs to be addressed experimentally and few other points that should be clarified in the text.</p><p>The validation of the mESCs Ko is incomplete/insufficient. Western blots for many targeted proteins (Neil2 and 3). The off-target effect inherent to CRISPR/Cas9 is a real issue both in the literature and in this study as well (see for instance Figure 6—figure supplement 1B that shows that 2 distinct deletions occur in a small region (+ 1kb) amplified by PCR in the triple Ko – Introduction). Whole genome sequencing is the only reliable way to rule out the possibility of off target mutations. At least uncropped gel images for all the KO cells have to be shown (I'm happy to hear from other reviewers and editors on this point).</p></disp-quote><p>We agree that potential off-target effects are an issue in CRISPR/Cas9 genome editing, and did further analysis.</p><p>1) We previously validated the knockouts in all generated cell lines by several means:</p><p>i) Genotyping PCR on gDNA with primers spanning the anticipated deletion region as presented in Figure 6—figure supplement 1, Figure 7—figure supplement 1, Figure 8—figure supplement 1, Figure 9—figure supplement 1 and Figure 9—figure supplement 2 (now also shown as uncropped agarose gels).</p><p>ii) Western blot analysis for endogenous proteins if antibodies were available and working (NEIL1 in Figure 6—figure supplement 1 and Figure 7—figure supplement 1, APEX1 in Figure 8—figure supplement 1, and TDG in Figure 9—figure supplement 1 and Figure 9—figure supplement 2).</p><p>iii) RT-qPCR for expression analysis of the targeted exons (Neil2 and Neil3, Figure 6—figure supplement 1, Figure 7—figure supplement 3). Together, these analyses unambiguously confirmed the anticipated knockouts in the respective lines.</p><p>2) We now analyzed with CRISPOR (PMID: 27380939) off-target probability and potential off-target regions of the 6 gRNAs used to generate the <italic>Neil1, Neil2</italic> and <italic>Apex1</italic> knockout lines. These are the cell lines that showed neural and cNCC differentiation defects and were subjected to RNAseq analysis as undifferentiated mESCs. All 6 gRNAs were scored &gt;75 in the CFD specificity score (scale from 0 – 100, the higher the specificity score, the lower the probability for off-targets in the genome). In addition, we found among the potential off-target regions 25 genes with exonic matches for the two <italic>Neil1</italic> gRNAs, 14 for <italic>Neil2</italic> and 12 for <italic>Apex1</italic> all of which had between 3-4 base mismatches. Frameshift mutations are frequently accompanied by RNA level deregulation due to non-sense mediated decay or compensatory upregulation, respectively. However, only 4 of the 51 total candidates showed slight (log2FC &lt;1.0) RNA deregulation in the respective knockout lines compared to control mESCs (data not shown).</p><p>3) It is not surprising to see two distinct bands when deleting a target region of a gene in both alleles with two gRNAs since the error prone non-homologous end-joining will most likely produce different repair outcomes at the two allelic loci. Two PCR bands are also detectable with the <italic>Neil1</italic> single-knockout clone #11 (Figure 7—figure supplement 1A). Such a result is not a sign of off-target effects of the gRNAs. Notably, most of the genotyping PCRs generated apparently a unique deletion band; however, it is more likely that such bands consist of two different PCR products with similar length not resolvable by an agarose gel. To this end, we sequenced the apparent single band PCR products of all three <italic>Neil2</italic> single knockout clones (as shown in Figure 7—figure supplement 1A) and could indeed reveal twice two distinct sequences:</p><p>Neil2 #1</p><p><named-content content-type="sequence">5’ACACTATAGTGATTAGTATTTGCTG---615bp---ATGACCCCACGCAGGATCAGAAGAA 3‘</named-content></p><p><named-content content-type="sequence">5’TAGTATTTGCTGTGTGGTTAAGGCT---587bp---AAAAGGATGGACCTGATGACCCCAC 3‘</named-content></p><p>Neil2 #11</p><p><named-content content-type="sequence">5’GTATTTGCTGTGTGGTTAAGGCTGA---586bp---AAAGGATGGACCTGATGACCCCACG 3‘</named-content></p><p>Neil2 #14</p><p><named-content content-type="sequence">5’ AAGACTCTGTCTTAACCAACCAAAC---695bp---AAGGATGGACCTGATGACCCCACGC 3‘</named-content></p><p><named-content content-type="sequence">5’ TGATTAGTATTTGCTGTGTGGTTAA---594bp---AGGATGGACCTGATGACCCCACGCA 3‘</named-content></p><p>4) Most importantly, stable expression of <italic>NEIL1</italic> and <italic>NEIL2</italic> in the respective <italic>Neil1</italic> and <italic>Neil2</italic> knockout lines rescued the neural and neural crest differentiation defects (Figure 7—figure supplement 3) showing the specificity of the knockout approach.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…] A problem that persists throughout the work, however, is the conflating of cranial neural crest formation/development with neural differentiation, which is confusing and detracts from the impact of the work. This is particularly odd given that they one late phenotype that the authors examine is craniofacial cartilage, which is clearly not an example of neural differentiation.</p><p>From the Xenopus work it appears that the main finding is that NEIL2 morphants and pyocyanin treated embryos show a loss of neural crest markers at neurula stages and that this ultimately results in a loss of neural crest derivatives as evidenced by the cartilage phenotype. The authors link this to an increase in tp53, and show that tp53 over-expression also leads to a decrease in neural crest markers. Oddly, the authors conclude from this that &quot;the cNCC defects in Neil2 morphants reflect a &quot;neural-restricted Tp53-response to oxidative DNA damage&quot;. However they look at Sox3 expression in the neural plate and it is relatively normal. If the authors wish to extend their conclusions to neural rather than neural crest development then they need to look at a broader range of neural markers, including at later stages. In the absence of this, they can really only make conclusions about neural crest cells.</p></disp-quote><p>We agree and we now emphasize that the phenotype of Neil2-morphant <italic>Xenopus</italic> is specific to cNCC- but not to neural differentiation.</p><disp-quote content-type="editor-comment"><p>The experiments with pyocyanin are problematic as the treatment appears to have been from early cleavage stages so any effects on neural crest could be very indirect – what happens if you treat later, for example at gastrulation?</p><p>We treated embryos with pyocyanin from stage 8.5 and 10 onwards and with different doses (25 and 80 µM) but could not detect a Tp53 DDR at stage 14/15 nor any strong phenotype at stage 32 (data not shown) with the exception of high dose pyocyanin from stage 8.5 onwards. The time may be too short for sufficient oxidative DNA damage accumulation and full Tp53 cascade induction. In addition, we showed that <italic>neil2</italic> expression is temporally restricted in <italic>Xenopus</italic> embryos until stage 10 (PMID: 26751644) indicative of a critical requirement for Neil2 in lesion repair in early stages prior to neural crest development. Hence, we conclude that to mimic Neil2-deficiency, Pyocyanin treatment needs to start from early stages onwards.</p><p>In Figure 1H the authors preclude an effect on proliferation using a western blot for p-H3 but one would not likely detect local effects by this assay – they should do whole mount staining.</p></disp-quote><p>We performed p-H3 whole mount immunoassays in Neil2 morphant embryos in our previous study (PMID: 26751644). The result is congruent with the western blot shown in the current study.</p><disp-quote content-type="editor-comment"><p>Tunnel staining in Figure 1J shows increased apoptosis in both neural and non-neural cells but the authors state that cell death is in neural cells.</p></disp-quote><p>We did not conclude from Figure 1J that apoptosis is restricted to neural cells: “Whole mount TUNEL assay of unilaterally neil2 MO-injected embryos confirmed elevated apoptosis by Neil2-deficiency in stage 16 embryos (Figure 1J).” However, we concluded from the western blot shown in Figure 1I that cleaved Caspase-3 levels (apoptosis) were elevated in neural- compared to non-neural tissues.</p><disp-quote content-type="editor-comment"><p>It is interesting that p53 expression is elevated at the neural folds relative to other tissues. One might think that would render these cells more rather than less protected against oxidative stress than their neighbors. The authors should comment on this.</p></disp-quote><p>We state in the Discussion:</p><p>“Neurogenesis is accompanied by a metabolic switch from glycolysis to oxidative phosphorylation, a concomitant increase in mass and number of mitochondria per cell, and hence escalated oxidative stress (Khacho and Slack, 2018). […] Hence, cells with high basal Tp53 expression will reach detrimental Tp53 levels more easily upon stress.”</p><disp-quote content-type="editor-comment"><p>Also what happens to p53 expression in Neil2 morphants or after pyocyanin treatment?</p></disp-quote><p>Tp53 expression is significantly elevated in both cases albeit less strong when compared to Tp53 target genes (Figure 1F and 3B).</p><disp-quote content-type="editor-comment"><p>The authors see a decrease in Slug expression after tp53 injection, but not loss of the lineage tracer β-galactosidase, so the cells are presumably still there. This call into question whether the decrease observed is really cell death dependent. They should block apoptosis with Bcl2 and determine if expression is rescued. Also given the authors continued focus on neural differentiation, does p53 injection alter sox3 expression or other neural markers such as neural tubulin?</p></disp-quote><p><italic>Bcl2l1</italic> (the <italic>Xenopus Bcl2</italic> homologue) mRNA injection indeed rescued <italic>Neil2</italic> MO-triggered malformations as well as elevated levels of cleaved Caspase-3 in neural tissues (new Figure 2A-B) supporting induced apoptosis by Neil2-deficiency in <italic>Xenopus</italic>, and a functional link between apoptosis and the observed malformations.</p><disp-quote content-type="editor-comment"><p>In the second half of the paper focusing on mESCs the authors interpret their findings as requirement for NEIL function in cNCC development is evolutionarily conserved between amphibians and mammals. However they draw this conclusion without convincing data for neural phenotypes in Xenopus and using only one marker each for neural and neural crest (Pax6/Pax3). Multiple markers for each cell type should be examined.</p></disp-quote><p>We have now added three additional markers for neural crest (<italic>Hoxa2, Tfapb2, Neurog1</italic>) and neural (<italic>Nestin, Sox1, Pax2</italic>) differentiation supporting our conclusion about cNCC and neural differentiation defects in <italic>Neil1</italic>- and <italic>Neil2</italic>-deficient mESCs. The results are presented in Figure 6—figure supplement 2 and Figure 7—figure supplement 2.</p></body></sub-article></article>